---
document_datetime: 2023-09-21 20:34:00
document_pages: 96
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/jardiance-h-c-002677-ii-0055-epar-assessment-report-variation_en.pdf
document_name: jardiance-h-c-002677-ii-0055-epar-assessment-report-variation_en.pdf
version: success
processing_time: 91.3445231
conversion_datetime: 2025-12-14 22:29:23.950876
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
<!-- image -->

20 March 2021 DOC\\_REF\\_ID Committee for Medicinal Products for Human Use (CHMP)

## Extension of indication variation assessment report

## Jardiance

International non-proprietary name: empagliflozin

Procedure No. EMEA/H/C/002677/II/0055

Invented name: Jardiance

## Note

Assessment report as adopted by the CHMP with all the information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Steps taken for the assessment

The PRAC/CHMP Rapporteurs should complete the 'actual' date at each stage of the procedure. This is the date of circulation of the report to CHMP/PRAC members.

<!-- image -->

| Status of this report and steps taken for the assessment   | Status of this report and steps taken for the assessment   | Status of this report and steps taken for the assessment   | Status of this report and steps taken for the assessment   | Status of this report and steps taken for the assessment   |
|------------------------------------------------------------|------------------------------------------------------------|------------------------------------------------------------|------------------------------------------------------------|------------------------------------------------------------|
| Current step¹                                              | Description                                                | Planned date                                               | Actual Date                                                | Need for discussion²                                       |
|                                                            | Start of procedure                                         | 31 Oct 2020                                                | 31 Oct 2020                                                |                                                            |
|                                                            | CHMP Rapporteur Assessment Report                          | 22 Dec 2020                                                | 22 Dec 2020                                                |                                                            |
|                                                            | PRAC Rapporteur Assessment Report                          | 04 Jan 2021                                                | 04 Jan 2021                                                |                                                            |
|                                                            | PRAC members comments                                      | 06 Jan 2021                                                | 06 Jan 2021                                                |                                                            |
|                                                            | Updated PRAC Rapporteur Assessment Report                  | 07 Jan 2021                                                | 07 Jan 2021                                                |                                                            |
|                                                            | PRAC endorsed relevant sections of the assessment report³  | 14 Jan 2021                                                | 14 Jan 2021                                                |                                                            |
|                                                            | CHMP members comments                                      | 18 Jan 2021                                                | 18 Jan 2021                                                |                                                            |
|                                                            | Updated CHMP Rapporteur(s) (Joint) Assessment Report       | 21 Jan 2021                                                | 21 Jan 2021                                                |                                                            |
|                                                            | Request for supplementary information                      | 28 Jan 2021                                                | 28 Jan 2021                                                |                                                            |
|                                                            | Responses due by                                           | 19 Feb 2021                                                | 19 Feb 2021                                                |                                                            |
|                                                            | Re-Start of procedure                                      | 22 Feb 2021                                                | 22 Feb 2021                                                |                                                            |
|                                                            | CHMP Rapporteur Assessment Report                          | 23 Mar 2021                                                | 25 Mar 2021                                                |                                                            |
|                                                            | PRAC Rapporteur Assessment Report                          | 26 Mar 2021                                                | 26 Mar 2021                                                |                                                            |
|                                                            | PRAC members comments                                      | 30 Mar 2021                                                | 30 Mar 2021                                                |                                                            |
|                                                            | Updated PRAC Rapporteur Assessment Report                  | 31 Mar 2021                                                | 31 Mar 2021                                                |                                                            |
|                                                            | PRAC endorsed relevant sections of the assessment report³  | 09 Apr 2021                                                | 09 Apr 2021                                                |                                                            |
|                                                            | CHMP members comments                                      | 12 Apr 2021                                                | 12 Apr 2021                                                |                                                            |
|                                                            | Updated CHMP Rapporteur(s) (Joint) Assessment Report       | 15 Apr 2021                                                | 15 Apr 2021                                                |                                                            |
|                                                            | 2 nd request for supplementary information                 | 22 Apr 2021                                                | 22 Apr 2021                                                |                                                            |
|                                                            | Responses due by                                           | 27 Apr 2021                                                | 27 Apr 2021                                                |                                                            |
|                                                            | Re-Start of procedure                                      | 28 Apr 2021                                                | 28 Apr 2021                                                |                                                            |
|                                                            | CHMP/PRAC Rapporteur Assessment Report                     | 05 May 2021                                                | 06 May 2021                                                |                                                            |
|                                                            | CHMP/PRAC members comments                                 | 10 May 2021                                                | 10 May 2021                                                |                                                            |
|                                                            | Updated CHMP/PRAC Rapporteur Assessment Report             | 12 May 2021                                                | 12 May 2021                                                |                                                            |
|                                                            | Opinion                                                    | 20 May 2021                                                | 20 May 2021                                                |                                                            |

¹ Tick the box corresponding to the applicable step - do not delete any of the steps. If not applicable, add n/a instead of the date.

<div style=\"page-break-after: always\"></div>

² Criteria for CHMP plenary discussion: substantial disagreement between the Rapporteur and other CHMP members and/or at the request of the Rapporteur or the Chair

Criteria for PRAC plenary discussion: proposal for update of SmPC/PL, introduction of or changes to imposed conditions or additional risk minimisation measures (except for generics aligning with the originator medicinal product), substantial changes to the pharmacovigilance plan (relating to additional pharmacovigilance activities, except for generics adapting aligning with the originator medicinal product), substantial disagreement between the Rapporteur and other PRAC members, at the request of the Rapporteur, any other PRAC member, the Chair or EMA.

³ Sections related to Risk Management Plan or on non-interventional PASS results. If PRAC advice was ad hoc requested by the CHMP, the relevant Attachment to the assessment report applies and has been endorsed by the PRAC.

<div style=\"page-break-after: always\"></div>

## Procedure resources

<!-- image -->

| Procedure resources   |                         |                               |
|-----------------------|-------------------------|-------------------------------|
| Rapporteur            | Johann Lodewijk Hillege | Johann Lodewijk Hillege       |
| PRAC Rapporteur       | Eva A. Segovia          | Eva A. Segovia                |
| EMA Product Lead      | Name: Tel:              | Maria Boulos +31 88781 7585   |
| Procedure Assistant   | Name: Tel:              | Vanessa Moreno +31 88781 8441 |

## Declarations

The assessor confirms that reference to ongoing assessments or development plans for other products is not included in this assessment report, including in the Product Information, if any.

Whenever the above box is un-ticked please indicate section and page where confidential information is located here:

N/A

<div style=\"page-break-after: always\"></div>

## Table of contents

| Steps taken for the assessment ..................................................................                           | 2                                                                                                                     |
|-----------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------|
| Procedure resources ...................................................................................                     | 4                                                                                                                     |
| Table of contents                                                                                                           | ........................................................................................ 5                            |
| List of abbreviations                                                                                                       | ................................................................................... 7                                 |
| 1. Background information on the procedure..............................................                                    | 9                                                                                                                     |
| 2. Recommendations.................................................................................                         | 11                                                                                                                    |
| 3. Scientific discussion..............................................................................                      | 12                                                                                                                    |
| 3.1. Introduction                                                                                                           | ...................................................................................................... 12             |
| 3.1.1. Problem statement                                                                                                    | .......................................................................................... 12                         |
| 3.1.2. About the product                                                                                                    | ........................................................................................... 13                        |
| 3.1.3. The development programme/compliance with CHMP guidance/scientific                                                   | advice...... 13                                                                                                       |
| 3.1.4. General comments on compliance with GLP, GCP                                                                         | ................................................ 14                                                                   |
| 3.2. Non-clinical aspects............................................................................................       | 14                                                                                                                    |
| 3.2.1. Pharmacology.................................................................................................        | 14                                                                                                                    |
| 3.2.2. Ecotoxicity/environmental risk assessment.........................................................                   | 16                                                                                                                    |
| 3.2.3. Discussion on non-clinical aspects .....................................................................             | 17                                                                                                                    |
| 3.2.4. Conclusion on the non-clinical aspects ...............................................................               | 18                                                                                                                    |
| 3.3. Clinical aspects                                                                                                       | .................................................................................................. 18                 |
| 3.3.1. Introduction....................................................................................................     | 18                                                                                                                    |
| 3.3.2. Pharmacokinetics                                                                                                     | ............................................................................................ 18                       |
| Pharmacokinetics in target population                                                                                       | ......................................................................... 19                                          |
| Pharmacokinetic interaction studies ............................................................................            | 25                                                                                                                    |
| 3.3.3. Pharmacodynamics..........................................................................................           | 25                                                                                                                    |
| Mechanism of action                                                                                                         | ................................................................................................. 25                  |
| 3.3.4. Discussion and Conclusions on clinical pharmacology                                                                  | ........................................... 26                                                                        |
| 3.3.5. Clinical efficacy                                                                                                    | ............................................................................................... 27                    |
| 3.3.6. Dose response study(ies) .................................................................................           | 27                                                                                                                    |
| 3.3.7. Main study(ies)                                                                                                      | ............................................................................................... 27                    |
| Methods                                                                                                                     | .................................................................................................................. 27 |
| Results.................................................................................................................... | 33                                                                                                                    |
| 3.3.8. Supportive study(ies)                                                                                                | ...................................................................................... 55                             |
| EMPERIAL Reduced/Preserved (1245.168 and 1245.167)...............................................                           | 55                                                                                                                    |
| Methods                                                                                                                     | .................................................................................................................. 55 |
| Results.................................................................................................................... | 57                                                                                                                    |
| 3.3.9. Discussion on clinical efficacy............................................................................          | 60                                                                                                                    |
| 3.3.10. Conclusions on the clinical efficacy...................................................................             | 63                                                                                                                    |
| 3.4. Clinical safety                                                                                                        | .................................................................................................... 63               |
| 3.4.1. Discussion on clinical safety..............................................................................          | 82                                                                                                                    |
| 3.4.2. Conclusions on clinical safety............................................................................           | 84                                                                                                                    |
| 3.4.3. PSUR cycle                                                                                                           | ..................................................................................................... 85              |

<div style=\"page-break-after: always\"></div>

| 4. Risk management plan.......................................................................... 86                                                                                                     |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 4.1. Overall conclusion on the RMP ............................................................................. 87                                                                                      |
| 5. Changes to the Product Information ..................................................... 88 5.1. User consultation ..................................................... Error! Bookmark not defined. |
| 6. Benefit-Risk Balance............................................................................. 89                                                                                                  |
| 6.1. Therapeutic Context ...........................................................................................                                                                                     |
| 89                                                                                                                                                                                                       |
| 6.1.1. Disease or condition ........................................................................................ 89                                                                                  |
| 6.1.3. Main clinical studies......................................................................................... 90                                                                                 |
| 6.2. Favourable effects.............................................................................................. 90                                                                                 |
| 91                                                                                                                                                                                                       |
| 6.3. Uncertainties and limitations about favourable effects.............................................                                                                                                 |
| 6.5. Uncertainties and limitations about unfavourable effects ......................................... 93                                                                                               |
| 6.6. Effects Table...................................................................................................... 94                                                                              |
| 6.7. Benefit-risk assessment and discussion................................................................. 95                                                                                          |
| 6.7.1. Importance of favourable and unfavourable effects.............................................. 95                                                                                                |
| 6.8. Conclusions ....................................................................................................... 96                                                                              |

<div style=\"page-break-after: always\"></div>

## List of abbreviations

6MWT

6-minute walk test

AE

Adverse event

AESI

Adverse event of special interest

AF

Atrial fibrillation or atrial flutter

ANCOVA

Analysis of covariance

ARB

Angiotensin receptor blocker

ARNi

Angiotensin receptor neprilysin inhibitor

BI

Boehringer Ingelheim

BIcMQ

BI-customised MedDRA query (used where SMQ is not available)

BMI

Body mass index

CEC

Clinical event committee

CI

Confidence interval

CKD-EPI

Chronic kidney disease epidemiology collaboration equation

CMH

Cochran-Mantel-Haenszel

CO

Clinical overview

CRT (-D/P)

Cardiac resynchronisation therapy (-defibrillator/pacemaker )

CTD

Common Technical Document

CTP

Clinical trial protocol

CTR

Clinical trial report

CV

Cardiovascular

DBP

Diastolic blood pressure

DMC

Data monitoring committee

ECG

Electrocardiogram

EF

Ejection fraction

eGFR

Estimated glomerular filtration rate

eGFR (CKD-EPI)cr

Glomerular filtration rate estimated by the chronic kidney disease epidemiology collaboration formula with serum creatinine measurement

eGFR (MDRD)

Glomerular filtration rate estimated by the modification of diet in renal disease formula

EMPA-VISION

A mechanistic trial of empagliflozin on cardiac physiology and metabolism in patients with chronic heart failure; trial 1245.148

EMPERIAL

Trials of empagliflozin on exercise ability and heart failure symptoms in patients with chronic heart failure; EMPERIAL-preserved: trial 1245.167; EMPERIAL-reduced: trial 1245.168

EMPEROR

Outcome trials of empagliflozin in patients with chronic heart failure; EMPEROR-reduced: trial 1245.121; EMPEROR-preserved: trial 1245.110

FPG

Fasting plasma glucose

GCP

Good clinical practice

gMean

Geometric mean

HbA1c

Glycated haemoglobin

HF

Heart failure

HFpEF

Heart failure with preserved ejection fraction

HFrEF

Heart failure with reduced ejection fraction

HHF

Hospitalisation for heart failure

FU

Follow up

ICD

Implantable cardioverter defibrillator

ICH

International conference on harmonisation

IQR

Interquartile range

ISS

Integrated summary of safety

ITT

Intent to treat

KCCQ

Kansas City cardiomyopathy questionnaire

LLA

Lower limb amputation

LLN

Lower limit of normal

LVEF

Left ventricular ejection fraction

MACE

Major adverse cardiovascular event

MDRD

Modification of diet in renal disease

MedDRA

Medical dictionary for regulatory activities

MI

Myocardial infarction

MMRM

Mixed model repeated measure

MRA

Mineralocorticoid receptor antagonist

NNT

Number needed to treat

NT-proBNP

N-terminal pro-brain natriuretic peptide

NYHA

New York heart association

PD

Pharmacodynamic(s)

PK

Pharmacokinetic(s)

PRO

Patient-reported outcome

PT

Preferred term

pt-yrs

Patient-years

qd

Once daily

RS

Randomised set

SAE

Serious adverse event

SAF-HF2

Safety analysis grouping for EMPERIAL trials 1245.167 and 1245.168

SBP

Systolic blood pressure

SCE

Summary of clinical efficacy

SCS

Summary of clinical safety

SCR

Screened set

SD

Standard deviation

SEM

Standard error of measurement

SGLT

Sodium-dependent glucose co-transporter

SMQ

Standardised MedDRA query

SOC

System organ class

T1DM

Type 1 diabetes mellitus

T2DM

Type 2 diabetes mellitus

TIA

Transient ischaemic attack

TS

Treated set

UACR

Urine albumin to serum creatinine ratio

ULN

Upper limit of normal

UTI

Urinary tract infection

WCI

Worst-case imputation

<div style=\"page-break-after: always\"></div>

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

Pursuant to Article 16 of Commission Regulation (EC) No 1234/2008, Boehringer Ingelheim International GmbH submitted to the European Medicines Agency on 13 October 2020 an application for a Type II variation.

The following changes were proposed:

| Variation requested   | Variation requested                                                                                                                 | Type   | Annexes affected   |
|-----------------------|-------------------------------------------------------------------------------------------------------------------------------------|--------|--------------------|
| C.I.6.a               | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one Type | II     | I, IIIA and IIIB   |

Extension of the indication to include treatment of adult patients with heart failure and reduced ejection fraction for Jardiance; as a consequence, sections 4.1, 4.2, 4.4, 4.8, 4.9 and 5.1 of the SmPC are updated. This is based on final results from the EMPEROR HFrEF study, a phase III randomised, doubleblind trial to evaluate efficacy and safety of once-daily empagliflozin 10 mg compared to placebo. The Package Leaflet and Labelling are updated in accordance. Version 15.0 of the RMP has also been submitted. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet.

The requested variation proposed amendments to the Summary of Product Characteristics, Labelling and Package Leaflet and to the Risk Management Plan (RMP).

## Information on paediatric requirements

Pursuant to Article 8 of Regulation (EC) No 1901/2006, the application included (an) EMA Decision(s) EMEA-000828-PIP05-17 on the granting of a (product-specific) waiver.

The waiver applies to:

- all subsets of the paediatric population from birth to less than 18 years of age;
- for film-coated tablet, oral use;
- on the grounds that the specific medicinal product is likely to be unsafe .

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the MAH did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

## MAH request for additional market protection

The MAH requested consideration of its application in accordance with Article 14(11) of Regulation (EC) 726/2004 - one year of market protection for a new indication.

<div style=\"page-break-after: always\"></div>

## Scientific advice

The MAH received Scientific advice from the CHMP on 10 November 2016 (EMA/CHMP/SAWP/715730/2016) and on 20 July 2017 (EMA/CHMP/SAWP/432773/2017). The Scientific advice pertained to clinical aspects of the dossier.

<div style=\"page-break-after: always\"></div>

## 2. Recommendations

Based on the review of the submitted data, this application regarding the following change:

| Variation requested   |                                                                                                                                | Type    | Annexes affected   |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a               | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I, IIIA and IIIB   |

Extension of the indication to include treatment of adult patients with heart failure and reduced ejection fraction for Jardiance; as a consequence, sections 4.1, 4.2, 4.4, 4.8, 4.9 and 5.1 of the SmPC are updated. This is based on final results from the EMPEROR HFrEF study, a phase III randomised, doubleblind trial to evaluate efficacy and safety of once-daily empagliflozin 10 mg compared to placebo. The Package Leaflet and Labelling are updated in accordance. Version 15.2 of the RMP has also been submitted. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet.

is recommended for approval.

## Amendments to the marketing authorisation

In view of the data submitted with the variation, amendments to Annex(es) I, IIIA and IIIB and to the Risk Management Plan are recommended.

<div style=\"page-break-after: always\"></div>

## 3. Scientific discussion

## 3.1. Introduction

## 3.1.1. Problem statement

## Disease or condition and claimed the therapeutic indication

The MAH initially proposed the following extension of indication:

## Heart failure

Jardiance is indicated in adult patients with heart failure (NYHA class II-IV) and reduced ejection fraction, with or without type 2 diabetes mellitus:

- to reduce the risk of cardiovascular death and hospitalization for heart failure
- to slow kidney function decline

This indication was modified by CMP during the procedure.

## Epidemiology and risk factors

Heart failure (HF) has emerged as a global epidemic over the last decades and an estimated prevalence of &gt;37.7 million individuals globally. In the United States alone, the prevalence is 5.7 million, and there are 670,000 new cases per year. The rise in cardiovascular risk factors, improved survival from ischaemic heart disease, as well as age distribution will contribute to a sustained increase in the prevalence of HF in developed high-income countries.

## Clinical presentation, diagnosis and stage/prognosis

Chronic heart failure (HF) is a progressive syndrome characterized by the inability of the heart to provide adequate circulation to meet the metabolic demand of different tissues or do it at the expense of elevated left ventricular filling pressure. HF occurs due to failure of the heart to pump adequately (systolic dysfunction) and/or impaired relaxation (diastolic dysfunction). Two types of HF have been defined mainly based on the Left ventricular ejection fraction (LVEF) and also other structural changes in heart muscle: heart failure with reduced ejection fraction (HFrEF) &lt;40% and heart failure with preserved ejection fraction (HFpEF) ≥ 50%. Patients with HF can clinically be classified according to the severity of their symptoms. The most commonly used classification system, the New York Heart Association (NYHA) Functional Classification, places patients in one of four categories based on how much they are limited during physical activity. The classes range from I, i.e. 0 limitation of physical activity, to IV, i.e. unable to carry on any physical activity without discomfort. The clinical course for HFrEF patients is often marked by acute episodes of clinical decompensation with increased symptoms such as dyspnea, fatigue, and oedema and in more severe cases cardiac asthma. The time in between these acute episodes can consist of periods with stability, but the normal progression of the disease is still associated with increasingly worsening symptoms, an increasing frequency of rehospitalizations, and ultimately a high rate of mortality. Approximately 50% of patients who develop HF die within 5 years after diagnosis. Annually, more than 1 million patients are hospitalized with a primary diagnosis of HF. HF is the most common cause of hospitalization among individuals above 65 years of age in the western countries. This worsening of chronic HF has been defined in the '2017 European Medicines Agency Guideline on clinical investigation of medicinal products for the treatment of chronic HF (EMA 2017)'.

## Management

Standard medications for patients with HFrEF and medium-to-severe chronic HF (NYHA classes II to IV) are well established and based on large randomized, controlled trials, with the results incorporated into

<div style=\"page-break-after: always\"></div>

guidelines issued by the ACCF/AHA and the European Society of Cardiology (ESC). The standard medications include an angiotensin-converting enzyme (ACE) inhibitor or/and an angiotensin receptor blocker (ARB), beta-blocker, angiotensin-receptor-neprilysin-inhibitor (ARNIs) and a diuretic in patients with evidence of fluid retention. An aldosterone receptor antagonist may be given, especially those who have experienced an acute myocardial infarction or have a history of diabetes mellitus. Despite considerable advances in the therapy of HF patients, even in patients on optimized therapy the normal progression of the disease is, as described above, still associated with increasingly worsening symptoms, an increasing frequency of rehospitalizations and a high rate of mortality.

Studies investigating the effect of sodium-glucose cotransporter-2 (SGLT 2) inhibitors observed beneficial effects on HF-related complications in patients with or without diabetes. Empagliflozin is an orally administered SGLT-2 inhibitor and is approved for the treatment of type 2 diabetes mellitus (T2DM) worldwide. The results of trial 1245.25 (EMPA-REG OUTCOME) in patients with T2DM and established CV disease showed that empagliflozin significantly reduced the risk of hospitalisation for heart failure (HHF) and the composite endpoint of HHF or CV death.

## 3.1.2. About the product

Empagliflozin (Jardiance) is an orally administered, potent and selective inhibitor of the human sodiumglucose cotransporter-2 (SGLT 2) developed by Boehringer Ingelheim (BI). By inhibition of SGLT 2 in the kidneys empagliflozin reduces the reabsorption of glucose by the kidneys leading to increased urinary glucose excretion and, in consequence, to a lowering of blood glucose. Empagliflozin is approved for the treatment of type 2 diabetes mellitus (T2DM) worldwide as an adjunct therapy to diet and exercise to improve glycaemic control in adults with type 2 diabetes. In the United States and several other countries, it is also approved to reduce the risk of cardiovascular (CV) death in patients with T2DM and established CV disease. The results of the EMPA-REG OUTCOME trial (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients) significantly improved the primary composite cardiovascular outcome (MACE-3) and significantly reduced cardiovascular death, hospitalization for heart failure (HHF) as well as death from any cause as compared to standard of care. These beneficial cardiovascular effects were found to be largely independent of the glucose-lowering effect of empagliflozin.

Empagliflozin exerts its effect by preventing sodium and glucose reabsorption. While natriuresis will be compensated within days of drug administration through changes in tubulo-glomerular feedback, glucosuria will last for as long as the medication is used. This leads to long-lasting hemodynamic changes associated with modest osmotic diuresis, blood pressure lowering effect, improvement in arterial stiffness, reduction in oxidative stress, and decrease in rate pressure product, an indirect measure of myocardial oxygen demands, with no increase in HR and no effect on sympathetic nerve activity. The non-glycosuric physiological and hemodynamic adaptations under empagliflozin may, therefore provide benefits for patients with HF with or without diabetes.

Based on the results of trial 1245.25 (EMPA-REG OUTCOME) in patients with T2DM and established CV disease, BI initiated a phase III program for empagliflozin 10 mg once daily in chronic heart failure regardless of diabetes status, including two pivotal CV outcome trials ('EMPEROR'), two functional capacity trials ('EMPERIAL'), and a mechanistic phase III trial ('EMPA-VISION') in patients with HFrEF (reduced ejection fraction) and HFpEF (preserved ejection fraction).

## 3.1.3. The development programme/compliance with CHMP guidance/scientific advice

## The development programme

The EMPEROR trials are pivotal outcome trials that investigate the long-term effect of empagliflozin in reducing the risk of hospitalisation for HF and of cardiovascular death in patients with heart failure. The

<div style=\"page-break-after: always\"></div>

EMPERIAL trials are additional trials that investigated the short-term (12 weeks) effect of empagliflozin on functional capacity, signs and symptoms of heart failure and quality of life. The EMPA-VISION trial is a supporting trial investigating the short-term (12 weeks) effects of empagliflozin on mechanistic cardiac physiology and metabolism.

The EMPEROR-reduced trial (1245.121) and the EMPERIAL trials (1245.168 and 1245.167) have been completed, and the clinical trial reports are available.

EMPA-VISION (1245.148) had been completed clinically, and the reporting of results is ongoing. The EMPEROR-preserved trial (1245.110) is still ongoing.

## Compliance with CHMP guidance

The most relevant CHMP guideline is 'Clinical investigation of medicinal products in the treatment of chronic heart failure' (CPMP/EWP/235/95, Rev.2). The compliance with this guideline is addressed in the discussion of the design of the trial.

## Scientific advice

In general, the EMPEROR trial was conducted according to the scientific advice from the CHMP on 10 November 2016 (EMA/CHMP/SAWP/715730/2016) and on 20 July 2017 (EMA/CHMP/SAWP/432773/2017). However, although the CHMP recommended not to use the eGFR slope as a key secondary endpoint, in the current application the eGFR slope was included as such. From a clinical perspective, the CHMP considers this approach questionable and the proposed slope analysis is not acceptable from a statistical perspective. Such a modelling exercise would be more suitable for providing supportive descriptive information on renal progression rather than key statistical evidence. CHMP recommended it to be better placed outside of the testing hierarchy.

## 3.1.4. General comments on compliance with GLP, GCP

## GLP

Not applicable

## GCP

According to the MAH, the trials were carried out in compliance with the CTP, in accordance with the principles of the Declaration of Helsinki, in accordance with the ICH GCP, and in accordance with applicable regulatory requirements and BI's standard operating procedures.

## 3.2. Non-clinical aspects

## 3.2.1. Pharmacology

Empagliflozin is a potent and selective inhibitor of the human sodium-glucose cotransporter-2 (SGLT 2).

By inhibition of SGLT 2 in the kidneys empagliflozin reduces the reabsorption of glucose by the kidney leading to increased urinary glucose excretion and in consequence to a lowering of blood glucose in patients with diabetes mellitus and healthy subjects.

In the clinical EMPA-REG OUTCOME trial empagliflozin significantly improved the primary composite cardiovascular outcome (MACE-3) and significantly reduced cardiovascular death, hospitalization for heart failure (HHF) as well as death from any cause as compared to standard of care. These beneficial cardiovascular effects were found to be largely independent of the glucose-lowering effect of empagliflozin.

<div style=\"page-break-after: always\"></div>

Upon these results, effects of empagliflozin on the pathophysiological processes in the cardiovascular system were studied. Studies were done in various pharmacological experimental settings, in particular in models of heart failure induced by different stimuli. These experiments were performed in different species like mice, rats and pigs. Importantly, studies were done in normoglycemic animals as well as animals with pre-existing diabetes in order to reproduce aspects of the beneficial results observed in the clinical studies and to investigate the mode of action of empagliflozin on the cardiovascular system.

In vitro empagliflozin significantly improved the myocardial stiffness both in tissue from end-stage HF patients as well as from mice with diabetic cardiomyopathy in vitro . The effects of empagliflozin may be mediated by a restoration of myofilament phosphorylation. In diabetic, hypertensive rats empagliflozin preserved endothelial function ex vivo , while a deterioration was observed in blood vessels taken from the sham-treated control group. The exact molecular mechanism of empagliflozin in these in vitro / ex vivo models, however, remains unclear.

In vivo , in diabetic animals, empagliflozin significantly ameliorated cardiac remodelling as shown by reduced cardiac and peri-coronary arterial fibrosis and LV mass/BW ratios. Further empagliflozin exerted anti-inflammatory properties and reduced cardiac oxidative stress by restoring levels of endogenous antioxidants. Impaired vascular endothelial function was restored. Cardiac energy supply was improved by empagliflozin. This beneficial effect correlated with increased plasma ketone levels. More importantly, empagliflozin restored parameters of cardiac function in rodent models of type 2 diabetes mellitus. Effects of empagliflozin have been additionally investigated in pharmacological models using animals without diabetes mellitus.

In doxorubicin-induced heart failure empagliflozin reduced cardiac remodelling and improved cardiac function in mice. Empagliflozin increased the plasma levels of ß-hydroxybutyrate that demonstrated antioxidative effects, cardiomyocytes in vitro . In rats with permanent coronary artery ligation empagliflozin prevented the progressive deterioration of cardiac function. Further cardiac remodelling was prevented and oxidative stress reduced. ATP levels were increased in an empagliflozin treated group compared to sham-treated controls. Empagliflozin increased plasma levels of ketone bodies and increased cardiac ketone utilization. Empagliflozin-treated pigs had higher myocardial ATP compared to sham-treated controls. Thus, in these preclinical studies, empagliflozin shifted the energy metabolism from glucose utilization to ketone bodies as an energy source resulting in improved myocardial ATP levels. Empagliflozin improved LV systolic and diastolic function and ameliorated cardiac in a model of myocardial infarction in pigs. The energy metabolism was switched from glucose toward ketone body utilization.

Empagliflozin has shown beneficial effects on functional parameters of heart failure in different experimental settings in vitro and in vivo . In models of heart failure induced by myocardial infarction or doxorubicin injection empagliflozin improved left ventricular function and reduced cardiac remodelling in different species. The failing heart appears to have an energy deficit; interestingly empagliflozin has been shown to improve energy supply to the organ. Moderately increased plasma levels of ketone bodies have been described in clinical studies. These ketone bodies are described as an alternative energy source for various organs, including the heart. In the reviewed studies, empagliflozin has been shown to moderately increase plasma levels of ketones in vivo . This source of energy supply might contribute to the beneficial effects of empagliflozin in patients with heart failure.

SGLT2 transporter protein has been detected in the proximal tubules of the kidneys of humans and animals. Inhibition of these transporters leads to glucosuria, the relevant mode of action of empagliflozin in the treatment of diabetes mellitus. SGLT2 receptors have recently been detected on cardiac endothelial cells under stress conditions in rats. Expression of these transporters under various stress conditions are presently under investigation and may help to explain the effects of empagliflozin beyond glucosuria.

Empagliflozin also reduces sodium reabsorption and increases the delivery of sodium to the distal tubule. By activation of the tubule-glomerular feedback, this may influence several physiological functions including, but not restricted to, lowering both pre-and afterload of the heart and downregulation of sympathetic activity.

<div style=\"page-break-after: always\"></div>

A concern was raised about a concomitant use of GLP-1 receptor agonists blunting the SGLT-2 inhibitorinduced hyperketonaemia, thus reducing empagliflozin efficacy for HF. The MAH stated that in the study of Ferranini et al. (2020), patients receiving a GLP-1 receptor agonist exenatide demonstrated a decreased plasma ketone levels compared to the baseline, which was counterbalanced by a concomitant use of a SGLT-2 inhibitor dapagliflozin in the combination arm of the study. Patients treated with both substances showed overall neutral effects on β -hydroxybutyrate levels. In the same study, the SGLT-2 inhibitor induced a moderate increase in haematocrit which was not impacted by the concomitant GLP-1 receptor agonist use. It has been suggested that SGLT-2 inhibition with empagliflozin may stimulate erythropoiesis via an early increase in erythropoietin production, which may contribute to improved myocardial tissue oxygenation and reduced left ventricular mass in the patients.

The precise molecular mechanisms of these effects are still not fully elucidated, and it is not clear which of these mechanisms are of clinical relevance or which one would be the dominant one, but this can be accepted.

Taken together, empagliflozin demonstrated beneficial effects on the cardiovascular system in vitro and in vivo in animals with or without diabetes mellitus. These results are supportive with regards to the use of empagliflozin as a medication for patients with heart failure.

The beneficial effects of empagliflozin on the cardiovascular system have been shown in normoglycemic animals and animals with diabetes mellitus. This mirrors data shown in clinical studies.

The following statement will be included in Section 5.1 of SmPC: ' Empagliflozin also reduces sodium reabsorption and increases the delivery of sodium to the distal tubule. This may influence several physiological functions including, but not restricted to, increasing tubuloglomerular feedback and reducing intraglomerular pressure, lowering both pre- and afterload of the heart, and downregulating of sympathetic activity .'

## 3.2.2. Ecotoxicity/environmental risk assessment

An Environmental Risk Assessment (ERA) for empagliflozin was submitted with the initial MAA and an updated ERA after completion of an additional study. The risk assessment resulted in the conclusion that no significant impact on the environment is expected.

In the current ERA, the estimation of the predicted environmental concentration (PEC) of empagliflozin in the various environmental compartments is based on the default market penetration factor (Fpen = 0.01), as provided in the EMA guideline, and the highest maximum daily dose of 25 mg. The recommended maximum daily dose of the newly proposed indication (chronic heart failure) will only be 10 mg.

The default Fpen is based on a very conservative worst-case estimation, meaning that 1% of all EU inhabitants are treated 365 d/a with the recommended maximum daily dose. The market penetration factor was not refined though, e.g. by using the much smaller actual amount of substance placed on the market.

Therefore, the effects on the environment by adding the indication chronic heart failure with a much smaller patient group are considered negligible and well covered by the used Fpen.

Hence, the ERA submitted with the initial MAA remains valid for the current type II variation application covering the additional proposed indication.

<div style=\"page-break-after: always\"></div>

Table 1 Summary of main study results

| Substance (INN/Invented Name): Empagliflozin                     | Substance (INN/Invented Name): Empagliflozin                                                                        | Substance (INN/Invented Name): Empagliflozin                                                                                                                                                                                                                                                                                                                                                | Substance (INN/Invented Name): Empagliflozin                                                                        |
|------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------|
| CAS-number (if available): 864070-44-0                           | CAS-number (if available): 864070-44-0                                                                              | CAS-number (if available): 864070-44-0                                                                                                                                                                                                                                                                                                                                                      | CAS-number (if available): 864070-44-0                                                                              |
| PBT-assessment                                                   | PBT-assessment                                                                                                      | PBT-assessment                                                                                                                                                                                                                                                                                                                                                                              | PBT-assessment                                                                                                      |
| Parameter                                                        | Result relevant for conclusion                                                                                      |                                                                                                                                                                                                                                                                                                                                                                                             | Conclusion                                                                                                          |
| Bioaccumulation                                                  | log K ow                                                                                                            |                                                                                                                                                                                                                                                                                                                                                                                             | B/not B                                                                                                             |
| Bioaccumulation                                                  | BCF                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                                                             | B/not B                                                                                                             |
| Persistence                                                      | DT50 or ready biodegradability                                                                                      | Transformation product M3 (stereoisomer of empagliflozin) DT 50, sediment (12°C) =189.8/140.9d TP M12: DT 50, water (12°C) =79.8 d                                                                                                                                                                                                                                                          | vP (for trans- formation product M3, stereoisomer of empagliflozin)                                                 |
| Toxicity                                                         | NOEC or CMR                                                                                                         |                                                                                                                                                                                                                                                                                                                                                                                             | T/not T                                                                                                             |
| PBT-statement :                                                  | The compound is not considered as PBT nor vPvB The compound is considered as vPvB The compound is considered as PBT | The compound is not considered as PBT nor vPvB The compound is considered as vPvB The compound is considered as PBT                                                                                                                                                                                                                                                                         | The compound is not considered as PBT nor vPvB The compound is considered as vPvB The compound is considered as PBT |
| Phase I                                                          | Phase I                                                                                                             | Phase I                                                                                                                                                                                                                                                                                                                                                                                     | Phase I                                                                                                             |
| Aerobic and Anaerobic Transformation in Aquatic Sediment systems | OECD 308                                                                                                            | Empagliflozin, 20 °C DT 50, water =1.2/ 1.1 d DT 50, sediment = 2.6/ 1.9 d DT 50, whole system = 1.3 /1.3 d %shifting to sediment: > 10% NER max : 50.5/ 42.4% CO 2 : 37.7/ 34.8% Relevant transformation products: M1: 32.9% day 1 (water) 10.3% day 7 (sediment) M3: 13.5% day 28(sediment) M12: 17.4% day 14 (water) M3: DT 50,20°C sediment = 88.9/ 66 d M12: DT 50,20°C water = 70.9 d | sediment 1: sandy loam sediment 2: silt loam                                                                        |

## 3.2.3. Discussion on non-clinical aspects

Additional information has been provided on the pharmacologic effects on the cardiovascular system. Although several factors have been mentioned that may contribute to the positive actions of empagliflozin on heart function, the precise molecular mechanisms of these effects are not clear. The MAH suggested that SGLT-2 inhibition by empagliflozin reduces sodium reabsorption and increases the delivery of sodium to the distal tubule. This may influence several physiological functions including, but not restricted to, increasing tubuloglomerular feedback and reducing intraglomerular pressure, lowering both pre- and afterload of the heart, and downregulating of sympathetic activity. Furthermore, the empagliflozininduced increase in ketone bodies may play a role by increasing an uptake and oxidization of β -hydroxybutyrate by the heart resulting in an improved energy supply. The increase in plasma ketone bodies induced by SGLT2 inhibitors is in general mild and does usually not exceed the physiological range. It has also been suggested that SGLT-2 inhibition with empagliflozin may stimulate erythropoiesis via an early increase in erythropoietin production, which may contribute to improved myocardial tissue oxygenation and reduced left ventricular mass in the patients.

It is currently not clear which of the numerous potential mechanisms of action are of clinical relevance or which one would be the dominant one. The proposed mechanisms have been supported by the literature data and are considered acceptable.

<div style=\"page-break-after: always\"></div>

It is agreed with the MAH that the ERA conclusions, based on the previous ERA of empagliflozin remain unchanged. The MAH has provided an updated ERA table, including new calculations for all proposed indications of Jardiance. Hereby, the ERA data for Jardiance is considered complete.

## 3.2.4. Conclusion on the non-clinical aspects

Although several factors have been mentioned that may contribute to the positive actions of empagliflozin on heart function, the precise molecular mechanisms of these effects are not clear.  Several possible mechanisms may play a role, such as a reduced sodium readsorption in the proximal tubules, resulting in reduced intraflomerular pressure and lowered cardiac pre- and afterload; increased level of ketone bodies, improving cardiac energy supply by increasing cardiac uptake and oxidization of β -hydroxybutyrate; and increased erythropoiesis which may contribute to improved myocardial tissue oxygenation and reduced left ventricular mass in the patients. It is currently not clear which of the numerous potential mechanisms of action are of clinical relevance or which one would be the dominant one. The provided information is endorsed.

The following statement will be included in Section 5.1 of SmPC: ' Empagliflozin also reduces sodium reabsorption and increases the delivery of sodium to the distal tubule. This may influence several physiological functions including, but not restricted to, increasing tubuloglomerular feedback and reducing intraglomerular pressure, lowering both pre- and afterload of the heart, and downregulating of sympathetic activity .'

It is agreed with the MAH that the ERA conclusions, based on the previous ERA of empagliflozin remain unchanged. An updated ERA table, including new calculations for all proposed indications of Jardiance, has been provided. The DT50-values for total system, sediment and for empagliflozin and the relevant transformation products M3, M1 and M12 are included in the updated ERA as well as the proposed molecular structures of M3 and M1. It is also mentioned in the ERA that M3 is proposed to be a stereoisomer of the active substance empagliflozin and thus might be pharmacologically active. In addition, it is mentioned that M3 is very persistent in the sediment (DT50 &gt; 180 days) and M12 is persistent in water (DT50 &gt; 40 days).

## 3.3. Clinical aspects

## 3.3.1. Introduction

In support of the extension of indication application, the MAH submitted the results from 1 clinical pharmacology trials and 3 clinical efficacy/safety trials.

## GCP

According to the MAH, the trials were carried out in compliance with the CTP, in accordance with the principles of the Declaration of Helsinki, in accordance with the ICH GCP, and in accordance with applicable regulatory requirements and BI's standard operating procedures.

## 3.3.2. Pharmacokinetics

Based on the results of trial 1245.25 (EMPA-REG OUTCOME) in patients with T2D and established cardiovascular (CV) disease, a phase 3 program was initiated for empagliflozin 10 mg once daily in patients with chronic heart failure regardless of diabetes status. This included two pivotal CV outcome trials ('EMPEROR'), two functional capacity trials ('EMPERIAL') and a mechanistic phase III trial ('EMPA-

<div style=\"page-break-after: always\"></div>

VISION') in patients with heart failure with reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF).

As a measure of systemic drug exposure to empagliflozin, steady-state trough pharmacokinetic samples were taken in the EMPEROR-reduced trial in a subset of patients. This trial was a phase 3 randomised, double-blind trial that evaluated the efficacy and safety of once-daily empagliflozin 10 mg compared to placebo in patients with chronic heart failure with reduced ejection fraction (HFrEF). Randomisation was stratified by geographical region, history of diabetes mellitus, and eGFR (based on chronic kidney disease epidemiology collaboration (CKD-EPI) formula). Pre-dose samples were collected at week 12 (day 85) to determine steady-state plasma trough concentrations. Samples outside the planned time window of 22 to 26h after dosing were excluded from the descriptive analysis. The effect of demographic and baseline characteristics, including sex, age, body weight, body mass index (BMI), geographical region, investigator country, race, ethnicity, renal impairment, New York Heart Association (NYHA) classification, heart failure physiology (based on left ventricular ejection fraction (LVEF) and N-terminal prohormone of brain natriuretic peptide (NT-proBNP)) and diabetes status on empagliflozin trough concentrations was also investigated descriptively.

The pharmacokinetics results are presented below, including a comparison with the pharmacokinetics observed in other phase 3 trials.

## Pharmacokinetics in target population

## Study EMPEROR reduced - 1245.121

A total of 915 pre-dose samples were collected (438 in placebo group and 477 in empagliflozin group). A total of 308 empagliflozin trough concentrations were summarised descriptively. The geometric mean (Coefficient of Variation (CV)) steady state trough concentration are summarised in Table 2.

<div style=\"page-break-after: always\"></div>

Table 2 The geometric mean (geometric CV%) steady state trough concentration (nmol/L) of empagliflozin 10 mg on Day 85 in trial 1245.121

<!-- image -->

|                          | All                                   | All                                  | All                                  | All                   | All                   | All   |
|--------------------------|---------------------------------------|--------------------------------------|--------------------------------------|-----------------------|-----------------------|-------|
| gMean (%gCV), N          | 67.3 (91.8), 308                      | 67.3 (91.8), 308                     | 67.3 (91.8), 308                     |                       |                       |       |
| Sex                      | Female                                | Female                               | Male                                 | Male                  | Male                  |       |
| gMean (%gCV), N          | 67.9 (105), 65                        | 67.9 (105), 65                       | 67.2 (88.5), 243                     | 67.2 (88.5), 243      | 67.2 (88.5), 243      |       |
| Race                     | Asia                                  | Black                                | White                                |                       | Other                 |       |
| gMean (gCV%), N          | 68.9 (82.2), 172                      | 63.9 (76.2), 13                      | 65.8 (114), 110                      |                       | 63.4 (55.6),13        |       |
| Ethnicity                | Hispanic / Latino                     | Hispanic / Latino                    | Not Hispanic / Latino                | Not Hispanic / Latino | Not Hispanic / Latino |       |
| gMean (gCV%), N          | 70.1(108), 45                         | 70.1(108), 45                        | 66.9 (89.2), 263                     | 66.9 (89.2), 263      | 66.9 (89.2), 263      |       |
| Age [years]              | <50                                   | 50 to <65                            | 65 to <75                            |                       | ≥75                   |       |
| glMean (gCV%), N         | 40.9 (95.0), 22                       | 58.4 (98.5), 84                      | 67.8 (82.0), 112                     |                       | 86.1 (84.6), 90       |       |
| Weight group [kg]        | ≤50                                   | >50 to ≤70                           | >70 to ≤90                           |                       | >90                   |       |
| glMean (gCV%), N         | 90.4 (84.6), 34                       | 73.6 (89.2), 126                     | 63.1 (80.3), 101                     |                       | 49.3 (113), 47        |       |
| BMI [kg/m²]              | <25                                   | 25 to <30                            | 30 to<35                             |                       | ≥35                   |       |
| gMean (gCV%), N          | 74.7 (83.4), 160                      | 62.9 (95.6), 88                      | 61.0 (81.7),43                       |                       | 46.5 (164), 17        |       |
| eGFR [mL/min/1.73m²]     | ≥90                                   | 60≤ to <90                           | 30≤to <60                            |                       | 15≤to <30             |       |
| glMean (gCV%), N         | 42.1 (84.6), 40                       | 51.9 (92.3), 119                     | 92.5 (72.4), 125                     |                       | 103 (62.6), 24        |       |
| Geographical region      | Asia                                  | Europe                               | Latin America                        | North America         | North America         |       |
| gMean (gCV%), N          | 68.3 (81.2), 168                      | 71.9 (61.5), 13                      | 74.5 (115), 39                       | 74.5 (115), 39        | 62.1(107), 88         |       |
| Investigator country     | Canada                                | China Germany                        | Japan                                | Mexico United, States | Mexico United, States |       |
| gMean (gCV%), N          | 54.1 (101), 30                        | 50.9 71.9 (61.5), (93.8), 49 13      | 77.0 (71.2), 119                     | 74.5 (115), 39        | 66.7 (109), 58        |       |
| NYHA classification      | II1                                   | III                                  | III                                  | IV                    | IV                    |       |
| glMean (gCV%), N         | 68.6 (91.4), 240                      | 63.0 (94.2), 67                      | 63.0 (94.2), 67                      | Not reportable,1      | Not reportable,1      |       |
| Heart failure physiology | LVEF <= 30% andproNT- proBNP < median | LVEF <= 30% and NT- proBNP >= median | LVEF <= 30% and NT- proBNP >= median | LVEF > 30%            | LVEF > 30%            |       |
| gMean (gCV%), N          | 61.3 (102), 104                       | 75.8 (72.3), 94                      | 75.8 (72.3), 94                      | 66.5 (97.3), 110      | 66.5 (97.3), 110      |       |
| Statusofdiabetes         | Non-Diabetic                          | Non-Diabetic                         | Diabetic                             | Diabetic              | Diabetic              |       |
| gMean (gCV%), N          | 63.5 (94.4), 145                      | 63.5 (94.4), 145                     | 71.0 (89.2), 163                     | 71.0 (89.2), 163      | 71.0 (89.2), 163      |       |
| Statusofdiabetes         | Normal (not pre-diabetes)             | Pre-diabetes                         | Pre-diabetes                         | Diabetes              | Diabetes              |       |
| gMean (gCV%), N          | 54.5 (117), 37                        | 66.9 (86.3), 108                     | 66.9 (86.3), 108                     | 71.0 (89.2), 163      | 71.0 (89.2), 163      |       |

## Comparison across studies

The geometric mean steady-state trough concentration of empagliflozin 10 mg in trial 1245.121 was approximately 2-fold higher than that of empagliflozin 10 mg in the previous phase 3 trials in patients with T2D, but was lower or similar to those of empagliflozin 25 mg (Table 3 and Table 4).

<div style=\"page-break-after: always\"></div>

Table 3 Comparison on the descriptive statistics for steady state trough concentrations of empagliflozin [nmol/L] in trial 1245.121 versus Phase III studies in T2DM patients

<!-- image -->

|                        |                                          | Empagliflozin 10 mg in Phase II studies in T2DM Patients   | Empagliflozin 10 mg in Phase II studies in T2DM Patients   | Empagliflozin 10 mg in Phase II studies in T2DM Patients   | Empagliflozin 10 mg in Phase II studies in T2DM Patients   | Empagliflozin 10 mg in Phase II studies in T2DM Patients   | Empagliflozin 10 mg in Phase II studies in T2DM Patients   |
|------------------------|------------------------------------------|------------------------------------------------------------|------------------------------------------------------------|------------------------------------------------------------|------------------------------------------------------------|------------------------------------------------------------|------------------------------------------------------------|
| Descriptive Statistics | Empagliflozin 10 mg trial 1245.1211 85D* | trial 1245.192 85D*/169D*                                  | trial 1245.203 85D*169D*                                   | trial 1245.234 85D*/169D*                                  | trial 1245.234 85D*/169D*                                  | trial 1245.255 84D*/364D*                                  | trial 1245.366 85D*/169D*                                  |
|                        |                                          |                                                            |                                                            | metformin + sulfonylurea                                   | metformin                                                  |                                                            |                                                            |
| N                      | 308                                      | 137/129                                                    | 181/180                                                    | 179/176                                                    | 156/148                                                    | 740/641                                                    | 83/76                                                      |
| gMean                  | 67.3                                     | 35.4/38.1                                                  | 30.7/29.5                                                  | 33.1/27.4                                                  | 28.6/28.5                                                  | 35.8/38.1                                                  | 36.5/34.3                                                  |
| gCV (%)                | 91.8                                     | 112/124                                                    | 105/91.0                                                   | 86.1/88.1                                                  | 84.8/108                                                   | 92.3/93.0                                                  | 92.9/ 93.3                                                 |
| Mean                   | 89.5                                     | 58.1/64.8                                                  | 49.0/43.4                                                  | 48.0/38.7                                                  | 41.5/50.0                                                  | 51.7/57.0                                                  | 57.0/51.9                                                  |
| CV (%)                 | 84.4                                     | 137/134                                                    | 152/134                                                    | 132/137                                                    | 148/179                                                    | 127/148                                                    | 148/147                                                    |
| SD                     | 75.5                                     | 79.4/87.0                                                  | 74.7/58.3                                                  | 63.5/53.0                                                  | 61.4/89.3                                                  | 65.5/84.5                                                  | 84.7/76.2                                                  |
| Min                    | 2.59                                     | 5.00/2.33                                                  | 1.85/3.15                                                  | 7.21/1.20                                                  | 1.82/1.34                                                  | 1.76/1.39                                                  | 8.97/2.27                                                  |
| Median                 | 66.7                                     | 31.9/32.4                                                  | 29.0/28.5                                                  | 29.1/25.8                                                  | 26.8/23.6                                                  | 33.2/35.6                                                  | 30.7/31.6                                                  |
| Max                    | 494                                      | 411/474                                                    | 580/374                                                    | 471/503                                                    | 486/560                                                    | 527/925                                                    | 471/468                                                    |

Table 4 Comparison on the descriptive statistics for steady state trough concentrations of empagliflozin [nmol/L] in trial 1245.121 versus Phase III studies in T2DM patients

|                        |                                     | Empagliflozin 25 mg in Phase II studies in T2DM Patients   | Empagliflozin 25 mg in Phase II studies in T2DM Patients   | Empagliflozin 25 mg in Phase II studies in T2DM Patients   | Empagliflozin 25 mg in Phase II studies in T2DM Patients   | Empagliflozin 25 mg in Phase II studies in T2DM Patients   | Empagliflozin 25 mg in Phase II studies in T2DM Patients   | Empagliflozin 25 mg in Phase II studies in T2DM Patients   | Empagliflozin 25 mg in Phase II studies in T2DM Patients   |
|------------------------|-------------------------------------|------------------------------------------------------------|------------------------------------------------------------|------------------------------------------------------------|------------------------------------------------------------|------------------------------------------------------------|------------------------------------------------------------|------------------------------------------------------------|------------------------------------------------------------|
| Descriptive Statistics | Empagliflozin 10 mg trial 1245.1211 | trial 1245.192 85D*/169D*                                  | trial 1245.203 85D*/169D*                                  | trial 1245.234 85D*/169D*                                  | trial 1245.234 85D*/169D*                                  | trial 1245.255 84D*/364D*                                  | trial 1245.297 85D*/169D*                                  | trial 1245.288 84D*/196D*                                  | trial 1245.366 85D*/169D*                                  |
|                        | 85D*                                |                                                            |                                                            | metformin + sulfonylurea                                   | metformin                                                  |                                                            |                                                            |                                                            |                                                            |
| N                      | 308                                 | 138/141                                                    | 178/176                                                    | 171/162                                                    | 152/144                                                    | 753/661                                                    | 46 /41                                                     | 530/472                                                    | 252/250                                                    |
| gMean                  | 67.3                                | 72.9/76.0                                                  | 68.8/70.3                                                  | 81.3/82.9                                                  | 73.5/77.8                                                  | 86.6/90.8                                                  | 62.6/101                                                   | 63.3/69.9                                                  | 112/110                                                    |
| gCV (%)                | 91.8                                | 119/117                                                    | 94.9/118                                                   | 108/103                                                    | 109/131                                                    | 91.0/99.3                                                  | 181/125                                                    | 100/114                                                    | 86.1/101                                                   |
| Mean                   | 89.5                                | 117/127                                                    | 102/136                                                    | 142/133                                                    | 124/141                                                    | 123/138                                                    | 126/163                                                    | 98.6/121                                                   | 156/158                                                    |
| CV (%)                 | 84.4                                | 137/148                                                    | 146/291                                                    | 167/143                                                    | 181/162                                                    | 125/147                                                    | 178/121                                                    | 165/167                                                    | 118/114                                                    |
| SD                     | 75.5                                | 160/188                                                    | 148/394                                                    | 236/191                                                    | 225/228                                                    | 154/202                                                    | 223/196                                                    | 163/202                                                    | 183/179                                                    |
| Min                    | 2.59                                | 3.26/4.84                                                  | 3.13/3.40                                                  | 7.24/15.4                                                  | 4.79/1.28                                                  | 1.13/1.40                                                  | 2.25/9.85                                                  | 1.60/2.00                                                  | 10.2/1.67                                                  |
| Median                 | 66.7                                | 73.4/66.4                                                  | 64.9/66.1                                                  | 67.8/71.8                                                  | 69.6/71.2                                                  | 79.4/86.4                                                  | 64.4/92.7                                                  | 58.9/61.8                                                  | 111/106                                                    |
| Max                    | 494                                 | 1070/1080                                                  | 1060/4900                                                  | 1570/1080                                                  | 1860/1360                                                  | 1310/1930                                                  | 1400/929                                                   | 1710/1510                                                  | 1290/1310                                                  |

To understand the potential reason(s) for the relatively higher empagliflozin exposure observed in patients with HFrEF, the MAH conducted a comparison between trial 1245.121 and trial 1245.25. The demographic and baseline characteristics between patients in trial 1245.121 and trial 1245.25 were different with respect to race, eGFR, age, body weight, and BMI (Table 5).

<div style=\"page-break-after: always\"></div>

Table 5 Patients' distributions in different subgroups, by age, body weight, BMI, eGFR, and race in trial 1245.121 and trial 1245.25.

|                                             | trial 1245.121 Empagliflozin 10 mg          | trial 1245.25 Empagliflozin 10 mg           | trial 1245.25 Empagliflozin 25 mg           |
|---------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|
| Number of Patients [N (%)]                  | 363 (100.0)                                 | 740 (100.0)                                 | 753 (100.0)                                 |
| Age groups [years] [N (%)]                  | Age groups [years] [N (%)]                  | Age groups [years] [N (%)]                  | Age groups [years] [N (%)]                  |
| <50                                         | 24 (6.6)                                    | 50(6.8)                                     | 44(5.8)                                     |
| ≥ 50 and <65                                | 93 (25.6)                                   | 345(46.6)                                   | 374 (49.7)                                  |
| ≥65 and< 75                                 | 140 (38.6)                                  | 273 (36.9)                                  | 270 (35.9)                                  |
| ≥75                                         | 106 (29.2)                                  | 72 (9.7)                                    | 65 (8.6)                                    |
| Baseline body weight groups [kg] [N (%o)]   | Baseline body weight groups [kg] [N (%o)]   | Baseline body weight groups [kg] [N (%o)]   | Baseline body weight groups [kg] [N (%o)]   |
| ≤50                                         | 35 (9.6)                                    | 4 (0.5)                                     | 4 (0.5)                                     |
| >50 and ≤70                                 | 137 (37.7)                                  | 138 (18.6)                                  | 135 (17.9)                                  |
| >70 and ≤90                                 | 130 (35.8)                                  | 301 (40.7)                                  | 327 (43.4)                                  |
| >90                                         | 61 (16.8)                                   | 297 (40.1)                                  | 287 (38.1)                                  |
| Baseline BMI groups [kg/m²] [N(%)]          | Baseline BMI groups [kg/m²] [N(%)]          | Baseline BMI groups [kg/m²] [N(%)]          | Baseline BMI groups [kg/m²] [N(%)]          |
| <25                                         | 177 (48.8)                                  | 106 (14.3)                                  | 91 (12.1)                                   |
| ≥25 and <30                                 | 105 (28.9)                                  | 250 (33.8)                                  | 291 (38.6)                                  |
| ≥30 and< 35                                 | 57 (15.7)                                   | 249 (33.6)                                  | 232 (30.8)                                  |
| ≥35                                         | 24 (6.6)                                    | 135 (18.2)                                  | 139 (18.5)                                  |
| Baseline eGFR groups [mL/min/1.73m²] [N(%)] | Baseline eGFR groups [mL/min/1.73m²] [N(%)] | Baseline eGFR groups [mL/min/1.73m²] [N(%)] | Baseline eGFR groups [mL/min/1.73m²] [N(%)] |
| ≥ 90                                        | 43 (11.8)                                   | 159 (21.5)                                  | 158 (21.0)                                  |
| ≥ 60 and <90                                | 145 (39.9)                                  | 383 (51.8)                                  | 403 (53.5)                                  |
| ≥30 and <60                                 | 147 (40.5)                                  | 195 (26.4)                                  | 187 (24.8)                                  |
| ≥ 15 and <30                                | 28 (7.7)                                    | 3 (0.4)                                     | 4 (0.5)                                     |
| <15                                         | 0                                           | 0                                           | 0                                           |
| Missing                                     |                                             | 0                                           | 1 (0.1)                                     |
| Race [N (%)]                                | Race [N (%)]                                | Race [N (%)]                                | Race [N (%)]                                |
| White                                       | 150 (41.3)                                  | 552 (74.6)                                  | 551 (73.2)                                  |
| Black or Afiican American                   | 18 (5.0)                                    | 35 (4.7)                                    | 34 (4.5)                                    |
| Asian                                       | 181 (49.9)                                  | 152 (20.5)                                  | 164 (21.8)                                  |
| Other                                       | 14 (3.9)                                    | 1 (0.1)                                     | 4 (0.5)                                     |

In the cross-study comparison evaluation (c33061043), the trough concentration inclusion time window was defined differently from the CTR of 1245.121(c28576542). A wide time window (&gt;20 and &lt;28 h post the most recent dose) was applied to trial 1245.121 to be consistent with trial 1245.25.

For all subgroups, the geometric steady-state trough concentrations of empagliflozin 10 mg in trial 1245.121 were always higher (1.35 to 2.76-fold) than those of empagliflozin 10 mg in trial 1245.25, and were lower or similar (0.42 to 1.00-fold) to those of empagliflozin 25 mg in trial 1245.25.

<div style=\"page-break-after: always\"></div>

Table 6 Fold differences in the geometric mean steady-state trough concentrations of empagliflozin trial 1245.121 with respect to those in trial 1245.25 for different subgroups

<!-- image -->

| Subgroups    | Subgroups                   | N (Empa 10 mg in 1245.121/ Empa 10 mg in 1245.25/ Empa 25 mg in 1245.25)   |   Empa 10 mg in 1245.121 with respect to Empa 10 mg in 1245.25 |   Empa 10 mg in 1245.121 with respect to Empa 25 mg in 1245.25 |
|--------------|-----------------------------|----------------------------------------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|
| All patients | All patients                | 363/740/753                                                                |                                                           1.86 |                                                           0.77 |
|              | ≥ 90 mL/min/1.73 m²         | 44/159/158                                                                 |                                                           1.57 |                                                           0.67 |
|              | ≥60 and <90 mL/min/1.73 m²  | 143/383/403                                                                |                                                           1.59 |                                                           0.63 |
|              | ≥30 and <60 mL/min/1.73 m²  | 145/195/187                                                                |                                                           1.68 |                                                           0.72 |
|              | ≥ 15 and <30 mL/min/1.73 m² | 31/3/4                                                                     |                                                           1.44 |                                                           0.59 |
|              | < 50 years                  | 24/50/44                                                                   |                                                           1.58 |                                                           0.7  |
|              | ≥ 50 and < 65 years         | 93/345/374                                                                 |                                                           1.75 |                                                           0.75 |
|              | ≥65 and< 75 years           | 140/273/270                                                                |                                                           1.71 |                                                           0.67 |
|              | ≥ 75 years                  | 106/72/65                                                                  |                                                           1.69 |                                                           0.64 |
|              | ≤50 kg                      | 35/4/4                                                                     |                                                           2.75 |                                                           1    |
|              | >50 and ≤70 kg              | 137/138/135                                                                |                                                           1.7  |                                                           0.73 |
|              | >70 and ≤90 kg              | 130/301/327                                                                |                                                           1.82 |                                                           0.74 |
|              | >90 kg                      | 61/297/287                                                                 |                                                           1.48 |                                                           0.61 |
|              | <25 kg/ m²                  | 177/106/91                                                                 |                                                           1.7  |                                                           0.78 |
|              | ≥25 and <30 kg/ m²          | 105/250/291                                                                |                                                           1.79 |                                                           0.68 |
|              | ≥30 and < 35 kg/ m²         | 57/249/232                                                                 |                                                           1.78 |                                                           0.76 |
|              | ≥35 kg/ m²                  | 24/135/139                                                                 |                                                           1.35 |                                                           0.57 |
|              | Male                        | 291/542/568                                                                |                                                           1.94 |                                                           0.79 |
|              | Female                      | 72/198/185                                                                 |                                                           1.64 |                                                           0.71 |

<div style=\"page-break-after: always\"></div>

Table 7 Fold differences in the geometric mean steady state trough concentrations of empagliflozin trial 1245.121 with respect to those in trial 1245.25 for different subgroups.

<!-- image -->

| Subgroups      | Subgroups                 | N (Empa 10 mg in 1245.121/ Empa 10 mg in 1245.25/ Empa25mgin1245.25)   | Empa 10 mg in 1245.121 with respect to Empa 10 mg in 1245.25   |   Empa 10 mg in 1245.121 with respect to Empa 25 mg in 1245.25 |
|----------------|---------------------------|------------------------------------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|
|                | Asian                     | 181/152/164                                                            | 1.84                                                           |                                                           0.76 |
|                | Black or African American | 18/35/34                                                               | 1.60                                                           |                                                           0.58 |
|                | White                     | 150/552/551                                                            | 1.85                                                           |                                                           0.77 |
|                | Other                     | 14/1/4                                                                 | N.C.                                                           |                                                           0.42 |
|                | Hispanic                  | 51/95/89                                                               | 1.85                                                           |                                                           0.86 |
|                | Non-Hispanic              | 312/643/663                                                            | 1.86                                                           |                                                           0.76 |
| Smoking Status | Current Smoker            | 42/105/93                                                              | 2.00                                                           |                                                           0.81 |
| Smoking Status | Ex-Smoker                 | 181/355/372                                                            | 1.93                                                           |                                                           0.82 |
| Smoking Status | Never Smoked              | 134/280/288                                                            | 1.68                                                           |                                                           0.68 |
|                | Drinks Alcohol            | 135/318/311                                                            | 1.95                                                           |                                                           0.77 |
|                | Does not Drink Alcohol    | 217/422/442                                                            | 1.80                                                           |                                                           0.78 |

N.C.: not calculable due to sample size &lt;3 in the subgroup for empagliflozin 10 mg in trial 1245.25

Analysis of covariance (ANCOVA) was performed to compare (log-transformed) steady-state trough concentrations of empagliflozin 10 mg in 1245.121 versus empagliflozin 10 mg in 1245.25, adjusting for multiple demographic and baseline characteristics simultaneously. In this analysis, a stepwise selection method was first used to select predictor covariates one at a time to fit the best generalized linear model. Body weight and eGFR were selected as the predictor covariates. The other tested covariates, including age, BMI, race, ethnicity, sex, smoking status, alcohol use, liver function enzymes (alanine transaminase, aspartate transaminase, alkaline phosphatase), total protein were not selected, suggesting that they were not important in describing the differences between trial 1245.121 and trial 1245.25 once eGFR and body weight were included in the model.

After adjusting for eGFR and body weight, the difference in geometric empagliflozin steady-state trough concentration between trial 1245.121 and trial 1245.25 was reduced to 1.47-fold [95% confidence interval (CI): 1.33, 1.63]. The remaining 1.47-fold difference between trial 1245.121 and trial 1245.25 in empagliflozin steady-state trough exposure is not clear. The possibility of slightly altered empagliflozin PK due to changes in physiology induced by heart failure disease cannot be ruled out.

Analysis of covariance (ANCOVA) was also performed for patients with both T2DM and heart failure conditions in trial 1245.121 and trial 1245.25. In this subset of patients, body weight and eGFR were also selected as the predictor covariates, and after adjusting for eGFR and body weight, the difference in gMean steady-state trough concentration of empagliflozin between trial 1245.121 and trial 1245.25 was reduced to 1.53-fold [95% CI: 1.26, 1.85].

No clear differences were observed for sex, race, ethnicity, geographic region, NYHA classification or heart physiology stratifications. Also, no major differences are identified by diabetes status.

<div style=\"page-break-after: always\"></div>

## Pharmacokinetic interaction studies

Sacubitril/valsartan was used in approximately 20% of the randomized patients in trial 1245.121 since the beginning of the trial but was not used in trial 1245.25. Sacubitril was reported to be an OATP1B1 and OATP1B3 inhibitor, whereas empagliflozin is a substrate of OATP1B1 and OATP1B3. Patients with/without sacubitril/valsartan had, however, similar empagliflozin trough concentrations (Figure 1).

Figure 1  Steady state trough concentration of empagliflozin 10 mg in trial 1245.121 by use of ARNi at baseline

<!-- image -->

No clear difference between patients with or without sacubitril/valsartan in the trough concentration of empagliflozin can be observed. Therefore, any interaction appears not to be clinically relevant.

## 3.3.3. Pharmacodynamics

## Mechanism of action

Empagliflozin is a reversible, highly potent (IC50 of 1.3 nmol) and selective competitive inhibitor of sodium-glucose co-transporter 2 (SGLT2). Empagliflozin does not inhibit other glucose transporters important for glucose transport into peripheral tissues and is 5000 times more selective for SGLT2 versus SGLT1, the major transporter responsible for glucose absorption in the gut. SGLT2 is highly expressed in the kidney, whereas expression in other tissues is absent or very low. It is responsible, as the predominant transporter, for the reabsorption of glucose from the glomerular filtrate back into the circulation. In patients with type 2 diabetes and hyperglycaemia, a higher amount of glucose is filtered and reabsorbed.

Empagliflozin improves glycaemic control in patients with type 2 diabetes by reducing renal glucose reabsorption. The amount of glucose removed by the kidney through this glucuronic mechanism is dependent on blood glucose concentration and GFR. Inhibition of SGLT2 in patients with type 2 diabetes and hyperglycaemia leads to excess glucose excretion in the urine. In addition, initiation of empagliflozin increases excretion of sodium, resulting in osmotic diuresis and reduced intravascular volume.

<div style=\"page-break-after: always\"></div>

In patients with type 2 diabetes, urinary glucose excretion increased immediately following the first dose of empagliflozin and is continuous over the 24-hour dosing interval. Increased urinary glucose excretion was maintained at the end of the 4-week treatment period, averaging approximately 78 g/day. Increased urinary glucose excretion resulted in an immediate reduction in plasma glucose levels in patients with type 2 diabetes.

Empagliflozin improves both fasting and post-prandial plasma glucose levels. The mechanism of action of empagliflozin is independent of beta-cell function and insulin pathway, and this contributes to a low risk of hypoglycaemia. Improvement of surrogate markers of beta-cell function, including Homeostasis Model Assessmentβ (HOMA -β) was noted. In addition, urinary glucose excretion triggers calorie loss, associated with body fat loss and body weight reduction. The glucosuria observed with empagliflozin is accompanied by diuresis, which may contribute to sustained and moderate reduction of blood pressure.

Empagliflozin also reduces sodium reabsorption and increases the delivery of sodium to the distal tubule. This may influence several physiological functions including, but not restricted to, increasing tubuloglomerular feedback and reducing intraglomerular pressure, lowering both pre- and afterload of the heart, and downregulating of sympathetic activity.

## 3.3.4. Discussion and Conclusions on clinical pharmacology

The pharmacokinetics in patients with HFrEF are clearly different from patients with T2D as almost a doubling in trough concentrations is observed. The differences can partly be explained by the difference in body weight and renal function between these populations. The trough concentrations, however, do not exceed the trough concentrations observed in T2D patients with the currently registered 25 mg dose. Therefore, no safety issues are to be expected as a result of this phenomenon.

The MAH describes as pharmacodynamic properties that empagliflozin lowers both pre- and afterload of the heart by increasing the tubuloglomerular feedback and reducing intraglomerular pressure due to increased delivery of sodium to the distal tubule. This is added to the SmPC.

The MAH provided an additional review of clinical data describing potential mechanism of action. Although uncertainties remain and the clinical study of Griffin et al. 2020 included a small number of subjects (n=20), the suggested mechanism of action described in the SmPC Section 5.1 are considered plausible and supported by these studies.

Other suggested mechanisms i.e. change in ketone metabolism and/or increase in erythrocytes are not included in the SmPC as research is still ongoing.

<div style=\"page-break-after: always\"></div>

## 3.3.5. Clinical efficacy

## 3.3.6. Dose response study(ies)

N.A.

## 3.3.7. Main study(ies)

The EMPEROR trials are phase III international, multicentre, double-blind, parallel-group, placebocontrolled, event-driven trials and are pivotal outcome trials that investigate the long-term effect of empagliflozin in reducing the risk of hospitalisation for HF and of cardiovascular death in patients with heart failure.

The EMPERIAL trials are additional supportive trials that investigated the short-term (12 weeks) effect of empagliflozin on functional capacity, signs and symptoms of heart failure and quality of life.

The EMPA-VISION trial is a supporting trial investigating the short-term (12 weeks) effects of empagliflozin on mechanistic cardiac physiology and metabolism.

The EMPEROR-reduced trial (1245.121) and the EMPERIAL trials (1245.168 and 1245.167) have been completed, and the clinical trial reports are available.

EMPA-VISION (1245.148) had been completed clinically, and the reporting of results is ongoing. The EMPEROR-preserved trial (1245.110) is still ongoing.

Based on the results of the pivotal trial 1245.121, BI sought a new indication for empagliflozin to reduce the risk of cardiovascular death and hospitalisation for heart failure and to slow kidney function decline in adult patients with heart failure (NYHA class II-IV) with reduced ejection fraction.

This section summarises the efficacy results from the EMPEROR-reduced (1245.121) and the EMPERIAL trials (1245.168 and 1245.167).

## Methods

## Trial design

BI initiated a Phase III program for empagliflozin 10 mg once daily in chronic heart failure regardless of diabetes status. There are two CV outcome trials ('EMPEROR'), two functional capacity trials ('EMPERIAL'), and a mechanistic Phase III trial ('EMPA-VISION') in patients with HFrEF (reduced ejection fraction) and HFpEF (preserved ejection fraction).

All 5 trials are placebo-controlled, randomised (empagliflozin 10 mg to placebo 1:1), double-blind, and parallel-group by design (Table 8).

Table 8 Clinical trials in patients with chronic heart failure

| Trial no.                                                 | Phase                                                     | No. randomised                                            | Patient population                                        | Treatment duration                                        | First patient screened                                    | Last patient completed                                    |
|-----------------------------------------------------------|-----------------------------------------------------------|-----------------------------------------------------------|-----------------------------------------------------------|-----------------------------------------------------------|-----------------------------------------------------------|-----------------------------------------------------------|
| CV outcome trials ('EMPEROR-preserved/reduced')           | CV outcome trials ('EMPEROR-preserved/reduced')           | CV outcome trials ('EMPEROR-preserved/reduced')           | CV outcome trials ('EMPEROR-preserved/reduced')           | CV outcome trials ('EMPEROR-preserved/reduced')           | CV outcome trials ('EMPEROR-preserved/reduced')           | CV outcome trials ('EMPEROR-preserved/reduced')           |
| 1245.121                                                  | III                                                       | 3730                                                      | HFrEF (LVEF ≤40%)                                         | Event driven                                              | Apr 2017                                                  | May 2020                                                  |
| 1245.110                                                  | III                                                       | 5988                                                      | HFpEF (LVEF >40%)                                         | Event driven                                              | Mar 2017                                                  | Q2 2021 (planned)                                         |
| Functional capacity trials ('EMPERIAL-preserved/reduced') | Functional capacity trials ('EMPERIAL-preserved/reduced') | Functional capacity trials ('EMPERIAL-preserved/reduced') | Functional capacity trials ('EMPERIAL-preserved/reduced') | Functional capacity trials ('EMPERIAL-preserved/reduced') | Functional capacity trials ('EMPERIAL-preserved/reduced') | Functional capacity trials ('EMPERIAL-preserved/reduced') |
| 1245.168                                                  | III                                                       | 312                                                       | HFrEF                                                     | 12 weeks                                                  | Mar 2018                                                  | Oct 2019                                                  |
| 1245.167                                                  | III                                                       | 315                                                       | HFpEF                                                     | 12 weeks                                                  | Apr 2018                                                  | Oct 2019                                                  |

<div style=\"page-break-after: always\"></div>

|   Mechanistic cardiac physiology and metabolism ('EMPA-VISION') | Mechanistic cardiac physiology and metabolism ('EMPA-VISION')   |   Mechanistic cardiac physiology and metabolism ('EMPA-VISION') | Mechanistic cardiac physiology and metabolism ('EMPA-VISION')   | Mechanistic cardiac physiology and metabolism ('EMPA-VISION')   | Mechanistic cardiac physiology and metabolism ('EMPA-VISION')   | Mechanistic cardiac physiology and metabolism ('EMPA-VISION')   |
|-----------------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|
|                                                         1245.15 | III                                                             |                                                              72 | HFrEF/HFpEF separate cohorts                                    | 12 weeks                                                        | Mar 2018                                                        | May 2020                                                        |

## Main Study EMPEROR-reduced trial (1245.121)

## Study participants

## Inclusion criteria

The key eligibility criteria for the EMPEROR trials are shown in Table 9, i.e. a population of T2DM and nonT2DM, aged &gt; 18 years, chronic HF (NYHA class II-IV).

## Table 9 Key eligibility criteria for the EMPEROR trials

Age ≥18 years Chronic HF New York heart association (NYHA) class II to IV eGFR (CKD-EPI)cr ≥20 mL/min/1.73 m 2

Reduced EF (LVEF ≤40%) and elevated NT

-proBNP for patients with/without atrial fibrillation or atrial flutter (AF):

| LVEF                                                                    | NT-proBNP without AF   | NT-proBNP with AF   |
|-------------------------------------------------------------------------|------------------------|---------------------|
| 36 to 40%                                                               | ≥2500 pg/ml            | ≥5000 pg/ml         |
| 31 to 35%                                                               | ≥1000 pg/ml            | ≥2000 pg/ml         |
| ≤30%                                                                    | ≥600 pg/ml             | ≥1200 pg/ml         |
| ≤40% and HHF ≤12 months( For patients not meeting the categories above) | ≥600 pg/ml             | ≥1200 pg/ml         |

Stable therapy for hospitalisation for heart failure (HF) consistent with local and international cardiology guidelines

## Exclusion criteria

Cardiovascular diseases or treatments that increase the unpredictability of or change the patients' clinical course, independent of heart failure:

- o Myocardial infarction (increase in cardiac enzymes in combination with symptoms of ischemia or new ischemic ECG changes), coronary artery bypass graft surgery, or other major cardiovascular surgery, stroke or transient ischemic attack in past 90 days
- o Heart transplant recipient or listed for heart transplant. Currently implanted left ventricular assist device
- o Cardiomyopathy based on infiltrative diseases (e.g. amyloidosis), accumulation diseases (e.g. haemochromatosis, Fabry disease), muscular dystrophies, cardiomyopathy with reversible causes (e.g. stress cardiomyopathy), hypertrophic obstructive cardiomyopathy, or known pericardial constriction
- o Diagnosis of peripartum cardiomyopathy or cardiomyopathy induced by chemotherapy within 12months
- o Any severe (obstructive or regurgitant) valvular heart disease expected to lead to surgery during the trial period
- o Acute decompensated heart failure requiring intravenous diuretics, vasodilators, inotropic agents or mechanical support within 1 week of screening and during the screening period prior to randomization
- o ICD or cardiac resynchronization therapy within 3 months prior to screening or if there is an intent to implant either device for 3 months following screening

Untreated or undertreated cardiovascular conditions that might influence the course of heart failure or tolerability of the study medications:

<div style=\"page-break-after: always\"></div>

- o Atrial fibrillation or atrial flutter with a resting heart rate &gt;110 bpm, documented by ECG at screening
- o Untreated ventricular arrhythmia with syncope in a patient without an ICD within 3 months prior to screening
- o Symptomatic bradycardia or second-or third-degree heart block without a pacemaker after adjustment of beta-blocker therapy, if appropriate
- o Systolic blood pressure ≥ 180mmHg at randomization. If systolic blood pressure is 151 -179 mmHg, the patient should be receiving ≥ 3 anti-hypertensive drugs
- o Symptomatic hypotension and/or a systolic blood pressure &lt;100mmHg at screening or at randomization

Significant co-morbid conditions that might influence the clinical course, independent of heart failure:

- o Chronic pulmonary disease requiring home oxygen, oral corticosteroid therapy or hospitalization for exacerbation within 12months; significant chronic pulmonary disease; or primary pulmonary arterial hypertension
- o Acute or chronic liver disease, defined by serum levels of transaminases or alkaline phosphatase more than three times the upper limit of normal at screening
- o Impaired renal function, defined as eGFR &lt;20 mL/min/1.73m2(CKD-EPI) or requiring dialysis at the time of screening
- o Hemoglobin &lt;9 g/dL at screening
- o Major surgery (major according to the investigator's assessment) performed within 90 daysprior to screening, or major scheduled elective surgery (e.g. hip replacement) within 90 days after screening
- o Gastrointestinal surgery or gastrointestinal disorder that could interfere with trial medication absorption
- o Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cellcarcinoma of the skin, in situ carcinoma of uterine cervix, or low risk prostate cancer (patients with pre-treatment PSA&lt;10 ng/mL, and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) · Presence of any other disease than heart failure with a life expectancy of &lt;1 year (in the opinion of the investigator)

Any condition that might jeopardize patient safety, limit the patients' participation in the trial, or undermine the interpretation of trial data:

- o Current use or prior use of a SGLT2 inhibitor or combined inhibitor of SGLT1 and SGLT2 within 12 weeks prior to screening or randomization.
- o Discontinuation of a SGLT2 inhibitor or combined inhibitor of SGLT1 and SGLT2 inhibitor for the purposes of study enrolment is not permitted
- o Known allergy or hypersensitivity to any SGLT2 inhibitors
- o History of ketoacidosis
- o Patients who must or wish to continue the intake of restricted medications or any drug considered likely to interfere with the safe conduct of the trial
- o Currently enrolled in another investigational device or drug study or are less than 30 days since the completion of a trial of another investigational device or drug study. Any patient receiving any investigational treatment other than the study medications for this trial
- o Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, will make the patient unlikely to fulfil the trial requirements or complete the trial
- o Women who are pregnant or are nursing or who plan to become pregnant while in the trial
- o Any other clinical condition that would jeopardize patient safety while participating in this trial or may prevent the subject from adhering to the trial protocol

<div style=\"page-break-after: always\"></div>

## Treatments

In the EMPEROR trial, all the patients were receiving appropriate treatments for heart failure, including diuretics, inhibitors of the renin-angiotensin system and neprilysin, beta-blockers, mineralocorticoid receptor antagonists, and, when indicated, cardiac devices. The design of the study included a screening period of 4-28 days, a randomized, double-blind treatment period (event-driven study duration), in which eligible patients started with 10 mg empagliflozin or matching placebo. The median follow up was 16 months of treatment. After the end of treatment, a follow-up period was used in which each subject will be followed for 30 days after the last treatment dose (see Figure 2).

Figure 2 Study design CV outcome trials ('EMPEROR-Reduced/Preserved')

Aim: To investigate the safety and efficacy of empagliflozin versus placebo on top of guideline-directed medical therapyinpatientswithheartfailurewithreduced orpreservedejectionfraction

Population:T2DM and non-T2DM,aged≥18years,chronic HF(NYHAclass II-IV)

<!-- image -->

## Objectives

The aim of the EMPEROR-reduced trial is to investigate the safety and efficacy of empagliflozin versus placebo on top of guideline-directed medical therapy in patients with HFrEF.

## Outcomes/endpoints

The following endpoints were pre-specified for 1245.121:

- Primary endpoint (confirmatory): the time to first event of adjudicated CV death or adjudicated HHF
- Key secondary endpoints (confirmatory):
- o Occurrence of adjudicated HHF (first and recurrent)
- o eGFR (CKD-EPI)cr slope of change from baseline
- Other secondary endpoints (exploratory):
- o Time to the first event in the composite renal endpoint: chronic dialysis (defined as dialysis with a frequency of twice per week or more for at least 90 days), renal transplant, or sustained 2  reduction in eGFR (CKD-EPI)cr   , measured by two or more consecutive postbaseline central laboratory measurements separated by at least 30 days (the first to last of the consecutive eGFR values), a reduction in eGFR from baseline of ≥40%, eGFR &lt;15 mL/min/1.73 m 2 for patients with baseline eGFR ≥30 mL/min/1 .73 m 2 , or eGFR &lt;10 mL/min/1.73 m 2  for patients with baseline eGFR &lt;30 mL/min/1.73 m 2
- o Time to first adjudicated HHF
- o Time to adjudicated CV death
- o Time to all-cause mortality
- o Time to onset of DM (defined as HbA1c ≥6.5% or as diagnosed by the investigator) i n patients with pre-DM   (defined as no history of DM and no HbA1c ≥6.5% before treatment, and a pre-treatment HbA1c value of ≥5.7% and &lt;6.5%)

<div style=\"page-break-after: always\"></div>

- o Change from baseline in Kansas City cardiomyopathy questionnaire (KCCQ) clinical summary score (measuring HF symptoms (frequency and burden) and physical limitations) at Week 52
- o Occurrence of all-cause hospitalisation (first and recurrent)
- Further endpoints (exploratory) include time to or occurrence of CV and/or renal events, progression or reversal of albuminuria, changes from baseline in eGFR, KCCQ scores, NYHA class, EQ-5D, NT-proBNP, albuminuria, body weight, blood pressure, pulse rate, HbA1c, FPG, etc.

## Sample size

This was an event-based trial. For the sample size calculation, a yearly event rate in the placebo group of 15% was assumed. The trial was designed to have a power of 90% for the primary endpoint at two-sided α of 0.05 to detect a hazard ratio of 0.8 between empagliflozin and placebo. Based on these assumptions, at least 841 confirmed primary events were to be observed and at least 2825 patients randomised and treated, given an accrual period of 18 months and a follow-up period of 20 months. The EMPERORreduced trial (1245.121) included 3730 subjects.

## Randomisation and Blinding

Subjects who fulfil all eligibility criteria were randomized double -blind in a 1:1 manner. Randomization was performed with a computer pseudo -random number generator and is stratified by (i) geographical region (North America, Latin America, Europe, Asia, other); (ii) diabetes status at screening; and (iii) estimated glomerular filtration rate (GFR) at screening (&lt;60 or ≥ 60 ml per minute per 1.73 m2 of body surface area), according to the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.

## Statistical methods

The trial was designed to have a power of 90% for the primary endpoint at twosided α of 0.05 to detect a hazard ratio of 0.8 between empagliflozin and placebo, which required at least 841 adjudicated primary endpoint events. After 544 events (planned approximately 500 events or about 60% of information), an interim analysis was performed by the independent Data monitoring committee (DMC). If the p-value for both the primary endpoint and for CV-death at the interim anal ysis were lower than α interim, the trial would be stopped for overwhelming efficacy. After the interim analysis, the DMC recommended continuing the trial as planned. The final α was therefore one -sided 0.0248, which was equivalent to twosided 0.0496. A hierarchical procedure (see Figure 3) was applied to the primary and key secondary endpoints. If a confirmatory endpoint was successful (i.e. empagliflozin superior to placebo), the α would be used for the subsequent step(s). If a confirmatory endpoint was not successful, all subsequent endpoints would be evaluated in an exploratory manner. After evaluation of the first key secondary endpoint (recurrent HHF), α was to be split into 0.001 (two -sided) for the analysis of eGFR slope, and the rest transferred to an efficacy metaanalysis. If the eGFR slope analysis was successful, the α of this branch would also be transferred to the meta-analysis.

<div style=\"page-break-after: always\"></div>

Figure 3  Overview of the planned hierarchical testing strategy

<!-- image -->

1 Based on 544 adjudicated primary endpoint events at the interim analysis, according to the α -spending function 2 Depends on the actual number of adjudicated primary endpoint events at the interim analysis, according to the α -spending function

If a test is successful (null hypothesis rejected), the corresponding alpha portion is maintained for the subsequent test. If a test is unsuccessful, the alpha portion is lost.

Unless otherwise specified, efficacy analyses followed the ITT principle and included all randomised patients (RS; treatment assigned as randomised) and all available data up to the planned treatment discontinuation (including 'off-treatment' data during unplanned treatment interruptions and after premature treatment discontinuations). Unless otherwise specified, the outcome events were based on adjudication results from the clinical event committee (CEC), according to prespecified definitions in the CEC charter.

## Primary endpoint (time to adjudicated CV death or HHF)

The primary analysis was a Cox regression with factors treatment, region (Asia, Europe, Latin America, North America, and other), baseline diabetes status (diabetic, pre-diabetes, and normal), age (continuous), sex, baseline LVEF ( ≤ 30%, &gt;30% to ≤ 35%, &gt;35%), and baseline eGFR (CKD-EPI)cr (continuous). Region, diabetes history, and eGFR (CKD-EPI)cr (&lt;60 or ≥ 60 mL/min/1.73 m ² ) at screening were randomisation stratification factors. Following the ITT principle, all data up to the end of the planned treatment period (including the data after the end of treatment for patients not completing the treatment period as planned) from all randomised patients were used. Patients without a specific endpoint event were considered censored at the last date, the patient was known to be free of the event or at the end of the planned treatment period, whichever was earlier. Cumulative incidence function curves that account for competing risks (i.e. non-CV deaths) and Kaplan-Meier curves of time to censoring were displayed. The individual components that contributed to the primary endpoint were summarized descriptively. Subgroup analyses by demographic and baseline characteristics (e.g. comorbidities, risk factors, and background HF medications) were carried out.

<div style=\"page-break-after: always\"></div>

## Key secondary endpoint 1 (adjudicated recurrent HHF)

The primary analysis for recurrent HHF used a joint frailty model that accounts for the dependence between recurrent HHF and CV death, with the same covariates used for the primary endpoint. All data up to the end of the planned treatment period (including the data after the end of treatment for patients not completing the treatment period as planned) from all randomised patients were used. The number of HHF events per patient was summarized descriptively. Negative binomial models were additionally fitted for recurrent HHF events. The mean cumulative incidence was displayed for adjudicated recurrent HHF. Subgroup analyses were carried out.

## Key secondary endpoint 2 (eGFR slope of change from baseline)

The primary analysis was a random coefficient model allowing for random intercept and random slope per patient, with the same factors used for the primary endpoint and additional factors 'time', 'treatment-bytime interaction', and 'baseline eGFR (CKD-EPI)cr-by-time interaction'. Only 'on-treatment' data (i.e. measurements up to 1 day after the last intake of study medication) were used. Subgroup analyses were carried out.

## Other secondary and further endpoints (exploratory)

Exploratory efficacy endpoints were analysed in the following way in general:

- Time-to-event endpoints: similar to the primary analysis of the primary endpoint. Subgroup analyses were performed for time to CV death and time to first HHF
- Recurrent events endpoints: similar to the primary analysis of the first key secondary endpoint

- Continuous endpoints: a mixed model repeated measure (MMRM) analysis

- Categorical endpoints: descriptive

## Results

## Participant flow

This trial was a multicentre trial conducted globally, see Table 10. Inclusion for the EMPEROR-reduced trial was from April 2017 through November 2019. The final date of follow-up data collection for the double-blind treatment period was April 29, 2020.

Table 10 Overview of screened and randomised patients by region in 1245.121

| Geographical region   | Countries                                                                                            |   Patients screened |   Patients randomised |
|-----------------------|------------------------------------------------------------------------------------------------------|---------------------|-----------------------|
| Total                 | 20 countries                                                                                         |                7220 |                  3730 |
| Europe                | Poland, Netherlands, Hungary, Germany, Czech Republic, Italy, France, Spain, United Kingdom, Belgium |                2359 |                  1353 |
| Latin America         | Brazil, Argentina, Mexico                                                                            |                2724 |                  1286 |
| Asia                  | Japan, China, Korea                                                                                  |                 771 |                   493 |
| North America         | United States, Canada                                                                                |                1049 |                   425 |
| Other                 | India, Australia                                                                                     |                 317 |                   173 |

About half of the screened patients (48.3%) were not randomised, most commonly because of NT-proBNP levels being below protocol-specified thresholds at screening (36.1% of screened patients). Of the 3730 randomised patients, 3688 patients (98.9%) had complete follow-up for the primary endpoint and the

<div style=\"page-break-after: always\"></div>

final vital status was known for 3709 patients (99.4%); see Table 11 and Figure 24. Of the 3726 patients treated with study medication, 993 patients prematurely discontinued treatment (26.7%, including patients who died). The most common reason for premature discontinuation of study medication was an AE (8.7% of patients with non-fatal events and 9.5% with fatal events).

Table 11 Disposition of patients in 1245.121

|                                             | Placebo N (%)   | Empa 10 mg N (%)   | Total N (%)   |
|---------------------------------------------|-----------------|--------------------|---------------|
| Screened                                    |                 |                    | 7220          |
| Randomised                                  | 1867 (100.0)    | 1863 (100.0)       | 3730 (100.0)  |
| Final vital status known                    | 1857 (99.5)     | 1852 (99.4)        | 3709 (99.4)   |
| Alive                                       | 1583 (84.8)     | 1591 (85.4)        | 3174 (85.1)   |
| Deceased                                    | 274 (14.7)      | 261 (14.0)         | 535 (14.3)    |
| Vital status unknown                        | 10 (0.5)        | 11 (0.6)           | 21 (0.6)      |
| Completed trial or died 1                   | 1847 (98.9)     | 1841 (98.8)        | 3688 (98.9)   |
| Prematurely discontinued trial              | 20 (1.1)        | 22 (1.2)           | 42 (1.1)      |
| Consent withdrawn                           | 9 (0.5)         | 11 (0.6)           | 20 (0.5)      |
| Limited follow-up agreed 2                  | 2 (0.1)         | 2 (0.1)            | 4 (0.1)       |
| Lost to follow-up to the primary endpoint 3 | 9 (0.5)         | 9 (0.5)            | 18 (0.5)      |
| Treated                                     | 1863 (100.0)    | 1863 (100.0)       | 3726 (100.0)  |
| Completed treatment                         | 1352 (72.6)     | 1381 (74.1)        | 2733 (73.3)   |
| Prematurely discontinued study medication   | 511 (27.4)      | 482 (25.9)         | 993 (26.7)    |
| Adverse event                               | 343 (18.4)      | 337 (18.1)         | 680 (18.3)    |
| Non-fatal events                            | 167 (9.0)       | 158 (8.5)          | 325 (8.7)     |
| Worsening of HF                             | 45 (2.4)        | 38 (2.0)           | 83 (2.2)      |
| Worsening of other pre-existing disease     | 20 (1.1)        | 20 (1.1)           | 40 (1.1)      |
| Other                                       | 102 (5.5)       | 100 (5.4)          | 202 (5.4)     |
| Fatal events                                | 176 (9.4)       | 179 (9.6)          | 355 (9.5)     |
| Worsening of HF                             | 56 (3.0)        | 50 (2.7)           | 106 (2.8)     |
| Worsening of other pre-existing disease     | 8 (0.4)         | 10 (0.5)           | 18 (0.5)      |
| Other                                       | 112 (6.0)       | 119 (6.4)          | 231 (6.2)     |
| Non-compliance with protocol                | 5 (0.3)         | 5 (0.3)            | 10 (0.3)      |
| Lost to follow-up                           | 11 (0.6)        | 17 (0.9)           | 28 (0.8)      |
| Withdrawal by patient                       | 124 (6.7)       | 92 (4.9)           | 216 (5.8)     |
| Other reason                                | 28 (1.5)        | 31 (1.7)           | 59 (1.6)      |

<div style=\"page-break-after: always\"></div>

Figure 4 Patient Recruitment and Disposition

<!-- image -->

Incomplete follow-up for the primary endpoint refers to incomplete information on either vital status or hospitalization until the planned end of the treatment period for those patients who had not experienced an adjudicated primary outcome. The 21 patients without known vital status at the end of the trial included 11 on empagliflozin and 10 on placebo. Three patients with missing vital status at the end of the trial experienced an adjudicated hospitalization for heart failure and are not considered to have an incomplete follow-up for the primary endpoint

## Baseline data

Patients in this trial represented a population with chronic heart failure with reduced ejection fraction (mean LVEF 27.5%, SD 6.0) with a NYHA class of II (75.1%), III (24.4%), or IV (20 patients, 0.5%). The average age was 66.8 years (SD 11.0); 23.9% were women, 70.5% White, 18.0% Asian, and 6.9% Black/African American. About half of patients (49.8%) had T2DM, and about half (48.2%) had an eGFR of &lt;60 mL/min/1.73 m 2  (of whom 205 patients, 5.5%, had an eGFR of &lt;30) at baseline. At study baseline, 31.4% had a defibrillator (ICD or CRT-D), 11.8% had a CRT, 88.3% were treated with ACE inhibitors/ARBs/ARNi (19.5% ARNi), 94.7% with beta-blockers, and 95.0% with diuretics (71.3% MRAs).

Details are provided below.

## Demographic characteristics

About three quarters of the patients were men. The majority of the patients were White (70.5%) and elderly (62.1% of patients were ≥ 65 years old, including 26.8% of patients ≥ 75 years old). See Table 12 for details.

Table 12  Demographic data in 1245.121

|                           | Placebo      | Empa 10 mg   | Total        |
|---------------------------|--------------|--------------|--------------|
| Number of patients, N (%) | 1867 (100.0) | 1863 (100.0) | 3730 (100.0) |
| Sex, N (%)                |              |              |              |
| Male                      | 1411 (75.6)  | 1426 (76.5)  | 2837 (76.1)  |

<div style=\"page-break-after: always\"></div>

| Female                     | 456 (24.4)   | 437 (23.5)   | 893 (23.9)   |
|----------------------------|--------------|--------------|--------------|
| Race (summary), N (%)      |              |              |              |
| White                      | 1304 (69.8)  | 1325 (71.1)  | 2629 (70.5)  |
| Black/African American     | 134 (7.2)    | 123 (6.6)    | 257 (6.9)    |
| Asian                      | 335 (17.9)   | 337 (18.1)   | 672 (18.0)   |
| Other including mixed race | 63 (3.4)     | 51 (2.7)     | 114 (3.1)    |
| Ethnicity, N (%)           |              |              |              |
| Not Hispanic/Latino        | 1178 (63.1)  | 1164 (62.5)  | 2342 (62.8)  |
| Hispanic/Latino            | 613 (32.8)   | 616 (33.1)   | 1229 (32.9)  |
| Region, N (%)              |              |              |              |
| North America              | 213 (11.4)   | 212 (11.4)   | 425 (11.4)   |
| Latin America              | 645 (34.5)   | 641 (34.4)   | 1286 (34.5)  |
| Europe                     | 677 (36.3)   | 676 (36.3)   | 1353 (36.3)  |
| Asia                       | 245 (13.1)   | 248 (13.3)   | 493 (13.2)   |
| Other                      | 87 (4.7)     | 86 (4.6)     | 173 (4.6)    |
| Age [years], mean (SD)     | 66.5 (11.2)  | 67.2 (10.8)  | 66.8 (11.0)  |
| <65, N (%)                 | 740 (39.6)   | 675 (36.2)   | 1415 (37.9)  |
| <50                        | 162 (8.7)    | 121 (6.5)    | 283 (7.6)    |
| 50 to <65                  | 578 (31.0)   | 554 (29.7)   | 1132 (30.3)  |
| ≥65, N (%)                 | 1127 (60.4)  | 1188 (63.8)  | 2315 (62.1)  |
| 65 to <75                  | 631 (33.8)   | 685 (36.8)   | 1316 (35.3)  |
| ≥75                        | 496 (26.6)   | 503 (27.0)   | 999 (26.8)   |
| 75 to <85                  | 455 (24.4)   | 445 (23.9)   | 900 (24.1)   |
| ≥85                        | 41 (2.2)     | 58 (3.1)     | 99 (2.7)     |

Patients with information missing are not shown

## Baseline characteristics and variables

Patients in this trial had an LVEF of ≤ 40%. Mean LVEF was 27.5%, and almost three-quarters of the patients had a value of ≤ 30%. Median NT-proBNP was 1910 pg/ml (Q1, Q3 1115, 3481). The majority of patients had SBP &lt;140 mmHg and DBP &lt;90 mmHg. eGFR &lt;60 mL/min/1.73 m2 was reported for 48.2% of patients, with 198 patients (5.3%) in the range of 20 to &lt;30 mL/min/1.73 m2. Normal UACR was reported for 55.7% of patients, while 33.1% of patients had microalbuminuria and 10.6% had macroalbuminuria. A history of atrial fibrillation or atrial flutter was reported for 38.6% of patients. Half of the patients were reported with type 2 diabetes, and none were reported with type 1 diabetes (Table 13).

Table 13 Baseline characteristics in 1245.121

|                                          | Placebo           | Empa 10 mg        | Total             |
|------------------------------------------|-------------------|-------------------|-------------------|
| Number of patients, N (%)                | 1867 (100.0)      | 1863 (100.0)      | 3730 (100.0)      |
| LVEF [%], mean (SD)                      | 27.2 (6.1)        | 27.7 (6.0)        | 27.5 (6.0)        |
| <20%, N (%)                              | 185 (9.9)         | 136 (7.3)         | 321 (8.6)         |
| 20 to 30%, N (%)                         | 1207 (64.6)       | 1201 (64.5)       | 2408 (64.6)       |
| >30 to 35%, N (%)                        | 361 (19.3)        | 398 (21.4)        | 759 (20.3)        |
| >35, N (%)                               | 114 (6.1)         | 128 (6.9)         | 242 (6.5)         |
| NT-proBNP [pg/ml]                        |                   |                   |                   |
| All patients, median (Q1, Q3)            | 1926 (1153, 3525) | 1887 (1077, 3429) | 1910 (1115, 3481) |
| Patients with no AF from baseline ECG, N | 1436              | 1493              | 2929              |
| Median (Q1, Q3)                          | 1719 (1016, 3155) | 1662 (973, 3214)  | 1698 (997, 3188)  |
| Patients with AF from baseline ECG, N    | 424               | 360               | 784               |
| Median (Q1, Q3)                          | 2524 (1659, 4450) | 2556 (1769, 4422) | 2529 (1704, 4437) |
| Blood pressure                           |                   |                   |                   |

<div style=\"page-break-after: always\"></div>

|                                                                           | Placebo      | Empa 10 mg   | Total        |
|---------------------------------------------------------------------------|--------------|--------------|--------------|
| SBP [mmHg], mean (SD)                                                     | 121.4 (15.4) | 122.6 (15.9) | 122.0 (15.6) |
| DBP [mmHg], mean (SD)                                                     | 73.7 (10.6)  | 74.0 (11.0)  | 73.9 (10.8)  |
| SBP <140 mmHg and DBP <90 mmHg, N (%)                                     | 1539 (82.4)  | 1469 (78.9)  | 3008 (80.6)  |
| SBP ≥140 mmHg or DBP ≥90 mmHg, N (%)                                      | 328 (17.6)   | 394 (21.1)   | 722 (19.4)   |
| Heart rate [bpm], mean (SD)                                               | 71.5 (11.8)  | 71.0 (11.7)  | 71.3 (11.7)  |
| BMI [kg/m 2 ], mean (SD)                                                  | 27.78 (5.33) | 27.97 (5.45) | 27.88 (5.39) |
| <30 kg/m 2 , N (%)                                                        | 1300 (69.6)  | 1263 (67.8)  | 2563 (68.7)  |
| ≥30 kg/m 2 , N (%)                                                        | 567 (30.4)   | 600 (32.2)   | 1167 (31.3)  |
| eGFR (CKD-EPI) [ml/min/1.73 m 2 ], mean (SD)                              | 62.2 (21.5)  | 61.8 (21.7)  | 62.0 (21.6)  |
| ≥60, N (%)                                                                | 960 (51.4)   | 969 (52.0)   | 1929 (51.7)  |
| ≥90                                                                       | 220 (11.8)   | 229 (12.3)   | 449 (12.0)   |
| 60 to <90                                                                 | 740 (39.6)   | 740 (39.7)   | 1480 (39.7)  |
| <60, N (%)                                                                | 906 (48.5)   | 893 (47.9)   | 1799 (48.2)  |
| 45 to <60                                                                 | 467 (25.0)   | 433 (23.2)   | 900 (24.1)   |
| 30 to <45                                                                 | 349 (18.7)   | 345 (18.5)   | 694 (18.6)   |
| 20 to <30                                                                 | 89 (4.8)     | 109 (5.9)    | 198 (5.3)    |
| <20                                                                       | 1 (0.1)      | 6 (0.3)      | 7 (0.2)      |
| UACR [mg/g], N (%)                                                        |              |              |              |
| Normal (<30)                                                              | 1040 (55.7)  | 1038 (55.7)  | 2078 (55.7)  |
| Microalbuminuria (30 to ≤300)                                             | 628 (33.6)   | 608 (32.6)   | 1236 (33.1)  |
| Macroalbuminuria (>300)                                                   | 189 (10.1)   | 207 (11.1)   | 396 (10.6)   |
| Patients with history of AF 1 , N (%)                                     | 738 (39.5)   | 703 (37.7)   | 1441 (38.6)  |
| Investigator-reported medical history                                     |              |              |              |
| Atrial fibrillation                                                       | 695 (37.2)   | 659 (35.4)   | 1354 (36.3)  |
| Atrial flutter                                                            | 116 (6.2)    | 135 (7.2)    | 251 (6.7)    |
| Baseline ECG                                                              | 424 (22.7)   | 360 (19.3)   | 784 (21.0)   |
| Atrial flutter                                                            | 30 (1.6)     | 25 (1.3)     | 55 (1.5)     |
| Atrial fibrillation                                                       | 396 (21.2)   | 337 (18.1)   | 733 (19.7)   |
| Patients with history of atrial fibrillation 1                            | 705 (37.8)   | 664 (35.6)   | 1369 (36.7)  |
| Diabetes status                                                           |              |              |              |
| Without diabetes, N (%)                                                   | 938 (50.2)   | 936 (50.2)   | 1874 (50.2)  |
| Without diabetes or pre-diabetes, N (%)                                   | 302 (16.2)   | 304 (16.3)   | 606 (16.2)   |
| With pre-diabetes 2 , N (%)                                               | 636 (34.1)   | 632 (33.9)   | 1268 (34.0)  |
| With diabetes, N (%)                                                      | 929 (49.8)   | 927 (49.8)   | 1856 (49.8)  |
| T2DM 3 , N (%)                                                            | 929 (49.8)   | 927 (49.8)   | 1856 (49.8)  |
| Investigator-reported medical history                                     | 799 (42.8)   | 787 (42.2)   | 1586 (42.5)  |
| Previously undiagnosed diabetes                                           | 129 (6.9)    | 140 (7.5)    | 269 (7.2)    |
| Missing information above and stratified to the group of diabetes via IRT | 1 (0.1)      | 0            | 1 (<0.1)     |
| T1DM 4 , N (%)                                                            | 0            | 0            | 0            |
| HbA 1c [%], mean (SD)                                                     | 7.39 (1.59)  | 7.40 (1.55)  | 7.40 (1.57)  |

Patients with missing information are not shown. AF Atrial fibrillation or flutter

1  Investigator-reported medical history or baseline ECG finding

2  Including patients with no investigator-reported medical history of diabetes and pretreatment HbA1c ≥5.7% and &lt;6.5%, or patients stratified to the group of pre-diabetes via IRT and pretreatment HbA1c &lt;6.5% (if available), or patients stratified to the group of no diabetes via IRT and pretreatment HbA1c ≥5.7% and &lt;6.5%

3  Patients without T1DM and with investigator-reported medical history of diabetes, or patients with previously undiagnosed diabetes (pretreatment HbA1c ≥6.5%), or (in case the information above was missing) patients stratified to the group of diabetes via IRT

4  Patients with investigator-reported medical history of diabetes and the type was T1DM

<div style=\"page-break-after: always\"></div>

## Heart failure-related medical history

Most patients were in NYHA class II or III. More than 40% of patients had been diagnosed with HF more than 5 years before the trial. The cause of HF was ischaemic for 51.7% of patients. A total of 31.4% of patients had a defibrillator, and 11.8% had a CRT device (Table 14)

Table 14 Heart failure-related medical history in 1245.121

|                                               | Placebo      | Empa 10 mg   | Total        |
|-----------------------------------------------|--------------|--------------|--------------|
| Number of patients, N (%)                     | 1867 (100.0) | 1863 (100.0) | 3730 (100.0) |
| NYHA class at baseline, N (%)                 |              |              |              |
| I                                             | 0            | 0            | 0            |
| II                                            | 1401 (75.0)  | 1399 (75.1)  | 2800 (75.1)  |
| III                                           | 455 (24.4)   | 455 (24.4)   | 910 (24.4)   |
| IV                                            | 11 (0.6)     | 9 (0.5)      | 20 (0.5)     |
| Time since diagnosis of HF [years], mean (SD) | 6.3 (6.5)    | 6.0 (6.1)    | 6.1 (6.3)    |
| ≤1, N (%)                                     | 340 (18.2)   | 352 (18.9)   | 692 (18.6)   |
| >1 to 5, N (%)                                | 705 (37.8)   | 710 (38.1)   | 1415 (37.9)  |
| >5 to 10, N (%)                               | 414 (22.2)   | 422 (22.7)   | 836 (22.4)   |
| >10, N (%)                                    | 408 (21.9)   | 379 (20.3)   | 787 (21.1)   |
| Cause of HF, N (%)                            |              |              |              |
| Ischaemic                                     | 946 (50.7)   | 983 (52.8)   | 1929 (51.7)  |
| Hypertensive                                  | 220 (11.8)   | 233 (12.5)   | 453 (12.1)   |
| Valvular heart disease                        | 43 (2.3)     | 62 (3.3)     | 105 (2.8)    |
| Diabetic                                      | 27 (1.4)     | 20 (1.1)     | 47 (1.3)     |
| Alcoholism                                    | 21 (1.1)     | 20 (1.1)     | 41 (1.1)     |
| Idiopathic                                    | 331 (17.7)   | 306 (16.4)   | 637 (17.1)   |
| Other                                         | 279 (14.9)   | 239 (12.8)   | 518 (13.9)   |
| Use of devices prior to baseline, N (%)       |              |              |              |
| Defibrillator (ICD or CRT-D)                  | 593 (31.8)   | 578 (31.0)   | 1171 (31.4)  |
| CRT (CRT-D or CRT-P)                          | 222 (11.9)   | 220 (11.8)   | 442 (11.8)   |
| Non-CRT pacemaker                             | 62 (3.3)     | 52 (2.8)     | 114 (3.1)    |

Patients with information missing are not shown

ICD, implantable cardioverter defibrillator; CRT, cardiac resynchronisation therapy (D for defibrillator and P for pacemaker)

## Concomitant therapies at baseline

For all but 2 patients heart failure medication at baseline was documented. A total of 88.3% of patients used ACE inhibitors/ARBs/ARNi at baseline, 19.5% used ARNi, 94.7% used beta-blockers, 95.0% used diuretics, and 71.3% used MRAs (Table 15)

Table 15 Patients taking drugs used in heart failure, anti-hypertensives, antithrombotic, or lipid-lowering drugs at baseline in 1245.121

|                             | Placebo N (%)   | Empa 10 mg N (%)   | Total N (%)   |
|-----------------------------|-----------------|--------------------|---------------|
| Number of patients          | 1867 (100.0)    | 1863 (100.0)       | 3730 (100.0)  |
| Drugs used in heart failure | 1866 (99.9)     | 1862 (99.9)        | 3728 (99.9)   |
| ACE inhibitors/ARBs/ARNi    | 1652 (88.5)     | 1641 (88.1)        | 3293 (88.3)   |
| ACE inhibitors/ARBs         | 1286 (68.9)     | 1314 (70.5)        | 2600 (69.7)   |
| ARNi                        | 387 (20.7)      | 340 (18.3)         | 727 (19.5)    |
| Beta-blockers               | 1768 (94.7)     | 1765 (94.7)        | 3533 (94.7)   |
| Diuretics                   | 1790 (95.9)     | 1755 (94.2)        | 3545 (95.0)   |

<div style=\"page-break-after: always\"></div>

| Mineralocorticoid receptor antagonists (MRAs)   | 1355 (72.6)   | 1306 (70.1)   | 2661 (71.3)   |
|-------------------------------------------------|---------------|---------------|---------------|
| Loop or high ceiling diuretics                  | 1588 (85.1)   | 1562 (83.8)   | 3150 (84.5)   |
| Ivabradine                                      | 125 (6.7)     | 135 (7.2)     | 260 (7.0)     |
| Cardiac glycosides                              | 311 (16.7)    | 283 (15.2)    | 594 (15.9)    |
| Nitrates                                        | 256 (13.7)    | 240 (12.9)    | 496 (13.3)    |
| Hydralazine                                     | 65 (3.5)      | 61 (3.3)      | 126 (3.4)     |
| Other anti-hypertensives                        | 131 (7.0)     | 151 (8.1)     | 282 (7.6)     |
| Lipid-lowering drugs                            | 1302 (69.7)   | 1311 (70.4)   | 2613 (70.1)   |
| Anti-thrombotic drugs                           | 1528 (81.8)   | 1538 (82.6)   | 3066 (82.2)   |

ARB: excluding valsartan when taken with sacubitril, because sacubitril/valsartan is shown as ARNi.

## Concomitant therapies during the trial

Concomitant therapies at baseline or any time up to the end of the planned treatment period were balanced across the treatment groups (Table 16)

Table 16 Patients taking drugs used in heart failure, anti-hypertensives, antithrombotic, or lipid-lowering drugs at baseline or any time up to the end of planned treatment period in 1245.121

|                                | Placebo N (%)   | Empa 10 mg N (%)   | Total N (%)   |
|--------------------------------|-----------------|--------------------|---------------|
| Number of patients             | 1867 (100.0)    | 1863 (100.0)       | 3730 (100.0)  |
| Drugs used in heart failure    | 1867 (100.0)    | 1862 (99.9)        | 3729 (100.0)  |
| ACE inhibitors/ARBs/ARNi       | 1714 (91.8)     | 1688 (90.6)        | 3402 (91.2)   |
| ACE inhibitors/ARBs            | 1360 (72.8)     | 1366 (73.3)        | 2726 (73.1)   |
| ARNi                           | 518 (27.7)      | 461 (24.7)         | 979 (26.2)    |
| Beta-blockers                  | 1803 (96.6)     | 1794 (96.3)        | 3597 (96.4)   |
| Diuretics                      | 1823 (97.6)     | 1793 (96.2)        | 3616 (96.9)   |
| MRAs                           | 1477 (79.1)     | 1396 (74.9)        | 2873 (77.0)   |
| Loop or high ceiling diuretics | 1684 (90.2)     | 1627 (87.3)        | 3311 (88.8)   |
| Ivabradine                     | 154 (8.2)       | 156 (8.4)          | 310 (8.3)     |
| Cardiac glycosides             | 388 (20.8)      | 348 (18.7)         | 736 (19.7)    |
| Nitrates                       | 354 (19.0)      | 334 (17.9)         | 688 (18.4)    |
| Hydralazine                    | 102 (5.5)       | 97 (5.2)           | 199 (5.3)     |
| Other anti-hypertensives       | 194 (10.4)      | 202 (10.8)         | 396 (10.6)    |
| Lipid-lowering drugs           | 1370 (73.4)     | 1386 (74.4)        | 2756 (73.9)   |
| Anti-thrombotic drugs          | 1603 (85.9)     | 1588 (85.2)        | 3191 (85.5)   |

ARB: excluding valsartan when taken with sacubitril, because sacubitril/valsartan is shown as ARNi.

Intensification of diuretic therapy after baseline was less frequent in the empagliflozin group vs placebo (16.0 vs 22.2% of patients), while a decrease of diuretic therapy was more frequent in the empagliflozin group vs placebo (15.1 vs 13.2%).

## Heart Failure Outcomes

## Primary outcome - CV death or HHF

The primary endpoint was the time to the first event of adjudicated CV death or adjudicated hospitalisation for heart failure. The primary analysis was a Cox regression based on all data up to the end of the planned treatment period (including the data after the end of treatment for patients not completing the treatment period as planned) from all randomised patients. Patients without a specific

<div style=\"page-break-after: always\"></div>

endpoint event were censored at the last date the patient was known to be event free or at the end of the planned treatment period, whichever was earlier.

CV death or HHF occurred in a lower proportion of patients in the empagliflozin group (361 of 1863 patients, 19.4%) than in the placebo group (462 of 1867 patients, 24.7%), and the risk of CV death or HHF was significantly reduced with empagliflozin treatment compared with placebo (HR empagliflozin vs. placebo 0.75; 95% CI 0.65 to 0.86, p&lt;0.0001; Table 17). During the trial period, the number of patients who would need to have been treated with empagliflozin to prevent one primary event (NNT) was 19 (95% CI, 13 to 37). The treatment effect of empagliflozin became apparent shortly after randomisation and was maintained throughout the trial (Figure 5). The number of patients with a HHF or CV death during the 30 days after treatment discontinuation was the same in each treatment arm (122 patients, 6.9%).

Table 17 Time to the first event of adjudicated CV death or HHF, Cox regression, trial 1245.121

|                                      | Placebo      | Empa 10 mg        |
|--------------------------------------|--------------|-------------------|
| Analysed patients, N (%)             | 1867 (100.0) | 1863 (100.0)      |
| Patients with event, N (%)           | 462 (24.7)   | 361 (19.4)        |
| HHF as the first event               | 341 (18.3)   | 246 (13.2)        |
| CV death as the first event          | 120 (6.4)    | 115 (6.2)         |
| Both on the same day                 | 1 (0.1)      | 0                 |
| Incidence rate per 100 years at risk | 21.00        | 15.77             |
| Hazard ratio vs. placebo (95% CI)    |              | 0.75 (0.65, 0.86) |
| (95.04% CI) 1                        |              | (0.65, 0.86)      |
| p-value                              |              | <0.0001           |

Cox regression model included factors age, baseline eGFR (CKD-EPI)cr, region, baseline diabetes status, sex, baseline LVEF, and treatment

1  Based on the reduced 2sided α level of 0.0496 resulting from the interim analysis

<div style=\"page-break-after: always\"></div>

Figure 5 Time to the first event of adjudicated CV death or HHF, estimated cumulative incidence function (considering non-CV death as a competing risk), trial 1245.121

<!-- image -->

In general, the results were consistent across the pre-defined subgroups by demographics, baseline characteristics (including T2DM status), and baseline HF medications, with the HR point estimate for all subgroups below (Figure 6). The subgroup analyses were not adjusted for multiple testing.

<div style=\"page-break-after: always\"></div>

Figure 6 Subgroup analyses for the time to the first event of adjudicated CV death or HHF, Cox regression, trial 1245.121

<!-- image -->

| Subgroup                       | Nwithevent/N analysed    | Nwithevent/N analysed   | Hazard ratio                      | Interaction   | Empabetter   | Placebobetter   |
|--------------------------------|--------------------------|-------------------------|-----------------------------------|---------------|--------------|-----------------|
| Category                       | Empa10mg vs              | Placebo                 | (95% CI)                          | p-value       | ←            |                 |
| Overall                        | 361/1863                 | 462/1867                | 0.75 (0.65,0.86)                  |               |              | HH              |
| BaselineDiabetesStatus         |                          |                         |                                   | 0.5690        |              |                 |
| Diabetic                       | 200/927                  | 265/ 929                | 0.72 (0.60,0.87)                  |               | 工⊥           |                 |
| Non-Diabetic                   | 161/ 936                 | 197/938                 | 0.78 (0.64,0.97)                  |               |              | T               |
| Age [years]                    |                          |                         |                                   | 0.4909        |              |                 |
| <65                            | 128/ 675                 | 193/ 740                | 0.71 (0.57,0.89)                  |               |              |                 |
| ≥65                            | 233/1188                 | 269/1127                | 0.78 (0.66,0.93)                  |               |              |                 |
| Sex                            |                          |                         |                                   | 0.0837        |              |                 |
| Male                           | 294/1426                 | 353/1411                | 0.80 (0.68,0.93)                  |               |              |                 |
| Female                         | 67/ 437                  | 109/ 456                | 0.59 (0.44,0.80)                  |               |              |                 |
| Race                           |                          |                         |                                   | 0.0082        |              |                 |
| White                          | 264/1325                 | 289/1304                | 0.88 (0.75,1.04)                  |               |              |                 |
| Black/African-American         | 24/ 123                  | 48/ 134                 | 0.46 (0.28,0.75)                  |               |              |                 |
| Asian                          | 62/ 337                  | 99/335                  | 0.57 (0.41,0.78)                  |               |              |                 |
| Otherincludingmixedrace        | 5/51                     | 14/63                   | 0.41 (0.15,1.14)                  |               |              |                 |
| Baseline BMI[kg/m2]            |                          |                         |                                   | 0.1694        |              |                 |
| <30                            | 226/1263                 | 322/1300                | 0.70 (0.59,0.83)                  |               |              |                 |
| ≥30                            | 135/ 600                 | 140/ 567                | 0.85 (0.67,1.08)                  |               |              |                 |
| BaselineeGFR(CKD-EPI)          |                          |                         |                                   | 0.1428        |              |                 |
| [mL/min/1.73m2]                |                          |                         |                                   |               |              |                 |
| ≥60                            | 159/969                  | 224/ 960                | 0.67 (0.55,0.83)                  |               |              |                 |
| <60                            | 202/ 893                 | 237/ 906                | 0.83 (0.69,1.00)                  |               |              |                 |
| History of HHF (in the last 12 |                          |                         |                                   | 0.4498        |              |                 |
| months)                        |                          |                         |                                   |               |              |                 |
| No                             | 208/1286                 | 285/1293                | 0.71 (0.60,0.85)                  |               |              |                 |
| Yes                            | 153/577                  | 177/ 574                | 0.79 (0.64,0.99)                  |               |              |                 |
| CauseofHeartfailure            |                          |                         |                                   | 0.1485        |              |                 |
| Ischemic                       | 207/ 983                 | 236/ 946                | 0.82 (0.68,0.99)                  |               |              |                 |
| Non-ischemic                   | 154/880                  | 226/ 921                | 0.67 (0.55,0.82)                  |               |              |                 |
| Baseline NYHA                  |                          |                         |                                   | 0.2716        |              |                 |
| II                             | 220/1399                 | 299/1401                | 0.71 (0.59,0.84)                  |               |              |                 |
| I/IV                           | 141/ 464                 | 163/ 466                | 0.83 (0.66,1.04)                  |               |              |                 |
| Heart FailurePhysiology        |                          |                         |                                   | 0.0420        |              |                 |
| LVEF≤30% andNTproBNP<median    | 80/699                   | 115/ 724                | 0.70 (0.53,0.93)                  |               |              |                 |
| LVEF≤30% and NTproBNP≥ median  | 169/ 631                 | 249/ 661                | 0.65 (0.53,0.79)                  |               |              |                 |
| LVEF >30%                      | 108/526                  | 97/ 475                 | 0.99 (0.76,1.31)                  |               |              |                 |
| Baselineuse ofMRA              |                          |                         |                                   | 0.9345        |              |                 |
| No                             | 118/ 557                 | 132/ 512                | 0.76 (0.59,0.97)                  |               |              |                 |
| Yes                            | 243/1306                 | 330/1355                | 0.75 (0.63,0.88)                  |               |              |                 |
| Baseline use ofARNi No Yes     | 310/1523 369/1480 51/340 | 93/387                  | 0.77 (0.66,0.90) 0.64 (0.45,0.89) | 0.3101 0.125  | 0.25         | 王 0.5 1 2 4     |

## Key Secondary endpoint - first and recurrent HHF

A lower proportion of patients in the empagliflozin group (246 patients, 13.2%) than in the placebo group (342 patients, 18.3%) had an adjudicated HHF event, and the total number of HHF events (first and recurrent) was also lower in the empagliflozin group (388) than in the placebo group (553). Treatment with empagliflozin reduced the risk of recurrent HHF by 30% compared with placebo (HR 0.70, 95.04% CI 0.58 to 0.85, p = 0.0003, Table 18)

Table 18 Result secondary endpoint: occurrence of adjudicated HHF (first and recurrent), joint frailty model, trial 1245.121

|                                                   | Placebo           | Empa 10 mg   |
|---------------------------------------------------|-------------------|--------------|
| Analysed patients, N (%)                          | 1867 (100.0)      | 1863 (100.0) |
| Patients with HHF, N (%)                          | 342 (18.3)        | 246 (13.2)   |
| Total number of HHF events                        | 553               | 388          |
| Hazard ratio vs placebo of recurrent HHF (95% CI) | 0.70 (0.58, 0.85) |              |
| (95.04% CI) 1                                     | (0.58, 0.85)      |              |

Hazardratio

<div style=\"page-break-after: always\"></div>

All p-values are 2-sided, if not otherwise specified

1  Based on the reduced 2sided α level of 0.0496 resulting from the interim analysis

The treatment effect of empagliflozin became apparent shortly after randomisation and was maintained throughout the trial (Figure 7)

Figure 7 Occurrence of adjudicated HHF (first and recurrent), mean cumulative function, trial 1245.121

<!-- image -->

All pre-specified sensitivity analyses were consistent with the primary analysis for recurrent HHF. The subgroup analyses of recurrent HHF showed similar trends to those observed for the primary endpoint, with the point estimate for all subgroups below 1.

## Other HHF-related endpoints

Exploratory HHF-related endpoints corroborated the treatment benefit of empagliflozin on reducing the risk of recurrent HHF (Figure 8)

<div style=\"page-break-after: always\"></div>

Figure 8 HHF-related endpoints, trial 1245.121

<!-- image -->

|                                       | Empagliflozin10mg   | Empagliflozin10mg   | Placebo          | Placebo       |                      |                   |
|---------------------------------------|---------------------|---------------------|------------------|---------------|----------------------|-------------------|
|                                       | N with events       | Rate/ 100 PY        | N with events    | Rate/ 100 PY  |                      | HR (95% CI)       |
| Firstandrecurrent HHF1 (confirmatory) | 388HHF events       | 388HHF events       | 553HHF events    | 553HHF events |                      | 0.70 (0.58, 0.85) |
| First HHF2                            | 246/1863 (13.2%)    | 10.75               | 342/1867 (18.3%) | 15.55         |                      | 0.69 (0.59, 0.81) |
| Firstinvestigator- defined HHF2       | 317/1863 (17.0%)    | 14.16               | 429/1867 (23.0%) | 20.08         |                      | 0.71 (0.61,0.82)  |
|                                       |                     |                     |                  |               | Favoursempagliflozin | Favours placebo   |

1  Key secondary endpoint; joint frailty model that accounts for the dependence between recurrent HHF and CV death

2  Cox regression, time-to-event analysis

The HHF results were supported by a higher win ratio for empagliflozin vs placebo (1.33, 95% CI 1.16,

1.54) when accounting for clinical hierarchies, where CV death was considered more important than HHF.

In line with the improvements in HF outcomes, there was a decrease in NT-proBNP levels in the empagliflozin group compared with placebo (adjusted gMean ratio of relative change to baseline at Week 52 for empagliflozin vs placebo 0.87, 95% CI 0.82, 0.93).

## Mortality endpoints - secondary endpoint

Fewer patients were reported with all-cause, CV, or non-CV mortality in the empagliflozin group than in the placebo group, but the treatment effects were not significant on a nominal level. The majority of the deaths were due to CV causes, and most of the CV deaths were classified as sudden cardiac death (empagliflozin: 70 patients, 3.8%; placebo: 81 patients, 4.3%) and heart failure death (empagliflozin: 64 patients, 3.4%; placebo: 62 patients, 3.3%), as expected in a population with heart failure (Figure 9). Further details are described below.

Figure 9 Time to all-cause mortality, CV death, and non-CV death, Cox regression, trial 1245.121

<!-- image -->

|                                      | Empagliflozin10 mg   | Empagliflozin10 mg   | Placebo          | Placebo               |                   |
|--------------------------------------|----------------------|----------------------|------------------|-----------------------|-------------------|
|                                      | Nwith events         | Rate/ 100PY          | N with events    | Rate/ 100PY           | HR (95% CI)       |
| All-cause mortality 249/1863 (13.4%) |                      | 10.06                | 266/1867 (14.2%) | 10.71                 | 0.92 (0.77,1.10)  |
| CV death                             | 187/1863 (10.0%)     | 7.55                 | 202/1867 (10.8%) | 8.13                  | 0.92 (0.75, 1.12) |
| Non-CV death                         | 62/1863 (3.3%)       | 2.50                 | 64/1867 (3.4%)   | 2.58                  | 0.91 (0.64, 1.30) |
|                                      |                      |                      |                  | Favours empagliflozin | Favours placebo   |

<div style=\"page-break-after: always\"></div>

## Time to all-cause mortality

The time to all-cause mortality was a secondary endpoint. Death from any cause occurred in 249 patients (13.4%) in the empagliflozin group and 266 patients (14.2%) in the placebo group (HR 0.92, 95% CI 0.77 to 1.10, nominal p = 0.3536). The majority of the deaths were due to CV causes (Table 19). The Kaplan-Meier estimate of time to all-cause mortality is displayed in Figure 10.

Table 19 Time to all-cause mortality, CV death, and non-CV death, Cox regression, trial 1245.121

|                                          | Placebo           | Empa 10 mg        |
|------------------------------------------|-------------------|-------------------|
| Analysed patients, N (%)                 | 1867 (100.0)      | 1863 (100.0)      |
| Patients with all-cause mortality, N (%) | 266 (14.2)        | 249 (13.4)        |
| Incidence rate per 100 years at risk     | 10.71             | 10.06             |
| Hazard ratio vs. placebo (95% CI)        | 0.92 (0.77, 1.10) | 0.92 (0.77, 1.10) |
| Nominal p-value                          | 0.3536            | 0.3536            |
| Patients with CV death, N (%)            | 202 (10.8)        | 187 (10.0)        |
| Incidence rate per 100 years at risk     | 8.13              | 7.55              |
| Hazard ratio vs. placebo (95% CI)        | 0.92 (0.75, 1.12) | 0.92 (0.75, 1.12) |
| Nominal p-value                          | 0.4133            | 0.4133            |
| Patients with non-CV death, N (%)        | 64 (3.4)          | 62 (3.3)          |
| Incidence rate per 100 years at risk     | 2.58              | 2.50              |
| Hazard ratio vs. placebo (95% CI)        | 0.91 (0.64, 1.30) | 0.91 (0.64, 1.30) |
| Nominal p-value                          | 0.6143            | 0.6143            |

Cox regression model included factors age, baseline eGFR (CKD-EPI)cr, region, baseline diabetes status, sex, baseline LVEF, and treatment

<div style=\"page-break-after: always\"></div>

Figure 10 Time to all-cause mortality, Kaplan-Meier estimate, trial 1245.121

<!-- image -->

## Time to CV death

The time to adjudicated CV death was an exploratory secondary endpoint. Adjudicated CV death occurred in 187 patients (10.0%) in the empagliflozin group and 202 patients (10.8%) in the placebo group (HR 0.92, 95% CI 0.75 to 1.12, nominal p = 0.4133: Table 19 above). The cumulative incidence of adjudicated CV death is displayed in Figure 11.

<div style=\"page-break-after: always\"></div>

Figure 11 Time to adjudicated CV death, estimated cumulative incidence function (considering non-CV death as a competing risk), trial 1245.121

<!-- image -->

The CEC categorised the causes of all CV deaths, with the most common categories being sudden cardiac death and heart failure death (Table 20). Fewer patients were reported with CEC-defined sudden cardiac death in the empagliflozin group (70 patients, 3.8%) than in the placebo group (81 patients, 4.3%).

Table 20 CEC-defined categories of CV death, trial 1245.121 - RS

|                      | Placebo N (%)   | Empa 10 mg N (%)   |
|----------------------|-----------------|--------------------|
| Analysed patients    | 1867 (100.0)    | 1863 (100.0)       |
| All with CV death    | 202 (10.8)      | 187 (10.0)         |
| Sudden cardiac death | 81 (4.3)        | 70 (3.8)           |
| Heart failure        | 62 (3.3)        | 64 (3.4)           |
| Undetermined         | 23 (1.2)        | 24 (1.3)           |
| Other CV causes      | 17 (0.9)        | 14 (0.8)           |
| Stroke               | 14 (0.7)        | 11 (0.6)           |
| Acute MI             | 4 (0.2)         | 3 (0.2)            |
| CV procedures        | 1 (0.1)         | 1 (0.1)            |

In general, the results for adjudicated CV death were consistent across the subgroups by demographics, baseline characteristics, and baseline HF medications.

## Hospitalisation endpoint - secondary endpoint

Treatment with empagliflozin reduced the risk of all-cause hospitalisations, including for recurrent events and when analysed together with all-cause mortality. The treatment effect of empagliflozin also became

<div style=\"page-break-after: always\"></div>

apparent shortly after randomisation and was maintained throughout the trial. First all-cause hospitalisation was reduced with empagliflozin treatment (688 patients, 36.9% vs placebo 796 patients, 42.6%; HR 0.85, 95% CI 0.75 to 0.95). This finding seems mainly driven by hospitalisation of investigator defined CV hospitalisation (empagliflozin 452 patients, 24.3% vs placebo 570 patients, 30.5%; HR 0.75, 95% CI 0.67 to 0.85).

Figure 12  Hospitalisation endpoints, trial 1245.121

<!-- image -->

|                                                                             | Empagliflozin 10 mg   | Empagliflozin 10 mg   | Placebo               | Placebo               |                  |
|-----------------------------------------------------------------------------|-----------------------|-----------------------|-----------------------|-----------------------|------------------|
|                                                                             | Nwith events          | Rate/ 100PY           | N with events         | Rate/ 100PY           | HR (95% CI)      |
| First and recurrent all-cause hospitalisationl                              | 1364 hospitalisations | 1364 hospitalisations | 1570 hospitalisations | 1570 hospitalisations | 0.85 (0.75,0.95) |
| First all-cause hospitalisation2                                            | 688/1863(36.9%)35.58  |                       | 796/1867 (42.6%)43.82 |                       | 0.82 (0.74,0.90) |
| Firstall-cause mortality or all-cause 743/1863(39.9%)38.43 hospitalisation? |                       |                       | 860/1867(46.1%)47.35  |                       | 0.81 (0.74,0.90) |
| First investigator- definedCV hospitalisation2                              | 452/1863 (24.3%)21.20 |                       | 570/1867 (30.5%)28.28 |                       | 0.75 (0.67,0.85) |

Favours empagliflozin

Favours placebo

1  Joint frailty model that accounts for the dependence between recurrent all-cause hospitalisation and all-cause mortality

2  Cox regression, time-to-event analysis

## Renal Outcomes

## Key Secondary endpoint - eGFR slope of change from baseline

The analysis of eGFR (CKD-EPI)cr slope of change from baseline showed a significantly slower decline in eGFR in the empagliflozin group, with an estimated difference in slope of 1.733 mL/min/1.73 m 2  per year vs placebo (99.9% CI 0.669, 2.796; p&lt;0.0001, Table 21). The calculation of the eGFR slope of change from baseline included all on-treatment data from the first to the last value on-treatment. This represents the 'chronic' slope which was defined due to the previously observed initial drop in eGFR with empagliflozin. The first scheduled on-treatment visit was on Day 28 (± 7 days).

Consistent results were observed across subgroups, including patients with or without T2DM and patients with different categories of baseline eGFR.

Table 21 Results secondary endpoint 2: eGFR (CKD-EPI)cr [mL/min/1.73 m2] slope of change from baseline, trial 1245.121 - RS

|                                    | Placebo                 | Empa 10 mg              |
|------------------------------------|-------------------------|-------------------------|
| Analysed patients                  | 1863                    | 1863                    |
| Intercept 2 , estimate (95% CI)    | -0.949 (-1.315, -0.583) | -3.024 (-3.387, -2.661) |
| Slope 2 [/year], estimate (95% CI) | -2.278 (-2.728, -1.828) | -0.546 (-0.991, -0.101) |
| Difference vs placebo (95% CI)     | 1.733 (1.100, 2.366)    | 1.733 (1.100, 2.366)    |
| (99.9% CI)                         | (0.669, 2.796)          | (0.669, 2.796)          |
| p-value                            | <0.0001                 | <0.0001                 |

<div style=\"page-break-after: always\"></div>

A histogram of the individual patient slopes showed a uniform shift in the empagliflozin group to slower eGFR decline compared with the placebo group, supporting that the effect of empagliflozin vs placebo treatment was observed across the population (Figure 13).

Figure 13  Distribution of individual patient eGFR slopes of change from baseline, trial 1245.121 - TS

<!-- image -->

## Further eGFR analyses - secondary endpoint

An exploratory Mixed model repeated measure (MMRM) analysis of eGFR change from baseline including also off-treatment values showed a similar trend of slowing of eGFR decline over time, consistent with the results of the slope analysis. In the empagliflozin group, there was an initial drop in eGFR at Week 4 which partially recovered at Week 12. Thereafter, a slower decrease in the empagliflozin group compared with placebo was observed (Figure 14)

<div style=\"page-break-after: always\"></div>

Figure 14 eGFR (CKD-EPI)cr value over time MMRM results, trial 1245.121 RS (OC-AD)

<!-- image -->

In an analysis of patients with valid baseline, last-value-on-treatment, and follow-up values, eGFR returned towards the baseline level in the empagliflozin group at the follow-up visit, about 30 days after treatment stop, while the decrease in eGFR in the placebo group persisted (Table 22).

Table 22 ANCOVA results for eGFR (CKD-EPI)cr change from baseline to last value ontreatment and follow-up - TS-FU

|                                                 | Placebo           | Empa 10 mg        |
|-------------------------------------------------|-------------------|-------------------|
| Analysed patients                               | 479               | 487               |
| Baseline, mean (SE)                             | 63.7 (1.0)        | 63.2 (1.0)        |
| Last value on-treatment, adjusted mean (95% CI) | 59.7 (58.7, 60.7) | 60.4 (59.4, 61.4) |
| Change from baseline                            | -3.8 (-4.8, -2.8) | -3.1 (-4.0, -2.1) |
| Comparison vs placebo                           | 0.7 (-0.6, 2.1)   | 0.7 (-0.6, 2.1)   |
| Follow-up, adjusted mean (95% CI)               | 59.3 (58.2, 60.3) | 62.5 (61.5, 63.6) |
| Change from baseline                            | -4.2 (-5.3, -3.2) | -0.9 (-2.0, 0.1)  |
| Comparison vs placebo                           | 3.3 (1.8, 4.8)    | 3.3 (1.8, 4.8)    |

Including only patients with valid baseline, last value on-treatment, and follow-up values; the numbers of patients with all 3 values were low because some end-of-treatment visits and some follow-up visits were carried out by telephone due to COVID-19

Adjusted with a model including baseline value and age as linear covariates and region, baseline diabetes status, sex, baseline LVEF, and treatment as fixed effects

## Further renal outcomes - secondary and exploratory endpoint

Empagliflozin treatment reduced the risk of the composite renal endpoint (chronic dialysis, renal transplant, or sustained reduction in eGFR) by 50%. For most patients the first recorded renal event was sustained reduction in eGFR from baseline of ≥40% ( Table 23). The treatment effect of empagliflozin started about 200 days after randomisation and was maintained throughout the trial ( Figure 15)

<div style=\"page-break-after: always\"></div>

Table 23 Time to the first event of the composite renal endpoint, Cox regression, trial 1245.121 - RS

|                                                                                                            | Placebo           | Empa 10 mg        |
|------------------------------------------------------------------------------------------------------------|-------------------|-------------------|
| Analysed patients, N (%)                                                                                   | 1867 (100.0)      | 1863 (100.0)      |
| Patients with the composite renal endpoint, N (%)                                                          | 58 (3.1)          | 30 (1.6)          |
| Sustained eGFR reduction ≥40% as the first event                                                           | 50 (2.7)          | 27 (1.4)          |
| Sustained eGFR <15 mL/min/1.73 m 2 (baseline ≥30) or <10 mL/min/1.73 m 2 (baseline <30) as the first event | 0                 | 0                 |
| Chronic dialysis as the first event                                                                        | 8 (0.4)           | 3 (0.2)           |
| Renal transplant as the first event                                                                        | 0                 | 0                 |
| Incidence rate per 100 years at risk                                                                       | 3.07              | 1.56              |
| Hazard ratio vs placebo (95% CI)                                                                           | 0.50 (0.32, 0.77) | 0.50 (0.32, 0.77) |
| Nominal p-value                                                                                            | 0.0019            | 0.0019            |

The composite renal endpoint: chronic dialysis (with a frequency of twice per week or more for at least 90 days), renal transplant, sustained reduction in eGFR from baseline of ≥40%, sustained eGFR &lt;15 mL/min/1.73 m 2  for patients with baseline eGFR ≥30 mL/min/1.73 m 2 , or sustained eGFR &lt;10 mL/min/1.73 m 2  for patients with baseline eGFR

&lt;30 mL/min/1.73 m 2 . Sustained was determined by two or more consecutive post-baseline central laboratory measurements separated by at least 30 days (the first to last of the consecutive eGFR values)

Cox regression model included factors age, baseline eGFR (CKD-EPI)cr, region, baseline diabetes status, sex, baseline LVEF, and treatment

Figure 15 Time to the first event of the composite renal endpoint, estimated cumulative incidence function (considering all-cause mortality as a competing risk), trial 1245.121 - RS

<!-- image -->

In this trial, 396 patients (10.6%) had macroalbuminuria (UACR &gt;300 mg/g), 1236 patients (33.1%) had microalbuminuria (30 to ≤300 mg/g), and 2078 patients (55.7%) had normoalbuminuria (&lt;30 mg/g) at baseline. There was a trend towards an improvement in the empagliflozin group versus placebo in the progression to or reversal of macroalbuminuria. Fewer patients in the empagliflozin group (116 of 1646 patients, 7.0%) than in the placebo group (143 of 1668 patients, 8.6%; HR 0.81, 95% CI 0.64, to 1.04) progressed to macroalbuminuria from normo- or microalbuminuria at baseline. More patients in the empagliflozin group reversed from macroalbuminuria to sustained normo- or microalbuminuria

<div style=\"page-break-after: always\"></div>

(empagliflozin: 99 of 207 patients, 47.8%; placebo: 85 of 189 patients, 45.0%; HR 1.24, 95% CI 0.92 to 1.67)

## Patient reported outcomes

## Patient reported outcomes measured by KCCQ at Week 52 - secondary endpoint

The KCCQ comprises 7 domains and 3 summary scores as shown in Figure 16. Each patient was also asked to identify the domain that was the most difficult to cope with at baseline (patient-preferred outcome). The scores of the KCCQ domains and summary scores range from 0 to 100, with higher score indicating better outcome.

## Figure 16 KCCQ individual domains and summary scores

<!-- image -->

Treatment with empagliflozin improved the KCCQ clinical summary score (an exploratory secondary endpoint) from baseline to Week 52 compared with placebo (placebo-corrected adjusted mean change from baseline 1.75, 95% CI 0.51 to 2.99; Figure 17). The score was higher at the first post-baseline assessment (Week 12) in the empagliflozin group than the placebo group, and the difference was sustained up to the last assessment (Week 52; Figure 18 green box).

A higher proportion of patients in the empagliflozin group (576 patients, 40.0%) than in the placebo group (512 patients, 35.9%; odds ratio 1.233, 95% CI 1.051 to 1.448) showed a clinically meaningful improvement in KCCQ clinical summary score at Week 52 of at least 5 points from baseline. Consistently, a lower proportion of patients in the empagliflozin group (473 patients, 32.8%) than in the placebo group (515 patients, 36.1%; odds ratio 0.844, 95% CI 0.722 to 0.987) showed clinically meaningful deterioration of at least 5 points from baseline.

The favourable effect of empagliflozin vs placebo was driven by all domains included in the KCCQ clinical summary score (symptom frequency, symptom burden, and physical limitations). Supportive analyses of other KCCQ summary scores (overall summary score and total symptoms score) were in line with these results (Figure 17 and Figure 18).

In this trial, each patient was asked to identify the domain that was the most difficult to cope with at baseline. The most common domain the patients identified was total symptom (i.e. symptom frequency and burden; 32% of patients) and physical limitation (21% of patients), illustrating that the use of clinical summary score was the most relevant from the patients' perspective.

The improvement in HF symptoms was in line with the HF clinical outcome results and also consistent with the observed improvements in NYHA class with empagliflozin treatment. More patients in the empagliflozin group (360 patients, 26.8%) than in the placebo group (303 patients, 22.8%) improved in NYHA class from baseline to Week 52, and fewer patients in the empagliflozin group (48 patients, 3.6%) than in the placebo group (75 patients, 5.6%) worsened.

<div style=\"page-break-after: always\"></div>

Figure 17 KCCQ individual domains and summary scores change from baseline at Week 52 MMRM, tri al 1245.121 - TS (OC -OT)

<!-- image -->

Figure 18 KCCQ summary scores and individual domains change from baseline MMRM results, trial 1245.121 - TS (OC -OT) The coloured boxes illustrate the derivation of the KCCQ summary scores.

<!-- image -->

## Other efficacy endpoints

The onset of DM in patients with pre-DM occurred in fewer patients in the empagliflozin group (71 of 632 patients, 11.2%) than in the placebo group (80 of 636 patients, 12.6%; HR 0.86, 95% CI 0.62 to 1.19). A sustained reduction in HbA1c of about 0.2% was only seen in the empagliflozin group compared with placebo in patients with T2DM at baseline. No relevant changes in fasting glucose were seen in either treatment group.

<div style=\"page-break-after: always\"></div>

Body weight was decreased by about 0.8 kg at Week 52 in the empagliflozin group compared with placebo, while no relevant treatment differences in blood pressure or heart rate were observed.

## Summary of main study(ies)

The following tables summarise the efficacy results from the main studies supporting the present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit-risk assessment (see later sections).

Table 24 Summary of Efficacy for EMEROR reduced trial 1245.121

## Methods

| Title:                    | EMPEROR reduced trial                                                                                        | EMPEROR reduced trial                                                                                        | EMPEROR reduced trial                                                                                                                        |
|---------------------------|--------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier          | Trial 1245.121                                                                                               | Trial 1245.121                                                                                               | Trial 1245.121                                                                                                                               |
| Design                    | Phase III international, multi-centre, double-blind, parallel-group, placebo-controlled, event-driven trials | Phase III international, multi-centre, double-blind, parallel-group, placebo-controlled, event-driven trials | Phase III international, multi-centre, double-blind, parallel-group, placebo-controlled, event-driven trials                                 |
| Design                    | Duration of main phase:                                                                                      | Duration of main phase:                                                                                      | event driven, median follow up of 16 months of treatment                                                                                     |
| Design                    | Duration of Run-in phase:                                                                                    | Duration of Run-in phase:                                                                                    | 4-28 days                                                                                                                                    |
| Design                    | Duration of Extension phase:                                                                                 | Duration of Extension phase:                                                                                 | 30 days                                                                                                                                      |
| Hypothesis                | Superiority                                                                                                  | Superiority                                                                                                  | Superiority                                                                                                                                  |
| Treatments groups         | empagliflozin                                                                                                | Empagliflozin 10mg once daily during study duration (median follow up of 16 months), n=1863 randomized       | Empagliflozin 10mg once daily during study duration (median follow up of 16 months), n=1863 randomized                                       |
| Treatments groups         | placebo                                                                                                      | Placebo during study duration (median follow up of 16 months), n=1867 randomized                             | Placebo during study duration (median follow up of 16 months), n=1867 randomized                                                             |
| Endpoints and definitions | Primary endpoint                                                                                             | CV death or HHF                                                                                              | time to the first event of adjudicated CV death or adjudicated hospitalisation for heart failure.                                            |
| Endpoints and definitions | Key secondary endpoint                                                                                       | first and recurrent HHF                                                                                      | Occurrence of adjudicated HHF (first or recurrent)                                                                                           |
| Endpoints and definitions | Key secondary endpoint                                                                                       | eGFR slope, change from baseline                                                                             | eGFR (CKD-EPI) cr slope of change from baseline                                                                                              |
| Endpoints and definitions | Secondary exploratory endpoint                                                                               | CV death                                                                                                     | Time to adjudicated CV death                                                                                                                 |
| Endpoints and definitions | Secondary exploratory endpoint                                                                               | All-cause mortality                                                                                          | Time to all-cause mortality                                                                                                                  |
| Endpoints and definitions | Secondary exploratory endpoint                                                                               | Composite renal event                                                                                        | Time to the first event in the composite renal endpoint: chronic dialysis 1 , renal transplant, or sustained 2 reduction in eGFR (CKD-EPI) 3 |
| Endpoints and definitions | Secondary exploratory endpoint                                                                               | Patient reported outcome                                                                                     | Change from baseline in KCCQ clinical summary score 5 at Week 52                                                                             |
| Endpoints and definitions | Secondary exploratory endpoint                                                                               | All-cause hospitalisation                                                                                    | Occurrence of all-cause hospitalisation (first and recurrent)                                                                                |
| Endpoints and definitions | Secondary exploratory endpoint                                                                               | Onset DM                                                                                                     | Time to onset of DM (defined as HbA1c ≥6.5% or as diagnosed by the investigator) in patients with pre- DM 4                                  |
| Database lock             | 18 Oct 2019                                                                                                  | 18 Oct 2019                                                                                                  | 18 Oct 2019                                                                                                                                  |

## Primary Analysis

| Analysis population and time point description   | Intent to treat                              | Intent to treat              | Intent to treat              |
|--------------------------------------------------|----------------------------------------------|------------------------------|------------------------------|
| Descriptive statistics and estimate variability  | Treatment group                              | placebo                      | empa 10mg                    |
| Descriptive statistics and estimate variability  | Number of subjects, n                        | 1867                         | 1863                         |
| Primary endpoint:                                | CV death or HHF, n (%)                       | 462 (24.7)                   | 361 (19.4)                   |
| Primary endpoint:                                | HR empagliflozin vs. placebo 95% CI, p-value | 0.75; 0.65 to 0.86, p<0.0001 | 0.75; 0.65 to 0.86, p<0.0001 |
| Key secondary                                    | patients with first and recurrent HHF,       | 342 (18.4)                   | 246 (13.2)                   |

<div style=\"page-break-after: always\"></div>

| endpoint:                      | n (%)                                                               |                                 |                                 |
|--------------------------------|---------------------------------------------------------------------|---------------------------------|---------------------------------|
|                                | HR 95% CI, p-value                                                  | 0.70 0.58 to 0.85, p = 0.0003   | 0.70 0.58 to 0.85, p = 0.0003   |
|                                | eGFR slope, change from baseline, Slope2 [/year], estimate (95% CI) | -2.278 (-2.728, -1.828)         | -0.546 (-0.991, -0.101)         |
|                                | Difference vs. placebo (95% CI) , p-value                           | 1.733 (1.100, 2.366), p<0.0001. | 1.733 (1.100, 2.366), p<0.0001. |
| Secondary exploratory endpoint | CV death, n (%)                                                     | 202 (10.8)                      | 187 (10.0)                      |
|                                | HR (95% CI)                                                         | HR 0.92 (0.75 to 1.12)          | HR 0.92 (0.75 to 1.12)          |
|                                | All-cause mortality, n (%)                                          | 266 (14.2)                      | 249 (13.6)                      |
|                                | HR (95% CI)                                                         | HR 0.92 (0.77 to 1.10)          | HR 0.92 (0.77 to 1.10)          |
|                                | Composite renal event, n (%)                                        | 58 (3.1)                        | 30 (1.6)                        |
|                                | HR (95% CI)                                                         | HR 0.50 (0.32 to 0.77)          | HR 0.50 (0.32 to 0.77)          |
|                                | KCCQ clinical summary score, change from baseline (95% CI)          | 4.46 3.20 to 4.97               | 5.67 4.96 to 6.70               |
|                                | mean diff. (95% CI)                                                 | 1.75 (0.51 to 2.99)             | 1.75 (0.51 to 2.99)             |
|                                | First all-cause hospitalization, n (%)                              | 796 (42.6)                      | 699 (36.9)                      |
|                                | HR (95% CI)                                                         | HR 0.82 (0.74 to 0.90)          | HR 0.82 (0.74 to 0.90)          |
|                                | Onset DM, n (%)                                                     | 80/636 (12.6)                   | 71/632 (11.2)                   |
|                                | HR (95% CI)                                                         | HR 0.86 (0.62 to 1.19)          | HR 0.86 (0.62 to 1.19)          |

1 Chronic dialysis was defined as dialysis with a frequency of twice per week or more for at least 90 days

2 Sustained was determined by two or more consecutive post-baseline central laboratory measurements separated by at least 30 days (the first to last of the consecutive eGFR values)

3  Reduction in eGFR (CKDEPI)cr was defined as reduction in eGFR from baseline of ≥40%, eGFR &lt;15 mL/min/1.73 m2 for p atients with baseline eGFR ≥30 mL/min/1.73 m2, or eGFR &lt;10 mL/min/1.73 m2 for patients with baseline eGFR &lt;30 mL/min/1.73 m2

4  PreDM was defined as no history of DM and no HbA1c ≥6.5% before treatment, and a pretreatment HbA1c value of ≥5.7% and &lt;6.5%

5  KCCQ, Kansas City cardiomyopathy questionnaire; clinical summary score measures HF symptoms (frequency and burden) and physical limitations

## 3.3.8. Supportive study(ies)

## EMPERIAL Reduced/Preserved (1245.168 and 1245.167)

## Methods

## Study participants

The eligibility criteria in the EMPERIAL trials were generally similar to those in the EMPEROR trials, with the exception that the thresholds for NT-proBNP were higher in EMPEROR-reduced, and that the EMPERIAL trials had the addition of criteria ensuring that patients could carry out the 6-minute walk test (6MWT) and a potential increase in the distance after 12 weeks could be detected (6MWT distance should be between 100 m and 350 m at baseline).

## Treatments

The additional EMPERIAL trials were comparable to regarding the screening and treatment, except for the treatment duration. The EMPERIAL trials were not event-driven but were designed to investigate the short-term (12 weeks) effect of empagliflozin on functional capacity, signs and symptoms of heart failure, and quality of life. Therefore, a treatment duration of 12 weeks was implemented (see Figure 19).

<div style=\"page-break-after: always\"></div>

## Figure 19 Study design Functional capacity trials ('EMPERIAL-Reduced/Preserved')

Aim: To evaluate the effect of empagliflozin 10 mg versus placebo on exercise ability using the 6MWT in patientswithHFwithreduced orpreserved ejectionfraction

Population: Chronic HF (HFrEF or HFpEF), with or without T2D

<!-- image -->

## Objectives

The aim of the EMPERIAL-reduced/preserved trials is to evaluate the effect of empagliflozin 10 mg versus placebo on exercise ability using the 6-minute walking test (6MWT) in patients with HFrEF or HFpEF.

## Outcomes/endpoints

The following endpoints were pre-specified for both 1245.168 and 1245.167:

- Primary endpoint: change from baseline to Week 12 in the 6-minute-walk test (6MWT) distance
- Key secondary endpoints:
- Change from baseline to Week 12 in KCCQ-TSS (, total symptom score)
- Change from baseline to Week 12 in CHQ-SAS (chronic heart failure questionnaire selfadministered standardised format) dyspnoea score
- Other secondary endpoints:
- Change from baseline to Week 6 in the 6MWT distance
- Change from baseline to Week 12 in Clinical Congestion Score
- Change from baseline to Week 12 in PGI-S (patient global impression of severity) of HF symptoms
- Change from baseline to Week 12 in PGI-S of dyspnoea
- PGI-C (patient global impression of change) in HF symptoms at Week 12
- PGI-C in dyspnoea at Week 12
- Change from baseline in NT-proBNP at Week 12

Further endpoints included responders in 6MWT distance, clinician- and patient-reported outcomes, changes in NYHA class, the occurrence of clinical events, and changes in blood pressure and body weight.

## Sample size

The EMPERIAL-reduced and -preserved trial (1245.168 and 1245.167) included 312 and 315 subjects, respectively.

## Statistical methods

For confirmatory testing of efficacy, a hierarchical procedure was applied to test the primary and key secondary endpoints.

<div style=\"page-break-after: always\"></div>

The main efficacy analyses followed the intent-to-treat (ITT) principle and included all randomised patients and all available values, including those obtained off-treatment. The primary analysis of the primary and both key secondary endpoints used a normal approximation of the Wilcoxon rank test. In order to rank the missing values at Week 12, imputation rules for the missing values according to the nature for missing were prespecified (worst-case imputation, WCI). The ranking for the imputed values was according to the following order, from the highest rank to the lowest. The ranking rules followed recommendations from the FDA.

Ranking for patients with missing values at Week 12:

- Without clinical event   (defined as SAEs or AEs leading to treatment discontinuation ongoing at Week 12, excluding deaths)
- o And with a post-baseline value (e.g. at Week 6): rank below the worst possible value that can be measured and by the available value (the higher the distance walked, the higher the rank)
- o And without post-baseline value: rank below the patients described in the previous point
- With clinical event 1 : rank below the patients described in the previous point, regardless of any postbaseline value
- The patient died before Week 12: rank below the patients described in the previous point and by the days from randomisation to death (the later the death, the higher the rank)

For estimation of the difference between treatments, the non-parametric Hodges-Lehmann estimate for the median difference was calculated with imputation of missing values.

The analyses and imputation rules for both key secondary endpoints were similar to those for the primary endpoint.

Other exploratory efficacy endpoints were analysed generally as follows:

- The change from baseline to Week 6 in the 6MWT distance: similar analyses as for the primary endpoint
- Ordinal endpoints (e.g. change in score category): Cochran-Mantel-Haenszel (CMH) test on the difference in mean treatment scores, based on modified ridit scores; shifts between categories were tabulated descriptively
- Continuous endpoints (e.g. change in score value): MMRM analyses
- Responder endpoints: a chi-square test to compare response between treatment groups
- Other binary endpoints (e.g. occurrence of clinical events): descriptive

Responder thresholds for KCCQ-TSS and CHQ-SAS dyspnoea score were based on clinically meaningful within-patient changes in scores, using an anchor-based method and derived specifically from the trial population. The anchors and the definitions for minimal clinically meaningful improvement were prespecified and agreed with the FDA.

## Results

## Baseline characteristics

Patients with chronic HF were screened and, if eligible, randomised according to the EF value to either trial 1245.168 (HFrEF) or 1245.167 (HFpEF). Almost all randomised patients in the two trials were from Europe and North America (Table 25).

Table 25 Overview of randomised patients by region in 1245.168 and 1245.167

| Geographical region Countries   | Geographical region Countries                                   |   1245.168 (HFrEF) 1245.167 (HFpEF) |   1245.168 (HFrEF) 1245.167 (HFpEF) |
|---------------------------------|-----------------------------------------------------------------|-------------------------------------|-------------------------------------|
| Total                           | 11 countries                                                    |                                 312 |                                 315 |
| North America                   | Canada, United States                                           |                                 131 |                                 124 |
| Europe                          | Germany, Greece, Italy, Norway, Poland, Portugal, Spain, Sweden |                                 179 |                                 189 |
| Australia                       | Australia                                                       |                                   2 |                                   2 |

<div style=\"page-break-after: always\"></div>

In 1245.168, a total of 312 patients were randomised, and 311 were treated with study medication. Of the 311 treated patients, 298 patients (95.8%) completed the trial and 283 patients (91.0%) completed the treatment with study medication. The completion was similar in both treatment groups. The most frequent reason for premature discontinuation of study medication was an AE (6.1%). The mean exposure of the patients was similar in both treatment groups (empagliflozin: 11.84 [SD 1.64] weeks; placebo: 11.80 [SD 1.84] weeks)

In 1245.167, of the 315 randomised patients treated with study medication, 301 (95.6%) completed the trial, and 291 (92.4%) completed the treatment with study medication. There were no relevant differences between the treatment groups. The most frequent reason for premature discontinuation of study medication was an AE (5.4%). The mean exposure of patients was similar in both treatment groups (empagliflozin: 11.71 weeks [SD 2.32]; placebo: 11.89 weeks [SD 2.12])

The main patient characteristics in both trials are shown in Table 26 below. The MAH states that the characteristics were generally balanced between the treatment groups within each trial. Between 1245.168 (HFrEF) and 1245.167 (HFpEF), the following differences in the patient populations were noted:

Both trials together included patients encompassing the entire range of EF values, with patients having reduced LVEF (≤40%) in 1245.168 and preserv ed LVEF in 1245.167 (&gt;40%)

- Patients with HFpEF were more often women than patients with HFrEF
- Patients with HFpEF tended to be older than patients with HFrEF
- Patients with HFpEF tended to have lower NT-proBNP values than patients with HFrEF
- Patients with HFpEF tended to have slightly higher SBP than patients with HFrEF
- Patients with HFpEF more often had atrial fibrillation than patients with HFrEF

Table 26 Demographic and baseline data in 1245.168 and 1245.167

| Characteristics at baseline     | 1245.168 (HFrEF)   | 1245.167 (HFpEF)   |
|---------------------------------|--------------------|--------------------|
| Number of patients, N (%)       | 312 (100.0)        | 315 (100.0)        |
| Male, N (%)                     | 232 (74.4)         | 179 (56.8)         |
| Female, N (%)                   | 80 (25.6)          | 136 (43.2)         |
| Race, N (%)                     |                    |                    |
| White                           | 263 (84.3)         | 275 (87.3)         |
| Black/African American          | 42 (13.5)          | 32 (10.2)          |
| Asian                           | 3 (1.0)            | 5 (1.6)            |
| Region, N (%)                   |                    |                    |
| Europe                          | 179 (57.4)         | 189 (60.0)         |
| North America                   | 131 (42.0)         | 124 (39.4)         |
| Australia                       | 2 (0.6)            | 2 (0.6)            |
| Age [years], mean (SD)          | 69.0 (10.2)        | 73.5 (8.8)         |
| LVEF [%], mean (SD)             | 30.3 (6.7)         | 53.1 (8.0)         |
| <20%, N (%)                     | 19 (6.1)           |                    |
| 20 to 30%, N (%)                | 140 (44.9)         |                    |
| >30 to 35%, N (%)               | 80 (25.6)          |                    |
| >35%, N (%)                     | 73 (23.4)          |                    |
| <50%, N (%)                     |                    | 114 (36.2)         |
| 50 to <60%, N (%)               |                    | 132 (41.9)         |
| ≥60%, N (%)                     |                    | 69 (21.9)          |
| SBP ≥140 or DBP ≥90 mmHg, N (%) | 65 (20.8)          | 106 (33.7)         |
| SBP [mmHg], mean (SD)           | 123.5 (16.0)       | 130.5 (15.8)       |
| DBP [mmHg], mean (SD)           | 74.5 (11.4)        | 74.3 (11.6)        |

<div style=\"page-break-after: always\"></div>

| BMI [kg/m 2 ], mean (SD)                                                      | 29.70 (4.93)         | 29.75 (5.03)                           |
|-------------------------------------------------------------------------------|----------------------|----------------------------------------|
| eGFR [mL/min/1.73 m 2 ], mean (SD)                                            | 58.2 (19.9)          | 57.1 (18.9)                            |
| ≥90, N (%)                                                                    | 26 (8.3)             | 12 (3.8)                               |
| 60 to <90, N (%)                                                              | 112 (35.9)           | 128 (40.6)                             |
| 45 to <60, N (%)                                                              | 81 (26.0)            | 88 (27.9)                              |
| 30 to <45, N (%)                                                              | 76 (24.4)            | 62 (19.7)                              |
| 20 to <30, N (%)                                                              | 17 (5.4)             | 25 (7.9)                               |
| <20, N (%)                                                                    | 0                    | 0                                      |
| NT-proBNP [pg/mL], median (Q1, Q3)                                            | 1489 (821, 2919)     | 898 (471, 1767)                        |
| Type 2 diabetes mellitus, N (%)                                               | 187 (59.9)           | 161 (51.1)                             |
| Years since diagnosis of HF, mean (SD)                                        | 7.3 (6.9)            | 5.15 (5.26)                            |
| Atrial fibrillation based on ECG at baseline                                  | 74 (23.7)            | 95 (30.2)                              |
| HHF and/or structural heart disease (for HFpEF), N (%)                        |                      |                                        |
| HHF within 12 mos. before screening only                                      |                      | 15 (4.8)                               |
| Structural heart disease only                                                 |                      | 257 (81.6)                             |
| Both                                                                          |                      | 13.7)                                  |
| Cause of HF, N (%)                                                            |                      |                                        |
| Ischaemic                                                                     | 158 (50.6)           | 128 (40.6)                             |
| Hypertensive                                                                  | 36 (11.5)            | 89 (28.3)                              |
| Valvular heart disease                                                        | 9 (2.9)              | 26 (8.3)                               |
| Diabetic                                                                      | 0                    | 4 (1.3)                                |
| Alcoholism                                                                    | 4 (1.3)              | 2 (0.6)                                |
| Idiopathic                                                                    | 27 (8.7)             | 18 (5.7)                               |
| Cardiomyopathy                                                                | 60 (19.2)            | 29 (9.2)                               |
| NYHA class, N (%)                                                             |                      |                                        |
| I                                                                             | 0                    | 1 (0.3)                                |
| II                                                                            | 202 (64.7)           | 243 (77.1)                             |
| III                                                                           | 110 (35.3)           | 71 (22.5)                              |
| IV                                                                            | 0                    | 0                                      |
| Drugs used in HFrEF or used in hypertension or heart disease for HFpEF, N (%) | 312 (100.0)          |                                        |
| ACE inhibitors/ARBs/ARNi                                                      | 282 (90.4)           | 246 (78.1)                             |
| ACE inhibitors/ARBs                                                           | 173 (55.4)           | 235 (74.6)                             |
| ARNi                                                                          | 114 (36.5)           | 11 (3.5)                               |
| Beta-blockers                                                                 | 295 (94.6)           | 281 (89.2)                             |
| Diuretics                                                                     | 294 (94.2)           | 277 (87.9)                             |
| MRAs                                                                          | 182 (58.3)           | 105 (33.3)                             |
| Loop or high ceiling diuretics                                                | 274 (87.8)           | 226 (71.7)                             |
| Other antihypertensives, N (%)                                                | 31 (9.9)             | 93 (29.5)                              |
| Lipid-lowering drugs, N (%)                                                   | 247 (79.2)           | 233 (74.0)                             |
| Antithrombotic drugs, N (%)                                                   | 274 (87.8)           | 278 (88.3)                             |
| 6MWT distance [m], median (Q1, Q3)                                            | 307.5 (254.5, 333.0) | 299.0 (245.0, 330.0)                   |
| KCCQ-TSS, median (Q1, Q3)                                                     | 68.75 (50.00, 84.90) | 66.67 (48.96, 85.42) 5.20 (3.80, 6.40) |
| CHQ-SAS dyspnoea, median (Q1, Q3)                                             | 5.00 (3.75, 6.20)    |                                        |

## Outcomes

In both trials, the primary endpoint (change from baseline to Week 12 in the 6MWT distance) did not show a statistically significant difference between empagliflozin and placebo. The two key secondary

<div style=\"page-break-after: always\"></div>

endpoints (change from baseline to Week 12 in KCCQ-TSS and in CHQ-SAS dyspnoea score) were therefore tested in an exploratory fashion.

In 1245.168 (HFrEF), treatment with empagliflozin numerically improved the KCCQ-TSS from baseline to Week 12 compared with placebo; the treatment difference was observed in the Hodges-Lehmann estimate (median difference 3.13, 95% CI 0.00, 7.29) and using MMRM (mean difference 4.55, 95% CI 1.18, 7.93). Supportive analyses of other KCCQ summary scores (overall summary score and clinical summary score) were in line with these results. The favourable effect of empagliflozin vs placebo was driven predominantly by numerical improvements in the KCCQ domains symptom frequency, symptom burden, and social limitation.

The findings of 1245.168, specifically the neutral results for 6MWT distance and the numerical improvements in KCCQ, are consistent with the findings from trials investigating the SGLT-2 inhibitor dapagliflozin in patients with HFrEF. A systematic review of clinical trials testing drugs currently approved for the treatment of patients with HFrEF demonstrated low correlation or interdependence between 6MWT results and CV mortality or HHF.

The KCCQ results in 1245.168 were qualitatively consistent with those in 1245.121, which had a much longer follow up and showed that the favourable effect of empagliflozin treatment was sustained up to the last planned assessment (Week 52).

No meaningful differences between treatment groups were observed in the efficacy endpoints in 1245.167 (HFpEF).

## 3.3.9. Discussion on clinical efficacy

## Design and conduct of clinical studies

The EMPEROR-reduced trial (1245.121) Phase III program for empagliflozin 10 mg once daily was a double-blind, randomised, parallel-group, placebo-controlled, multi-national trial in patients with HFrEF with or without T2DM. The trial consisted of an event-driven study duration (resulting in a median follow up of 16 months of treatment) and followed by a 30-days period off study-drug. The (combined) primary outcome was the time to the first event of adjudicated CV death or adjudicated HHF. The design of the trial is in line with the EMA guideline 'Clinical investigation of medicinal products in the treatment of chronic heart failure' (CPMP/EWP/235/95, Rev.2). The MAH has provided a statement that the trials are carried out in compliance with the CTP, with the principles of the Declaration of Helsinki, with the ICH GCP, and with applicable regulatory requirements and BI's standard operating procedures.

The inclusion criteria in the EMPEROR-reduced trial included a cut-off value of NT proBNP that was defined depending on EF. About half of the screened patients (48.3%) were not randomised, most commonly because of NT-proBNP levels being below protocol-specified thresholds at screening (36.1% of screened patients). It, therefore, raises the question if the selection of patients represents the general population of patients with HFrEF and if the observed results are also applicable on the HFrEF patients that do not fully meet this inclusion criterium, as can often be the case in clinical practice. The MAH provided an analysis showing that the effect was similar between the NT-proBNP subgroups and that in other studies (EMPA-REG, DAPA-HF), the benefits on CV outcomes were similar although the NT-proBNP levels were lower. This suggests that the effect is not dependent on NT-proBNP levels. It is not shown that the population in the EMPEROR-Reduced trial is representative for the general population, but it is considered plausible that the findings could be extrapolated to the patients who were excluded from the study based on lower NT-proBNP values.

Although the list of exclusion criteria seems extensive, the described exclusion criteria are reasonable and do not seem to further hamper the translation of the trial results to the general population with HFrEF in clinical practice.

<div style=\"page-break-after: always\"></div>

The statistical analyses in the trial design are based on an intention to treat analysis and the primary analysis was a Cox regression. This is acceptable. The analysis of eGFR decline uses a model with random intercept and slope. The estimated slope should be seen in conjunction with the intercept, as the initial dip will (in part) be estimated by the intercept. To confirm that the primary analysis of eGFR slope did not hide a potentially deleterious effect by ignoring the initial dip, the MAH performed an additional ANCOVA analysis.

## Efficacy data and additional analyses

In the EMPEROR-reduced trial, about half of the screened patients (48.3%) were not randomised, most commonly because of NT-proBNP levels being below protocol-specified thresholds at screening (36.1% of screened patients). This raised the question if the selection of patients represents the general population of patients with HFrEF, and if the observed results are also applicable on the HFrEF patients that do not fully meet this inclusion criterium. As mentioned above, it is considered plausible that the findings could be extrapolated to the patients that were excluded from the study based on lower NT-proBNP values. No difference was observed in premature discontinuation rates between the empagliflozin group and placebo.

In general, demographics were well balanced between the treatment groups in the EMPEROR-reduced trial. The majority of subjects were elderly, white male subjects, which is in line with the prevalence of HFrEF in the general population. However, there is a small difference in the percentage of subjects with a SBP &lt; 140 mmHg, i.e. 82.4% in the placebo group and 78.9 empagliflozin group, and for subjects with a BMI &gt; 30 kg/m2, i.e. 30.4% in the placebo group and 32.2% in the empagliflozin group. The higher percentage of subjects with a lower SBP (i.e. &lt; 140 mmHg) in the placebo group is not likely to alter the interpretation of the results in the empagliflozin group and is therefore not a large concern in this study.

The use of concomitant therapies was as expected and in line with the treatment guidelines for HF and was at baseline equally distributed between the treatment groups, but intensification of diuretic therapy after baseline was less frequent in the empagliflozin group vs placebo (16.0 vs 22.2% of patients).

The primary endpoint of CV death or HHF occurred in a lower proportion of patients in the empagliflozin group than in the placebo group (HR 0.75; 95% CI 0.65 to 0.86, p&lt;0.0001). This effect is regardless of diabetes status. However, the reduction in events of CV death or HHF with empagliflozin was less pronounced in the white population. This is remarkable because this is the largest group and represents the largest group of patients with HFrEF. To explain the finding of white race as a modifier, the MAH evaluated baseline characteristics and therapies by race. There were small differences, i.e. White patients were older (mean (SD), White 68.0 (10.5), Black/African American 62.1 (11.5), Asian 64.7 (12.0) year), had a higher rate of atrial fibrillation or flutter and of COPD, as well as lower mean eGFR, but the differences were modest. This may partly contribute to the differences in observed effect between races, but it is still not elucidated why the effect on CV death or HHF is less pronounced in White patients. However, as it is considered also beneficial in this population, this is not a major issue.

In subjects with a LVEF &gt; 30% the HR estimate for reduction in events of CV death or HHF was close to 1. The MAH performed additional analyses, dividing the patients in different LVEF subgroups (≤ 30%, 31 -35% and 36-40%), and compared baseline characteristics and the use of other medication for the treatment of heart failure between the subgroup of LVEF. Only the subgroup LVEF 31-35% had a HR above 1 (HR 1.1, 95% CI 0.79-1.53). Small differences were described on baseline characteristics or use of medication but are considered unlikely to explain the finding of decreased effect of empagliflozin in patients with LVEF 31-35%. A pathophysiological reason is not very likely to explain this finding and it could therefore be explained by chance. Comparing the findings on the primary outcome with the DAPAHF study, the primary outcome was observed in the current EMPEROR study more frequently (i.e. in DAPA-HF dapagliflozin 16.3% vs placebo 21.2%, in EMPEROR empagliflozin 19.4% vs placebo 24.7%). This finding cannot be fully explained by a larger percentage of patients with severe HF in the EMPEROR trial, as the distribution of NYHA classification between the studies was quite comparable (DAPA-HF NYHA II 67%, III 32%, IV 1%, vs EMPEROR NYHA II 75%, III 24%, IV 1%) and the mean LVEF did not differ largely (mean LVEF in DAPA-HF 31%, in EMPEROR 27%).

<div style=\"page-break-after: always\"></div>

No meaningful difference in events was observed on all-cause mortality, especially not on CV-death (HR 0.92 (95% CI, 0.75 to 1.12). This may indicate that the results in primary endpoint are mainly driven by HHF related outcomes, but not a reduction in CV death. It is plausible that this may in part explain this finding. A meta-analysis was performed of both trials and a test for heterogeneity of effect size between the trials was performed. This did not result in heterogeneity between dapagliflozin and empagliflozin overall or within subgroup category. In addition, HHF related outcome is a less hard clinical endpoint and this endpoint could be influenced by the clinical practice in different centres. As the number of events in each centre was limited, a subgroup analysis was considered not feasible. Adjudication of potential events was performed by an independent and blinded CEC to ensure that a uniform definition was applied to confirm an HHF event, irrespective of from which centre the event was reported. The evaluation of HF outcomes across the spectrum of clinical thresholds resulted in consistent findings. This supports that the EMPEROR-Reduced HHF result is not sensitive to what precise clinical criteria are applied. Although it is acknowledged by the MAH that the clinical decision to hospitalise a patient might be influenced by many factors, the performed evaluation does not show a difference between centers. It has to be taken into account that the event rate of CV deaths is lower compared to HHF related events, but a claim of lower reduction of CV death cannot be made based on these results.

The change of eGFR slope from baseline was a secondary endpoint and showed a slower decline in eGFR in the empagliflozin group, with an estimated difference in slope of 1.733 mL/min/1.73 m2 per year vs placebo (99.9% CI 0.669, 2.796; p&lt;0.0001). However, in the same analysis, the intercept was lower for the empagliflozin group, likely caused by the initial dip. The effect on the slope can only be interpreted if seen in conjunction with intercept. To confirm that the primary analysis of eGFR slope did not hide a potentially deleterious effect by ignoring the initial dip, the MAH performed an additional ANCOVA analysis. This analysis weighed the observations by the squared time to follow up for each patient, which is acceptable since the longer the follow up time the better the slope can be differentiated from the initial dip. The results confirmed the primary analysis (1.74 vs 1.73). The MAH also adapted section 5.1 of the SmPC by adding the intercept of the primary analysis model as requested. The slope data support the effect on the renal composite endpoint, which would be actually preferred, i.e. a beneficial effect on the exploratory renal composite endpoint of (i.e. chronic dialysis, renal transplant, or sustained reduction in eGFR), HR 0.50, 95% CI 0.32 - 0.77, p=0.0019), which suggests that the observation may still be beneficial on the long term. This was mainly driven by the GFR &gt;40% reduction endpoint, and the number of composite endpoints was limited (30/1863 in the empagliflozin group and 58/1867 in the placebo group, HR 0.50, 95% CI 0.32 - 0.77).

The KCCQ was used to measure patient-reported outcomes. KCCQ consists of several domains and summary scores. Treatment with empagliflozin improved the KCCQ clinical summary score from baseline to Week 52 compared with placebo (mean change from baseline 1.75, 95% CI 0.51 to 2.99). The MAH justifies the choice for the KCCQ clinical summary score as most relevant to the patient. However, in this trial, each patient was asked to identify the domain that was the most difficult to cope with from the patients' perspective at baseline and the most common domain the patients identified was total symptom (i.e. symptom frequency and burden; 32% of patients) and physical limitation (21% of patients). Patients preferred KCCQ outcome did not differ between treatment groups. But the 'patient preferred outcome' has limitations, as this was only asked once at baseline and no time-dependency was assessed, in contrast to the standard KCCQ. The validated scores of the KCCQ are therefore considered more reliable to evaluate the patient related outcomes.

## EMPERIAL trials

The MAH describes that the demographic and baseline characteristics of the individual EMPERIAL trials (1245.168 (HFrEF) or 1245.167 (HFpEF)) were similar between the treatment groups and similar to the EMPEROR trial. Comparing the baseline characteristics between the two EMPERIAL trials, the subjects in the EMPERIAL HFpEF trial were more often women, older, and had a lower NT proBNP, a higher SBP and had more often atrial fibrillation compared with the subjects in the EMPERIAL HFrEF trial. This may support the difference in population between patients with HFrEF versus HFpEF. In both trials, the primary endpoint (change from baseline to Week 12 in the 6MWT distance) did not show a statistically

<div style=\"page-break-after: always\"></div>

significant difference between empagliflozin and placebo. This, therefore, does not support a beneficial effect of empagliflozin on HF related symptoms.

## 3.3.10. Conclusions on the clinical efficacy

The finding from EMPEROR-reduced trial of reduced occurrence of HHF or CV death is an important benefit. It is, however, important to point out that this finding seems mainly due to the effect on HHF, as no relevant reduction in CV death was observed butthe study was not powered and designed to assess CV death as independent endpoint. With the current indication, the beneficial effect on HFF or CV death results in a positive benefit-risk ratio, especially as no new major safety issues have been observed. The findings on change eGFR slope and renal outcomes are supportive and promising and are addressed in section 5.1 of the SmPC.

## 3.4. Clinical safety

## Introduction

Safety analyses followed the 'treatment-emergent' principle and included all treated patients (Treated Set, TS). Unless otherwise specified, treatment was assigned as randomised and the analyses of AEs were based on the number of patients with AEs. AE analyses were restricted to 'on-treatment' AEs, defined as AEs with an onset date between the first trial medication intake and 7 days after the last intake, unless otherwise stated. Exposure-adjusted AEs were also displayed as incidence rates per 100 patient-years.

As trial 1245.121 (EMPEROR-Reduced) represented most of the exposure in the completed trials in patients with chronic HF, the evaluation of the safety results in this document focuses on the data from 1245.121. Between 1245.168 (HFrEF) and 1245.167 (HFpEF), no relevant differences in the safety results were observed.

Overall, treatment with empagliflozin 10 mg in patients with HFrEF revealed no new safety findings compared with the known safety profile of empagliflozin in patients with T2DM. The safety profile for patients with HFrEF and without T2DM was similar to those with T2DM. Detailed information is provided below.

## Patient exposure

In 1245.121, 3730 patients with HFrEF were randomised. The majority of included patients were from Europe and Latin America. In SAF-HF2, 311 patients with HFrEF were treated in 1245.168 and 315 patients with HFpEF in 1245.167. Almost all patients were from Europe or North America (Table 27)

Table 27 Number of patients in 1245.121 and SAF-HF2 by region

|               | Placebo N (%)   | Empa 10mg N (%)   | Total N (%)   |
|---------------|-----------------|-------------------|---------------|
| 1245.121 - RS | 1867 (100.0)    | 1863 (100.0)      | 3730 (100.0)  |
| North America | 213 (11.4)      | 212 (11.4)        | 425 (11.4)    |
| Latin America | 645 (34.5)      | 641 (34.4)        | 1286 (34.5)   |
| Europe        | 677 (36.3)      | 676 (36.3)        | 1353 (36.3)   |
| Asia          | 245 (13.1)      | 248 (13.3)        | 493 (13.2)    |
| Other         | 87 (4.7)        | 86 (4.6)          | 173 (4.6)     |

<div style=\"page-break-after: always\"></div>

| SAF-HF2 - TS     | 314 (100.0)   | 312 (100.0)   | 626 (100.0)   |
|------------------|---------------|---------------|---------------|
| 1245.167 (HFpEF) | 158 (50.3)    | 157 (50.3)    | 315 (50.3)    |
| 1245.168 (HFrEF) | 156 (49.7)    | 155 (49.7)    | 311 (49.7)    |
| Europe           | 182 (58.0)    | 185 (59.3)    | 367 (58.6)    |
| North America    | 131 (41.7)    | 124 (39.7)    | 255 (40.7)    |
| Australia        | 1 (0.3)       | 3 (1.0)       | (0.6)         |

Of the 3730 randomised patients in 1245.121, 3688 patients (98.9%) had complete follow-up for the primary endpoint and the final vital status was known for 3709 patients (99.4%). Of the 3726 patients treated with study medication, 993 patients prematurely discontinued treatment (26.7%, including patients who died). The most common reason for premature discontinuation of study medication was an AE (8.7% of patients with non-fatal events and 9.5% with fatal events).

In 1245.121, the median exposure to study medication was about 14 months in both treatment groups, with 61% of patients treated for at least 1 year (Table 28).

Table 28 Exposure to study medication in 1245.121 - TS

|                             | Placebo           | Empa 10mg         |
|-----------------------------|-------------------|-------------------|
| Number of patients, N (%)   | 1863 (100.0)      | 1863 (100.0)      |
| Exposure categories, N (%)  |                   |                   |
| ≥12weeks                    | 1722 (92.4)       | 1748 (93.8)       |
| ≥26weeks                    | 1622 (87.1)       | 1644 (88.2)       |
| ≥52weeks                    | 1133 (60.8)       | 1135 (60.9)       |
| ≥78weeks                    | 612 (32.9)        | 609 (32.7)        |
| ≥104weeks                   | 214 (11.5)        | 210 (11.3)        |
| ≥156weeks                   | 0                 | 0                 |
| Duration of exposure [year] |                   |                   |
| Median (Q1, Q3)             | 1.17 (0.69, 1.69) | 1.19 (0.73, 1.67) |
| Mean (SD)                   | 1.19 (0.63)       | 1.20 (0.61)       |
| Total                       | 2222.6            | 2238.8            |

Exposure was calculated as date of last intake of study medication minus date of first intake, plus 1 day.

In SAF-HF2, 91.7% of treated patients completed 12 weeks of treatment. The most frequent reason for premature discontinuation of treatment was an adverse event (5.8%). There were no relevant differences between treatment groups. The mean exposure was about 12 weeks in both treatment groups.

## Adverse events

In 1245.121, empagliflozin and placebo groups had similar overall frequencies of patients with at least one reported AE (Table 29). Adverse events reported during this trial were primarily of mild or moderate intensity. Proportions of patients were also similar between groups for severe AEs and AEs, leading to premature study medication discontinuation. The frequency of investigator defined drug-related AEs was higher in the empagliflozin group than the placebo group. Serious AEs were less commonly reported for the empagliflozin group than for the placebo group; this was driven by a smaller proportion of the empagliflozin group reporting SAEs that required or prolonged hospitalisation compared with the placebo group. The frequency of fatal AEs was the same in both groups during the on-treatment period.

In SAF-HF2, all categories of AEs were reported at similar or lower frequencies in the empagliflozin group than in the placebo group (Table 30)

<div style=\"page-break-after: always\"></div>

Table 29 Overall summary of adverse events in 1245.121 - TS

| Category of AEs                                    | Placebo N (%)   | Empa 10 mg N (%)   |
|----------------------------------------------------|-----------------|--------------------|
| Number of patients                                 | 1863 (100.0)    | 1863 (100.0)       |
| Patients with any AEs                              | 1463 (78.5)     | 1420 (76.2)        |
| Severe AEs                                         | 502 (26.9)      | 459 (24.6)         |
| Investigator defined drug-related AEs              | 227 (12.2)      | 283 (15.2)         |
| AEs leading to discontinuation of study medication | 328 (17.6)      | 322 (17.3)         |
| Serious AEs                                        | 896 (48.1)      | 772 (41.4)         |
| Results in death                                   | 181 (9.7)       | 181 (9.7)          |
| Is life threatening                                | 85 (4.6)        | 68 (3.7)           |
| Persistent or significant disability/incapacity    | 18 (1.0)        | 24 (1.3)           |
| Requires or prolongs hospitalisation               | 688 (36.9)      | 596 (32.0)         |
| Congenital anomaly or birth defect                 | 0               | 0                  |
| Other medically important serious event            | 360 (19.3)      | 311 (16.7)         |

Percentages calculated using total number of patients per treatment as the denominator.

A patient may be counted in more than 1 seriousness criterion.

Table 30 Overall summary of adverse events in SAF-HF2 - TS

| Category of AEs                                    | Placebo N (%)   | Empa 10 mg N (%)   |
|----------------------------------------------------|-----------------|--------------------|
| Number of patients                                 | 314 (100.0)     | 312 (100.0)        |
| Patients with any AEs                              | 167 (53.2)      | 153 (49.0)         |
| Severe AEs                                         | 21 (6.7)        | 20 (6.4)           |
| Investigator defined drug-related AEs              | 25 (8.0)        | 28 (9.0)           |
| AEs leading to discontinuation of study medication | 18 (5.7)        | 18 (5.8)           |
| Serious AEs                                        | 56 (17.8)       | 41 (13.1)          |
| Results in death                                   | 3 (1.0)         | 4 (1.3)            |
| Is life threatening                                | 6 (1.9)         | 4 (1.3)            |
| Persistent or significant disability/incapacity    | 0               | 1 (0.3)            |
| Requires or prolongs hospitalisation               | 38 (12.1)       | 32 (10.3)          |
| Other medically important serious event            | 23 (7.3)        | 13 (4.2)           |

## Most frequently reported AEs

In 1245.121, the most frequent AEs were expected from a patient population with HFrEF. AEs were most frequently reported in the system organ class (SOC) cardiac disorders (empagliflozin 571 patients, 30.6% vs placebo 697 patients, 37.4%), infections and infestations (510 patients, 27.4% vs 542 patients, 29.1%), and metabolism and nutrition disorders (411 patients, 22.1% vs 476 patients, 25.6%). The most frequently reported PTs were cardiac failure (332 patients, 17.8% vs 444 patients, 23.8%), hypotension (130 patients, 7.0% vs 119 patients, 6.4%), and hyperkalaemia (101 patients, 5.4% vs 115 patients, 6.2%). Adverse events with preferred terms PTs reported in ≥5% of patients in either group are summarised in Table 31.

Table 31 Patients with adverse events in 1245.121 (frequency &gt;5% in either treatment group at the PT level), exposure adjusted - TS

| MedDRA SOC         | Placebo      |                  | Empa 10 mg          |
|--------------------|--------------|------------------|---------------------|
| MedDRA PT          | N (%)        | Rate/100 pt-yrsN | (%) Rate/100 pt-yrs |
| Number of patients | 1863 (100.0) |                  | 1863 (100.0)        |

<div style=\"page-break-after: always\"></div>

| MedDRA SOC                            | Placebo     |                  | Empa 10 mg   | Rate/100   |
|---------------------------------------|-------------|------------------|--------------|------------|
| MedDRA PT                             | N (%)       | Rate/100 pt-yrsN | (%)          | pt-yrs     |
| Total with adverse events             | 1463 (78.5) | 166.17           | 1420 (76.2)  | 149.07     |
| Cardiac disorders                     | 697 (37.4)  | 39.59            | 571 (30.6)   | 30.24      |
| Cardiac failure                       | 444 (23.8)  | 22.72            | 332 (17.8)   | 16.08      |
| Infections and infestations           | 542 (29.1)  | 29.78            | 510 (27.4)   | 27.37      |
| Pneumonia                             | 100 (5.4)   | 4.57             | 97 (5.2)     | 4.40       |
| Nasopharyngitis                       | 94 (5.0)    | 4.34             | 89 (4.8)     | 4.06       |
| Metabolism and nutrition disorders476 | (25.6)      | 26.03            | 411 (22.1)   | 21.53      |
| Hyperkalaemia                         | 115 (6.2)   | 5.33             | 101 (5.4)    | 4.62       |
| Hyperuricaemia                        | 115 (6.2)   | 5.36             | 63 (3.4)     | 2.85       |
| Renal and urinary disorders           | 275 (14.8)  | 13.37            | 280 (15.0)   | 13.52      |
| Renal impairment                      | 93 (5.0)    | 4.26             | 105 (5.6)    | 4.78       |
| Vascular disorders                    | 239 (12.8)  | 11.56            | 241 (12.9)   | 11.51      |
| Hypotension                           | 119 (6.4)   | 5.53             | 130 (7.0)    | 5.99       |

Adverse events reported during this trial were primarily of mild or moderate intensity. Of the severe AEs, the most frequent events at the SOC level were cardiac disorders (empagliflozin 250 patients, 13.4% vs placebo 294 patients, 15.8%), infections and infestations (80 patients, 4.3% vs 66 patients, 3.5%), and general disorders and administration site (47 patients, 2.5% vs 57 patients, 3.1%). The most frequent severe AEs at the PT level were cardiac failure (140 patients, 7.5% vs 165 patients, 8.9%), pneumonia (25 patients, 1.3% vs 33 patients, 1.8%), and death (20 patients, 1.1% vs 27 patients, 1.4%) (see Table 32)

Table 32 Patients with AEs by worst intensity and the most frequent severe AEs (frequency &gt;1% in either treatment group at the PT level) in 1245.121 - TS

|                                           | Placebo N (%)   | Empa 10 mg N (%)   |
|-------------------------------------------|-----------------|--------------------|
| Number of patients                        | 1863 (100.0)    | 1863 (100.0)       |
| Patients with any AEs                     |                 |                    |
| Mild                                      | 393 ( 21.1)     | 445 ( 23.9)        |
| Moderate                                  | 568 ( 30.5)     | 516 ( 27.7)        |
| Severe                                    | 502 ( 26.9)     | 459 ( 24.6)        |
| Patients with severe AEs                  |                 |                    |
| MedDRA SOC                                |                 |                    |
| MedDRA PT                                 |                 |                    |
| Cardiac disorders                         | 294 (15.8)      | 250 (13.4)         |
| Cardiac failure                           | 165 (8.9)       | 140 (7.5)          |
| Ventricular tachycardia                   | 16 (0.9)        | 21 (1.1)           |
| Cardiac failure congestive                | 19 (1.0)        | 15 (0.8)           |
| Infections and infestations               | 66 (3.5)        | 80 (4.3)           |
| Pneumonia                                 | 33 (1.8)        | 25 (1.3)           |
| Renal and urinary disorders               | 50 (2.7)        | 37 (2.0)           |
| Acute kidney injury                       | 25 (1.3)        | 15 (0.8)           |
| General disorders and administration site | 57 (3.1)        | 47 (2.5)           |
| Death                                     | 27 (1.4)        | 20 (1.1)           |

<div style=\"page-break-after: always\"></div>

Investigator-defined drug-related AEs generally matched the adverse reactions in the product information. The most frequent events were reported in the SOC renal and urinary disorders (empagliflozin 69 patients, 3.7% vs placebo 48 patients, 2.6%), metabolism and nutrition disorders (57 patients, 3.1% vs 43 patients, 2.3%), and infections and infestations (54 patients, 2.9% vs 43 patients, 2.3%). The most frequent PTs were hypotension (43 patients, 2.3% vs 34 patients, 1.8%), urinary tract infection (27 patients, 1.4% vs 26 patients, 1.4%), and renal impairment (27 patients, 1.4% vs 20 patients, 1.1%)

In SAF-HF2 the frequency of patients with any AE was comparable between treatment groups (49.0% for empagliflozin vs 53.2% for placebo). At PT level, the most reported AE was cardiac failure, reported less frequently for patients in the empagliflozin group than in the placebo group. For further details, see Table 33 below.

Table 33 Patients with adverse events in SAF-HF2 (frequency &gt;2% in either treatment group at the PT level), exposure adjusted - TS

| MedDRA SOC                           | Placebo     |                  | Empa 10 mg   | Empa 10 mg      |
|--------------------------------------|-------------|------------------|--------------|-----------------|
| MedDRA PT                            | N (%)       | Rate/100 pt-yrsN | (%)          | Rate/100 pt-yrs |
| Number of patients                   | 314 (100.0) | 314 (100.0)      | 312 (100.0)  | 312 (100.0)     |
| Total with adverse events            | 167 (53.2)  | 307.82           | 153 (49.0)   | 282.47          |
| Infections and infestations          | 43 (13.7)   | 59.37            | 37 (11.9)    | 51.52           |
| Bronchitis                           | 7 (2.2)     | 9.16             | 5 (1.6)      | 6.62            |
| Metabolism and nutrition disorders32 | (10.2)      | 44.09            | 21 (6.7)     | 28.61           |
| Hyperkalaemia                        | 7 (2.2)     | 9.22             | 1 (0.3)      | 1.31            |
| Nervous system disorders             | 28 (8.9)    | 37.84            | 25 (8.0)     | 33.99           |
| Dizziness                            | 14 (4.5)    | 18.52            | 8 (2.6)      | 10.66           |
| Cardiac disorders                    | 40 (12.7)   | 54.83            | 30 (9.6)     | 41.56           |
| Cardiac failure                      | 26 (8.3)    | 34.94            | 14 (4.5)     | 18.86           |
| Vascular disorders                   | 19 (6.1)    | 25.43            | 16 (5.1)     | 21.60           |
| Hypotension                          | 5 (1.6)     | 6.54             | 10 (3.2)     | 13.42           |
| Hypertension                         | 9 (2.9)     | 11.81            | 5 (1.6)      | 6.59            |
| Gastrointestinal disorders           | 24 (7.6)    | 32.58            | 24 (7.7)     | 32.97           |
| Diarrhoea                            | 5 (1.6)     | 6.55             | 7 (2.2)      | 9.36            |
| Nausea                               | 7 (2.2)     | 9.18             | 3 (1.0)      | 3.95            |

## AESIs and specific AEs

AESIs (adverse events of special interest) and specific AEs that represent medical concepts were analysed. To capture all events related to a specific medical concept, a combination of investigatordefined events, applicable CEC-adjudication results, standardised MedDRA query (SMQ), BI-customised MedDRA query (BIcMQ; when no SMQ was available), and/or additional definitions were used to analyse AESIs and specific AEs. The MedDRA queries or additional definitions used for the AESIs and specific AEs are consistent for all trials and the pooled analyses.

The results of the AESIs and specific AEs were consistent with the known safety profile of empagliflozin in patients with T2DM (Table 34)

<div style=\"page-break-after: always\"></div>

Table 34 Overall summary of AESIs and specific AEs in 1245.121 - TS

| Category of AESIs and specific AEs                               | Placebo      |                  | Empa 10 mg   |                  |
|------------------------------------------------------------------|--------------|------------------|--------------|------------------|
|                                                                  | N (%)        | Rate/ 100 pt-yrs | N (%)        | Rate/ 100 pt-yrs |
| Number of patients                                               | 1863 (100.0) | 1863 (100.0)     | 1863 (100.0) | 1863 (100.0)     |
| Acute renal failure (narrow SMQ)                                 | 192 (10.3)   | 9.02             | 175 (9.4)    | 8.13             |
| Serious                                                          | 95 (5.1)     | 4.31             | 59 (3.2)     | 2.63             |
| Leading to discontinuation                                       | 16 (0.9)     | 0.71             | 15 (0.8)     | 0.66             |
| Hepatic injury (narrow SMQs)                                     | 84 (4.5)     | 3.83             | 76 (4.1)     | 3.43             |
| Serious                                                          | 17 (0.9)     | 0.76             | 13 (0.7)     | 0.57             |
| Leading to discontinuation                                       | 4 (0.2)      | 0.18             | 2 (0.1)      | 0.09             |
| Up to 30 days after treatment discontinuation                    | 88 (4.7)     | 3.85             | 82 (4.4)     | 3.55             |
| Ketoacidosis (broad BIcMQ)                                       | 18 (1.0)     | 0.80             | 11 (0.6)     | 0.49             |
| Ketoacidosis (narrow BIcMQ)                                      | 0            |                  | 0            |                  |
| AEs leading to LLA up to trial completion (investigator-defined) | 10 (0.5)     | 0.39             | 13 (0.7)     | 0.51             |
| Urinary tract infection (UTI; BIcMQ)                             | 83 (4.5)     | 3.76             | 91 (4.9)     | 4.13             |
| Complicated                                                      | 15 (0.8)     | 0.67             | 19 (1.0)     | 0.84             |
| Leading to discontinuation                                       | 6 (0.3)      | 0.27             | 8 (0.4)      | 0.35             |
| Genital infection (BIcMQ)                                        | 12 (0.6)     | 0.53             | 31 (1.7)     | 1.38             |
| Complicated                                                      | 5 (0.3)      | 0.22             | 6 (0.3)      | 0.26             |
| Leading to discontinuation                                       | 0            |                  | 3 (0.2)      | 0.13             |
| Volume depletion (narrow BIcMQ)                                  | 184 (9.9)    | 8.76             | 197 (10.6)   | 9.26             |
| Hypotension (BIcMQ)                                              | 163 (8.7)    | 7.69             | 176 (9.4)    | 8.22             |
| Serious                                                          | 28 (1.5)     | 1.25             | 36 (1.9)     | 1.60             |
| Leading to discontinuation                                       | 6 (0.3)      | 0.27             | 10 (0.5)     | 0.44             |
| Symptomatic hypotension (investigator-defined)                   | 103 (5.5)    | 4.75             | 106 (5.7)    | 4.83             |
| Confirmed hypoglycaemic events 1                                 | 28 (1.5)     | 1.25             | 27 (1.4)     | 1.20             |
| In patients with T2DM 2                                          | 22/926 (2.4) | 2.00             | 20/927 (2.2) | 1.79             |
| In patients with pre-diabetes 2                                  | 5/635 (0.8)  | 0.67             | 6/632 (0.9)  | 0.79             |
| In patients without diabetes or pre-diabetes 2                   | 1/302 (0.3)  | 0.26             | 1/304 (0.3)  | 0.27             |
| Bone fracture (BIcMQ)                                            | 42 (2.3)     | 1.89             | 45 (2.4)     | 2.01             |
| Serious                                                          | 21 (1.1)     | 0.94             | 25 (1.3)     | 1.11             |
| Leading to discontinuation                                       | 1 (0.1)      | 0.04             | 3 (0.2)      | 0.13             |
| Up to trial completion                                           | 48 (2.6)     | 1.89             | 49 (2.6)     | 1.93             |
| Urinary tract malignancy up to trial completion (BIcMQ)          | 7 (0.4)      | 0.27             | 9 (0.5)      | 0.35             |

SMQ, standardised MedDRA query; BIcMQ, Boehringer Ingelheim customised MedDRA query

1 Hypoglycaemic AEs with a plasma glucose value of ≤70 mg/dL or where assistance was required

2  Patients with events/patients in subgroup (%)

In SAF-HF2, the number of patients with any type of AESI or specific AE were low and the pattern was qualitatively similar to that in 1245.121.

## Decreased renal function

The frequencies of acute renal failure (narrow SMQ) were similar in the empagliflozin and placebo groups (Table 35) Serious events were reported with a lower frequency for the empagliflozin group than placebo. Similar frequencies in both groups were observed for the events leading to treatment discontinuation.

<div style=\"page-break-after: always\"></div>

Fewer patients were reported with serum creatinine ≥2x the baseline value and above the normal range in the empagliflozin group (22 patients, 1.2%) than in the placebo group (35 patients, 1.9%).

Table 35 Patients with acute renal failure (SMQ) in 1245.121, exposure adjusted - TS

| MedDRA PT                               | Placebo N (%)   | Rate/100 pt-yrs   | Empa 10 mg N (%)   | Rate/100 pt-yrs   |
|-----------------------------------------|-----------------|-------------------|--------------------|-------------------|
| Number of patients                      | 1863 (100.0)    |                   | 1863 (100.0)       |                   |
| Acute renal failure (narrow SMQ)        | 192 (10.3)      | 9.02              | 175 (9.4)          | 8.13              |
| Renal impairment                        | 93 (5.0)        | 4.26              | 105 (5.6)          | 4.78              |
| Acute kidney injury                     | 55 (3.0)        | 2.47              | 35 (1.9)           | 1.55              |
| Renal failure                           | 48 (2.6)        | 2.16              | 44 (2.4)           | 1.96              |
| Azotaemia                               | 3 (0.2)         | 0.13              | 0                  |                   |
| Nephropathy toxic                       | 2 (0.1)         | 0.09              | 0                  |                   |
| Oliguria                                | 1 (0.1)         | 0.04              | 0                  |                   |
| Prerenal failure                        | 0               |                   | 1 (0.1)            | 0.04              |
| Serious                                 | 95 (5.1)        | 4.31              | 59 (3.2)           | 2.63              |
| Leading to discont. of study medication | 16 (0.9)        | 0.71              | 15 (0.8)           | 0.66              |

## Hepatic injury

Similar frequencies in both treatment groups were observed for hepatic injury (narrow SMQs), for events reported as SAEs, or for those leading to treatment discontinuation (Table 36). Hepatic events adjudicated by the independent CEC as possibly related to study medication were reported for 6 patients (0.3%) in the empagliflozin group and 4 patients (0.2%) in the placebo group. The hepatic injury of 1 patient in the empagliflozin group was adjudicated as probably related to study medication. The patient took concomitantly atorvastatin which is known to negatively impact liver function and which was discontinued about 1 week after the hepatic injury. No relevant differences in the liver function laboratory parameters or elevated transaminase values were observed between the 2 treatment groups.

Table 36 Patients with hepatic injury (SMQ; frequency &gt;0.2% in either treatment group at the PT level) in 1245.121, exposure adjusted - TS

| MedDRA PT                                                            | Placebo N (%)   | Rate/100 pt-yrs   | Empa 10 mg N (%)   | Rate/100 pt-yrs   |
|----------------------------------------------------------------------|-----------------|-------------------|--------------------|-------------------|
| Number of patients                                                   | 1863 (100.0)    |                   | 1863 (100.0)       |                   |
| Hepatic injury (narrow SMQs)                                         | 84 (4.5)        | 3.83              | 76 (4.1)           | 3.43              |
| Gamma-glutamyltransferase increased                                  | 12 (0.6)        | 0.53              | 9 (0.5)            | 0.40              |
| Hepatic function abnormal                                            | 12 (0.6)        | 0.53              | 12 (0.6)           | 0.53              |
| Hepatic enzyme increased                                             | 11 (0.6)        | 0.49              | 4 (0.2)            | 0.18              |
| Liver injury                                                         | 10 (0.5)        | 0.44              | 8 (0.4)            | 0.35              |
| Aspartate aminotransferase increased                                 | 5 (0.3)         | 0.22              | 6 (0.3)            | 0.26              |
| Hyperbilirubinaemia                                                  | 4 (0.2)         | 0.18              | 6 (0.3)            | 0.27              |
| Alanine aminotransferase increased                                   | 5 (0.3)         | 0.22              | 4 (0.2)            | 0.18              |
| Blood bilirubin increased                                            | 5 (0.3)         | 0.22              | 3 (0.2)            | 0.13              |
| Liver function test increased                                        | 1 (0.1)         | 0.04              | 5 (0.3)            | 0.22              |
| Hepatic injury (narrow SMQs), serious                                | 17 (0.9)        | 0.76              | 13 (0.7)           | 0.57              |
| Hepatic injury (narrow SMQs) leading to discont. of study medication | 4 (0.2)         | 0.18              | 2 (0.1)            | 0.09              |

<div style=\"page-break-after: always\"></div>

| Hepatic injury (narrow SMQs) up to 30days after treatment discontinuation   | 88 (4.7)     | 3.85   | 82 (4.4)     | 3.55   |
|-----------------------------------------------------------------------------|--------------|--------|--------------|--------|
| With T2DM                                                                   | 51/926 (5.5) |        | 46/927 (5.0) |        |
| Without T2DM                                                                | 33/937 (3.5) |        | 30/936 (3.2) |        |

For subgroups, patients in subgroup with events/all patients in subgroup (%) are shown.

## Ketoacidosis

For a comprehensive analysis in 1245.121, ketoacidosis was investigated using both broad and narrow BI-customised MedDRA query (BIcMQ). Based on the broad BIcMQ, events suggestive of ketoacidosis were reported for 11 patients (0.6%) in the empagliflozin group and for 18 patients (1.0%) in the placebo group (Table 37). Metabolic acidosis was the most frequent PT of the broad BIcMQ; there was no relevant increase in frequency for the empagliflozin group. All events in the broad BIcMQ were adjudicated, and none of the events was confirmed as certain ketoacidosis. One patient in the placebo group was adjudicated with potential ketoacidosis (mild intensity). No ketoacidosis was identified based on the narrow BIcMQ.

Table 37 Patients with ketoacidosis (BIcMQ) in 1245.121, exposure adjusted -TS

| MedDRA PT                           | Placebo      |                  | Empa 10 mg   | Rate/100 pt- yrs   |
|-------------------------------------|--------------|------------------|--------------|--------------------|
|                                     | N (%)        | Rate/100 pt- yrs | N (%)        |                    |
| Number of patients                  | 1863 (100.0) |                  | 1863 (100.0) |                    |
| Ketoacidosis (broad BIcMQ)          | 18 (1.0)     | 0.80             | 11 (0.6)     | 0.49               |
| Metabolic acidosis                  | 8 (0.4)      | 0.36             | 9 (0.5)      | 0.40               |
| Diabetic metabolic decompensation   | 7 (0.4)      | 0.31             | 2 (0.1)      | 0.09               |
| Acidosis                            | 2 (0.1)      | 0.09             | 0            |                    |
| Urine ketone body present           | 1 (0.1)      | 0.04             | 0            |                    |
| Ketoacidosis (broad BIcMQ), serious | 12 (0.6)     | 0.53             | 6 (0.3)      | 0.26               |
| Ketoacidosis (narrow BIcMQ)         | 0            |                  | 0            |                    |

In 1245.121, more patients in the empagliflozin group (174 patients, 11.0%) than the placebo group (113 patients, 7.1%) had bicarbonate values that shifted from normal at baseline to below normal at last value on treatment. The frequency of patients with Potentially Clinically Significant Abnormalities (PCSA) of low bicarbonate values (&lt;18 mmol/L) was greater in the empagliflozin group (273 patients, 16.1%) than the placebo group (197 patients, 11.6%). No noteworthy changes were observed in mean (SD) bicarbonate values from baseline to last value on treatment in either group: empagliflozin group -0.25 (2.18) mEq/L; placebo group 0.01 (2.09) mEq/L.

No ketoacidosis was reported in SAF-HF2. No clinically relevant differences between treatment groups in bicarbonate or urine ketone was observed

## AEs leading to lower limb amputation (LLA)

Adverse events leading to LLA on treatment or up to trial completion were infrequent and comparable in the empagliflozin and placebo groups (Table 34)

## Urinary tract infection

In 1245.121, the frequencies for urinary tract infection (narrow sub BIcMQ) were similar in both treatment groups (table 38). The most frequently reported PT was urinary tract infection, which was also reported with similar frequencies in both treatment groups. Other PTs were reported with similar

<div style=\"page-break-after: always\"></div>

frequencies in both treatment groups except for cystitis, which was reported with numerically higher frequencies in the empagliflozin group (13 patients, 0.7%) than in the placebo group (6 patients, 0.3%). The frequencies for complicated urinary tract infections and the PTs included in this BIcMQ were similar in the empagliflozin group and the placebo group.

<div style=\"page-break-after: always\"></div>

Table 38 Patients with urinary tract infection (BIcMQ) in 1245.121, exposure adjusted - TS

| MedDRA PT                               | Placebo N (%)   | Rate/100   | Empa 10 mg pt-yrs N (%)   | Rate/100   |
|-----------------------------------------|-----------------|------------|---------------------------|------------|
| Number of patients                      | 1863 (100.0)    |            | 1863 (100.0)              |            |
| Urinary tract infection (narrow BIcMQ)  | 83 (4.5)        | 3.76       | 91 (4.9)                  | 4.13       |
| Urinary tract infection                 | 72 (3.9)        | 3.25       | 69 (3.7)                  | 3.10       |
| Cystitis                                | 6 (0.3)         | 0.27       | 13 (0.7)                  | 0.58       |
| Urinary tract infection bacterial       | 2 (0.1)         | 0.09       | 4 (0.2)                   | 0.18       |
| Urosepsis                               | 0               |            | 4 (0.2)                   | 0.18       |
| Escherichia urinary tract infection     | 0               |            | 2 (0.1)                   | 0.09       |
| Pyelonephritis acute                    | 2 (0.1)         | 0.09       | 0                         |            |
| Asymptomatic bacteriuria                | 1 (0.1)         | 0.04       | 0                         |            |
| Kidney infection                        | 0               |            | 1 (0.1)                   | 0.04       |
| Pyelitis                                | 1 (0.1)         | 0.04       | 0                         |            |
| Pyelonephritis                          | 1 (0.1)         | 0.04       | 1 (0.1)                   | 0.04       |
| Complicated                             | 15 (0.8)        | 0.67       | 19 (1.0)                  | 0.84       |
| Leading to discont. of study medication | 6 (0.3)         | 0.27       | 8 (0.4)                   | 0.35       |

Subgroup analyses were performed by age, sex, race, and baseline eGFR, T2DM, and history of chronic or recurrent urinary tract infection. The results of the subgroup analyses were generally similar to the main analyses.

Investigator-defined urinary tract infection (including urosepsis and acute pyelonephritis) were reported for 92 patients (4.9%) in the empagliflozin group and 83 patients (4.5%) in the placebo group. Urinary tract infections were mostly infections of the lower urinary tract (bladder and below) or asymptomatic bacteriuria. Most patients with urinary tract infection in both treatment groups had a single episode rather than multiple episodes of urinary tract infection.

Similar frequencies in both treatment groups were observed for the analysis including the PT urosepsis and pyelonephritis based on the narrow sub BIcMQ (empagliflozin: 5 patients, 0.3%; placebo: 4 patients, 0.2%) . In this analysis, 4 patients (0.2%) on empagliflozin and none on placebo had urosepsis. Acute pyelonephritis was doc umented for none of the patients on empagliflozin but for 2 patients (0.1%) on placebo. In 1245.121, investigator-defined sepsis with the source urinary tract infection occurred in few patients (empagliflozin: 5 patients, 0.3%; placebo: 1 patient, 0.1%) Fo ur of the 5 patients in the empagliflozin group were reported with the PT urosepsis. The 5 patients on empagliflozin with sepsis (source UTI) were female, whereas 1 patient on placebo was male (table 39).

<div style=\"page-break-after: always\"></div>

Table 39 Patients with acute pyelonephritis or urosepsis in 1245.121 - TS

|                                                     | Placebo N (%)   | Rate/ 100   | Empa 10 mg N (%)   | Rate/ 100 pt-yrs   |
|-----------------------------------------------------|-----------------|-------------|--------------------|--------------------|
| Number of patients                                  | 1863 (100.0)    |             | 1863 (100.0)       |                    |
| Urosepsis (PT) or pyelonephritis (narrow sub BIcMQ) | 4 (0.2)         | 0.18        | 5 (0.3)            | 0.22               |
| Male                                                | 4/1410 (0.3)    | 0.23        | 1/1426 (0.1)       | 0.06               |
| Female                                              | 0/453           |             | 4/437 (0.9)        | 0.74               |
| With T2DM                                           | 3/926 (0.3)     | 0.27        | 1/927 (0.1)        | 0.09               |
| Without T2DM                                        | 1/937 (0.1)     | 0.09        | 4/936 (0.4)        | 0.35               |
| Acute pyelonephritis (investigator-defined)         | 4 (0.2)         | 0.18        | 1 (0.1)            | 0.04               |
| Male                                                | 4/1410 (0.3)    | 0.23        | 1/1426 (0.1)       | 0.06               |
| Female                                              | 0/453           |             | 0/437              |                    |
| Sepsis with source from UTI (investigator-defined)  | 1 (0.1)         | 0.04        | 5 (0.3)            | 0.22               |
| Male                                                | 1/1410 (0.1)    | 0.06        | 0/1426             |                    |
| Female                                              | 0/453           |             | 5/437 (1.1)        | 0.93               |

For subgroups, patients in subgroup with events/all patients in subgroup (%) are shown.

In SAF-HF2, 11 patients (3.5%) in the empagliflozin group and 8 patients (2.5%) in the placebo group were reported with urinary tract infection. Investigator-defined urinary tract infection was reported for the same patients as those captured using BIcMQ.

## Genital infection

Genital infections (narrow BIcMQ) were more frequent in the empagliflozin group than the placebo group (Table 40). Genital infections occurred in male and female patients, and in patients with and without T2DM (Table 41). No relevant difference between treatment groups was observed in the frequency of complicated genital infections or those leading to treatment discontinuation.

Table 40 Patients with genital infection (BIcMQ; occurrence in &gt;1 patient in either treatment group at the PT level) in 1245.121, exposure adjusted - TS

| MedDRA PT                               | Placebo N (%)   | Rate/100   | Empa 10 mg pt-yrs N (%)   | Rate/100   |
|-----------------------------------------|-----------------|------------|---------------------------|------------|
| Number of patients                      | 1863 (100.0)    |            | 1863 (100.0)              |            |
| Genital infection (narrow BIcMQ)        | 12 (0.6)        | 0.53       | 31 (1.7)                  | 1.38       |
| Balanoposthitis                         | 0               |            | 5 (0.3)                   | 0.22       |
| Genital infection fungal                | 0               |            | 5 (0.3)                   | 0.22       |
| Orchitis                                | 0               |            | 4 (0.2)                   | 0.18       |
| Vulvovaginal candidiasis                | 2 (0.1)         | 0.09       | 4 (0.2)                   | 0.18       |
| Genital candidiasis                     | 1 (0.1)         | 0.04       | 3 (0.2)                   | 0.13       |
| Vulvovaginal mycotic infection          | 1 (0.1)         | 0.04       | 3 (0.2)                   | 0.13       |
| Genital infection                       | 0               |            | 2 (0.1)                   | 0.09       |
| Prostatitis                             | 2 (0.1)         | 0.09       | 1 (0.1)                   | 0.04       |
| Vulvovaginitis                          | 1 (0.1)         | 0.04       | 2 (0.1)                   | 0.09       |
| Complicated                             | 5 (0.3)         | 0.22       | 6 (0.3)                   | 0.26       |
| Leading to discont. of study medication | 0               |            | 3 (0.2)                   | 0.13       |

<div style=\"page-break-after: always\"></div>

Table 41 Patients with genital infection (BIcMQ) in subgroups in 1245.121 (by sex and T2DM status), exposure adjusted - TS

| Subgroup     | Placebo       | Placebo         | Empa 10 mg    | Empa 10 mg      |
|--------------|---------------|-----------------|---------------|-----------------|
|              | n/N (%)       | Rate/100 pt-yrs | n/N (%)       | Rate/100 pt-yrs |
| All patients | 12/1863 (0.6) | 0.53            | 31/1863       | 1.38            |
| Male         | 6/1410 (0.4)  | 0.35            | 20/1426 (1.4) | 1.17            |
| Female       | 6/453 (1.3)   | 1.13            | 11/437 (2.5)  | 2.08            |
| With T2DM    | 4/926 (0.4)   | 0.36            | 18/927 (1.9)  | 1.62            |
| Without T2DM | 8/937 (0.9)   | 0.71            | 13/936 (1.4)  | 1.15            |

## Volume depletion and hypotension

There was a numerical increase in the narrow BIcMQ volume depletion (empagliflozin: 197 patients, 10.6%; placebo: 184 patients, 9.9%) and in the BIcMQ hypotension (empagliflozin: 176 patients, 9.4%; placebo: 163 patients, 8.7%) for the empagliflozin group when compared with placebo (Table 42). The small increases were not considered clinically relevant, as the frequencies of investigator-defined symptomatic hypotension events, which represent clinically relevant hypotension events, were balanced in the empagliflozin (106 patients, 5.7%) and placebo groups (103 patients, 5.5%. However, the frequencies for volume depletion (narrow BIcMQ) and hypotension (BIcMQ) leading to discontinuation or reported as SAEs were numerically higher in the empagliflozin group than in the placebo group.

Table 42 Patients with volume depletion (narrow BIcMQ) and hypotension (BIcMQ) in 1245.121, exposure adjusted - TS

| MedDRA PT                                                               | Placebo      | Placebo          | Empa 10 mg   | Empa 10 mg       |
|-------------------------------------------------------------------------|--------------|------------------|--------------|------------------|
|                                                                         | N (%)        | Rate/ 100 pt-yrs | N (%)        | Rate/ 100 pt-yrs |
| Number of patients                                                      | 1863 (100.0) | 1863 (100.0)     | 1863 (100.0) | 1863 (100.0)     |
| Volume depletion (narrow BIcMQ)                                         | 184 (9.9)    | 8.76             | 197 (10.6)   | 9.26             |
| Dehydration                                                             | 21 (1.1)     | 0.94             | 25 (1.3)     | 1.11             |
| Hypovolaemia                                                            | 3 (0.2)      | 0.13             | 1 (0.1)      | 0.04             |
| Hypotension (BIcMQ; part of volume depletion)                           | 163 (8.7)    | 7.69             | 176 (9.4)    | 8.22             |
| Hypotension                                                             | 119 (6.4)    | 5.53             | 130 (7.0)    | 5.99             |
| Syncope                                                                 | 26 (1.4)     | 1.16             | 33 (1.8)     | 1.47             |
| Orthostatic hypotension                                                 | 13 (0.7)     | 0.58             | 18 (1.0)     | 0.80             |
| Presyncope                                                              | 6 (0.3)      | 0.27             | 9 (0.5)      | 0.40             |
| Circulatory collapse                                                    | 5 (0.3)      | 0.22             | 0            |                  |
| Blood pressure decreased                                                | 1 (0.1)      | 0.04             | 0            |                  |
| Hypovolaemic shock                                                      | 1 (0.1)      | 0.04             | 0            |                  |
| Volume depletion (narrow BIcMQ), serious                                | 33 (1.8)     | 1.48             | 43 (2.3)     | 1.91             |
| Hypotension (BIcMQ), serious                                            | 28 (1.5)     | 1.25             | 36 (1.9)     | 1.60             |
| Volume depletion (narrow BIcMQ) leading to discont. of study medication | 6 (0.3)      | 0.27             | 14 (0.8)     | 0.62             |
| Hypotension (BIcMQ) leading to discont. of study medication             | 6 (0.3)      | 0.27             | 10 (0.5)     | 0.44             |

<div style=\"page-break-after: always\"></div>

## Hypoglycaemia

The frequencies for confirmed hypoglycaemic events overall and in subgroups by T2DM status at baseline were balanced between treatment groups (Table 34). Patients without T2DM did not have any severe hypoglycaemic events requiring assistance (investigator-defined).

## Bone fracture

The frequencies for bone fracture (BIcMQ) were similar between treatment groups. Investigator-defined bone fractures were reported for 45 patients (2.4%) in the empagliflozin group and for 43 patients (2.3%) in the placebo group. No relevant difference was observed for events leading to discontinuation or reported as SAEs or when including also the events up to trial completion (Table 34).

## Urinary tract malignancy

Urinary tract malignancy events on treatment or up to trial completion were infrequent and balanced in both treatment groups, with 9 patients (0.5%) in the empagliflozin group and 7 patients (0.4%) in the placebo group (Table 34).

## Unexpected AEs

## Fall

In 1245.121, the PT fall was reported for more patients in the empagliflozin group (43patients, 2.3%) than in the placebo group (27patients, 1.4%). Very few patients discontinued study medication due to the fall (Table 43)

Table 43 Patients with the PT fall in 1245.121 - TS

|                                      | Placebo N (%)   | Rate/100 pt-yrs   | Empa 10 mg N (%)   | Rate/100 pt-yrs   |
|--------------------------------------|-----------------|-------------------|--------------------|-------------------|
| Number of patients                   | 1863 (100.0)    |                   | 1863 (100.0)       |                   |
| PT fall                              | 27 (1.4)        | 1.21              | 43 (2.3)           | 1.92              |
| Severe                               | 4 (0.2)         |                   | 5 (0.3)            |                   |
| Investigator defined drug-related    | 1 (0.1)         | 0.04              | 0                  |                   |
| Leading to treatment discontinuation | 1 (0.1)         | 0.04              | 2 (0.1)            | 0.09              |

Fall occurred in a similar number of patients between groups up to Day 240, suggesting no relation to initiation of treatment with empagliflozin. After Day 240, the increase in number of patients with falls was steady in the empagliflozin group, while the increase in the placebo group appeared to level off.

Medical review of all patients who had fallen did not identify any predominant pathophysiological cause for falls (e.g. volume depletion, hypotension, or hypoglycaemia). The imbalance appeared to be mainly due to falls from an external cause; some falls were initially reported as 'accidental fall' or 'mechanical fall', implying there was an external influence causing the patient to fall or it was stated that the fall was due to the patients' carelessness, such as tripping over something while walking. Furthermore, hypoglycaemia, investigator-defined symptomatic hypotension, and the PT loss of consciousness (reported for 3 patients in each group, 0.2%) were balanced between treatment groups. Furthermore, hypoglycaemia, investigator-defined symptomatic hypotension and the PT loss of consciousness (reported for 3 patients in each group, 0.2%) were balanced between treatment groups.

In the previous large outcome trial in patients with T2DM and established CV disease (1245.25, EMPAREG OUTCOME), patients with fall trended to disfavour empagliflozin (placebo 60 (2.6%), empagliflozin 10mg 68 (2.9%), empagliflozin 71 (3.0%)).

<div style=\"page-break-after: always\"></div>

Post-marketing data for empagliflozin were examined and no case suggestive for a causal association between empagliflozin and fall other than falls as a consequence of presyncope or syncope (a known side effect of empagliflozin) was identified.

## Constipation

In 1245.121, the PT constipation was reported for more patients in the empagliflozin group (57 patients, 3.1%) than in the placebo group (27 patients, 1.4%), which was observed across all subgroups. Few patients had serious events or discontinued treatment due to the events (Table 44).

Table 44 Patients with the PT constipation in 1245.121 - TS

|                                      | Placebo N (%)   | Rate/100   | Empa 10 mg N (%)   | Rate/100 pt-yrs   |
|--------------------------------------|-----------------|------------|--------------------|-------------------|
| Number of patients                   | 1863            | (100.0)    | 1863 (100.0)       |                   |
| PT constipation                      | 27 (1.4)        | 1.21       | 57 (3.1)           | 2.56              |
| Severe                               | 0               |            | 0                  |                   |
| Investigator defined drug-related    | 1 (0.1)         | 0.04       | 5 (0.3)            | 0.22              |
| Leading to treatment discontinuation | 0               |            | 2 (0.1)            | 0.09              |
| Serious                              | 1 (0.1)         | 0.04       | 3 (0.2)            | 0.13              |
| Fatal                                | 0               |            | 0                  |                   |

In SAF-HF2, very few patients had constipation (empagliflozin: 3 patients, 1.0%; placebo: 4 patients, 1.3%), and none of the events was severe, drug-related, led to treatment discontinuation, or serious.

## Serious adverse event/deaths/other significant events

In 1245.121, SAEs (but not AESIs) that were components of efficacy endpoints or consequences/complications of the underlying disease were exempted from reporting on the SAE form, regardless of relationship to the study medication.

In 1245.121, the overall frequency of SAEs was lower in the empagliflozin group than the placebo group (Table 45). Serious adverse events were most frequently reported in the SOC cardiac disorders. On the PT level, cardiac failure, pneumonia, ventricular tachycardia (see below for details), and acute kidney injury were the most frequently reported SAEs. All other PTs in the SOC cardiac disorders were reported for &lt;3.0% of patients in either group.

Table 45 Patients with SAEs in 1245.121 (frequency &gt;1% in either treatment group at the PT level), exposure adjusted - TS

| MedDRA SOC                  | Placebo      | Placebo          | Empa 10 mg   | Empa 10 mg       |
|-----------------------------|--------------|------------------|--------------|------------------|
| MedDRA PT                   | N (%)        | Rate/100 pt- yrs | N (%)        | Rate/100 pt- yrs |
| Number of patients          | 1863 (100.0) |                  | 1863 (100.0) |                  |
| Total with SAEs             | 896 (48.1)   | 55.13            | 772 (41.4)   | 43.86            |
| Cardiac disorders           | 634 (34.0)   | 34.96            | 500 (26.8)   | 25.63            |
| Cardiac failure             | 444 (23.8)   | 22.72            | 332 (17.8)   | 16.08            |
| Ventricular tachycardia     | 37 (2.0)     | 1.66             | 55 (3.0)     | 2.46             |
| Atrial fibrillation         | 44 (2.4)     | 1.98             | 24 (1.3)     | 1.06             |
| Cardiac failure congestive  | 41 (2.2)     | 1.84             | 26 (1.4)     | 1.15             |
| Cardiac failure chronic     | 32 (1.7)     | 1.43             | 18 (1.0)     | 0.80             |
| Cardiac failure acute       | 29 (1.6)     | 1.30             | 19 (1.0)     | 0.84             |
| Acute myocardial infarction | 18 (1.0)     | 0.80             | 24 (1.3)     | 1.06             |

<div style=\"page-break-after: always\"></div>

| Infections and infestations                          | 136 (7.3)   |   6.25 | 139 (7.5)   |   6.33 |
|------------------------------------------------------|-------------|--------|-------------|--------|
| Pneumonia                                            | 62 (3.3)    |   2.79 | 53 (2.8)    |   2.37 |
| Renal and urinary disorders                          | 107 (5.7)   |   4.87 | 71 (3.8)    |   3.17 |
| Acute kidney injury                                  | 55 (3.0)    |   2.47 | 35 (1.9)    |   1.55 |
| Renal impairment                                     | 27 (1.4)    |   1.21 | 17 (0.9)    |   0.75 |
| Nervous system disorders                             | 74 (4.0)    |   3.33 | 94 (5.0)    |   4.24 |
| Ischaemic stroke                                     | 20 (1.1)    |   0.89 | 19 (1.0)    |   0.84 |
| General disorders and administration site conditions | 70 (3.8)    |   3.13 | 54 (2.9)    |   2.39 |
| Death                                                | 27 (1.4)    |   1.2  | 20 (1.1)    |   0.88 |
| With investigator-defined drug-related SAEs          | 51 (2.7)    |   2.29 | 51 (2.7)    |   2.27 |

Patient #2616033010 (empagliflozin group; post-treatment, on 10 Nov 2019) and #2616033021 (placebo group; ontreatment, on 27 Aug 2019) were each reported with an SAE 'exacerbation of HF' after the database was locked and were therefore not included in the study database.

In SAF-HF2, the frequency of patients reported with SAEs was lower in the empagliflozin group (41 patients, 13.1%) than in the placebo group (56 patients, 17.8%). The difference was mainly due to PT cardiac failure, reported for fewer patients in the empagliflozin group (12 patients, 3.8%) than in the placebo group (25 patients, 8.0%).

## Ventricular tachycardia

In 1245.121, serious events of PT ventricular tachycardia were reported for more patients in the empagliflozin group (55 patients, 3.0%) than in the placebo group (37 patients, 2.0%). Very few patients discontinued the study medication due to ventricular tachycardia. When medically relevant PTs were analysed together in the SMQ ventricular tachyarrhythmia ( post hoc ), the incidence rate of the serious events between the treatment groups was similar (incidence rate adjusted for the time at risk: empagliflozin 2.92/100 pt-yrs vs placebo 2.39/100 pt-yrs)

Except for the PT ventricular tachycardia, no obvious differences between groups were observed for other PTs in the SMQ ventricular tachyarrhythmia. Especially, no differences were seen in the proportion of patients with clinically less severe ventricular tachyarrhythmia such as isolated premature ventricular complexes (extrasystoles) or patients with more severe ventricular tachyarrhythmia such as ventricular fibrillation or torsade de pointes (Table 46)

Table 46 Patients with PT ventricular tachycardia or SMQ ventricular tachyarrhythmia in 1245.121 - TS

|                                              | Placebo N (%)   | Rate/100 pt-yrs   | Empa 10 mg N (%)   | Rate/100 pt-yrs   |
|----------------------------------------------|-----------------|-------------------|--------------------|-------------------|
| Number of patients                           | 1863 (100.0)    | 1863 (100.0)      | 1863 (100.0)       | 1863 (100.0)      |
| PT ventricular tachycardia                   | 37 (2.0)        | 1.66              | 56 (3.0)           | 2.51              |
| Serious                                      | 37 (2.0)        | 1.66              | 55 (3.0)           | 2.46              |
| Severe                                       | 16 (0.9)        |                   | 21 (1.1)           |                   |
| Investigator defined drug-related            | 1 (0.1)         | 0.04              | 2 (0.1)            | 0.09              |
| Leading to treatment discontinuation         | 1 (0.1)         | 0.04              | 2 (0.1)            | 0.09              |
| Fatal                                        | 0               |                   | 1 (0.1)            | 0.04              |
| SMQ ventricular tachyarrhythmia ( post hoc ) | 64 (3.4)        | 2.90              | 80 (4.3)           | 3.61              |
| PT ventricular tachycardia                   | 37 (2.0)        | 1.66              | 56 (3.0)           | 2.51              |
| PT ventricular extrasystoles                 | 12 (0.6)        | 0.53              | 14 (0.8)           | 0.62              |
| PT ventricular fibrillation                  | 8 (0.4)         | 0.36              | 10 (0.5)           | 0.44              |
| PT ventricular arrhythmia                    | 9 (0.5)         | 0.40              | 4 (0.2)            | 0.18              |
| PT torsade de pointes                        | 0               |                   | 1 (0.1)            | 0.04              |
| PT ventricular flutter                       | 1 (0.1)         | 0.04              | 1 (0.1)            | 0.04              |
| PT ventricular tachyarrhythmia               | 1 (0.1)         | 0.04              | 0                  |                   |

Extension of indication variation assessment report

EMA/CHMP/275072/2021

<div style=\"page-break-after: always\"></div>

| Serious                              | 53 (2.8)   | 2.39   | 65 (3.5)   | 2.92   |
|--------------------------------------|------------|--------|------------|--------|
| Severe                               | 24 (1.3)   |        | 28 (1.5)   |        |
| Investigator defined drug-related    | 1 (0.1)    | 0.04   | 3 (0.2)    | 0.13   |
| Leading to treatment discontinuation | 5 (0.3)    | 0.22   | 6 (0.3)    | 0.26   |
| Fatal                                | 4 (0.2)    | 0.18   | 4 (0.2)    | 0.18   |

The frequency of patients with new ECG findings any time in the study after baseline was balanced between treatment groups (empagliflozin 39.6% vs placebo 39.8%). Furthermore, the risk of heart failure hospitalisations, recurrent heart failure hospitalisations, and investigator-defined CV hospitalisations were reduced with empagliflozin treatment, and fewer patients were reported with CECdefined sudden cardiac death in the empagliflozin group (70 patients, 3.8%) than in the placebo group (81 patients, 4.3%).

In the previous large outcome trial in patients with T2DM and established CV disease (1245.25, EMPAREG OUTCOME), the SMQ ventricular tachyarrhythmia or PT ventricular tachycardia was reported for fewer patients in the 2 empagliflozin groups than in the placebo group (placebo 13 patients, 0.6%, empagliflozin 10mg 3 patients, 0.1%, empagliflozin 25mg 9 patients, 0.4%)

## Laboratory findings

Safety laboratory values measured within 3 days after the last intake of study medication were considered as 'on-treatment', except for creatinine and eGFR (up to 1 day after the last intake were used, to reflect the rapid change in plasma volume).

Haemoglobin and haematocrit values increased and then partially returned to baseline in the empagliflozin group at follow up (about 30 days after treatment stop); almost no change was observed in the placebo group. Uric acid decreased in the empagliflozin group and then partially returned to baseline at follow up. There were no relevant changes in the rest of the safety laboratory parameters in 1245.121.

In SAF-HF2, the trends were consistent with those in 1245.121

## Safety in special populations

Subgroup analyses of AEs were carried out by demographic and baseline characteristics (age, sex, race, geographic region, ethnicity, diabetes status at baseline, baseline eGFR, baseline blood pressure, and baseline use of certain heart failure medications).

In 1245.121, AEs in the subgroups showed trends generally consistent with the overall AE profile in the trial, including in subgroups with or without T2DM and by eGFR categories at baseline (including patients with an eGFR of &lt;30 mL/min/1.73 m 2 ). No relevant difference in renal adverse events or volume depletion including hypotension was observed in patients with or without controlled blood pressure or certain HF medications such as RAAS blockade and diuretics at baseline.

In SAF-HF2, no relevant treatment differences were observed in any subgroup, including between HFrEF and HFpEF.

## Diabetes status at baseline

In 1245.121, AE profile by T2DM status at baseline was consistent with the overall AE profile in the trial Table 47

<div style=\"page-break-after: always\"></div>

Table 47 AEs by baseline T2DM status in 1245.121 - TS

| Category of AEs                             | Placebo N (%)   | Empa 10 mg Rate/100 pt-yrs   | N (%)       | Rate/100 pt-yrs   |
|---------------------------------------------|-----------------|------------------------------|-------------|-------------------|
| T2DM                                        | 926 (100.0)     | 926 (100.0)                  | 927 (100.0) | 927 (100.0)       |
| Any AE                                      | 741 (80.0)      | 177.31                       | 716 (77.2)  | 150.97            |
| Leading to discont. of study medication     | 176 (19.0)      | 15.82                        | 175 (18.9)  | 15.58             |
| SAEs                                        | 457 (49.4)      | 57.62                        | 397 (42.8)  | 45.10             |
| Acute renal failure (SMQ)                   | 98 (10.6)       | 9.29                         | 98 (10.6)   | 9.20              |
| Hepatic injury (SMQ)                        | 51 (5.5)        | 4.71                         | 46 (5.0)    | 4.19              |
| Ketoacidosis (narrow BIcMQ)                 | 0               |                              | 0           |                   |
| AEs leading to LLA (up to trial completion) | 9 (1.0)         | 0.70                         | 12 (1.3)    | 0.94              |
| Urinary tract infection (BIcMQ)             | 49 (5.3)        | 4.47                         | 52 (5.6)    | 4.74              |
| Genital infection (BIcMQ)                   | 4 (0.4)         | 0.36                         | 18 (1.9)    | 1.62              |
| Volume depletion (narrow BIcMQ)             | 84 (9.1)        | 7.99                         | 103 (11.1)  | 9.68              |
| Hypotension (BIcMQ)                         | 72 (7.8)        | 6.78                         | 91 (9.8)    | 8.51              |
| Confirmed hypoglycaemic events 1            | 22 (2.4)        | 2.00                         | 20 (2.2)    | 1.79              |
| Bone fracture (BIcMQ)                       | 26 (2.8)        | 2.36                         | 20 (2.2)    | 1.79              |
| Non-diabetic                                | 937 (100.0)     | 937 (100.0)                  | 936 (100.0) | 936 (100.0)       |
| Any AE                                      | 722 (77.1)      | 156.10                       | 704 (75.2)  | 147.19            |
| Leading to discont. of study medication     | 152 (16.2)      | 13.46                        | 147 (15.7)  | 12.97             |
| SAEs                                        | 439 (46.9)      | 52.76                        | 375 (40.1)  | 42.62             |
| Acute renal failure (SMQ)                   | 94 (10.0)       | 8.74                         | 77 (8.2)    | 7.07              |
| Hepatic injury (SMQ)                        | 33 (3.5)        | 2.97                         | 30 (3.2)    | 2.69              |
| Ketoacidosis (narrow BIcMQ)                 | 0               |                              | 0           |                   |
| AEs leading to LLA (up to trial completion) | 1 (0.1)         | 0.08                         | 1 (0.1)     | 0.08              |
| Urinary tract infection (BIcMQ)             | 34 (3.6)        | 3.06                         | 39 (4.2)    | 3.52              |
| Genital infection (BIcMQ)                   | 8 (0.9)         | 0.71                         | 13 (1.4)    | 1.15              |
| Volume depletion (narrow BIcMQ)             | 100 (10.7)      | 9.54                         | 94 (10.0)   | 8.84              |
| Hypotension (BIcMQ)                         | 91 (9.7)        | 8.61                         | 85 (9.1)    | 7.93              |
| Confirmed hypoglycaemic events 1            | 6 (0.6)         | 0.53                         | 7 (0.7)     | 0.62              |
| Bone fracture (BIcMQ)                       | 16 (1.7)        | 1.42                         | 25 (2.7)    | 2.23              |

1 Hypoglycaemic AEs with a plasma glucose value of ≤70 mg/dL or where assistance was required

## Baseline eGFR

In 1245.121, AE profile by eGFR at baseline (including for patients with an eGFR of &lt;30 mL/min/1.73 m 2 ) was consistent with the overall AE profile in the trial (Table 48)

Table 48 AEs by baseline eGFR in 1245.121 - TS

| Category of AEs                         | Placebo N (%)   | Rate/100 pt-yrs   | Empa 10 mg N (%)   | Rate/100 pt-yrs   |
|-----------------------------------------|-----------------|-------------------|--------------------|-------------------|
| eGFR ≥90 mL/min/1.73 m 2                | 220 (100.0)     |                   | 229 (100.0)        |                   |
| Any AE                                  | 156 (70.9)      | 131.02            | 155 (67.7)         | 110.87            |
| Leading to discont. of study medication | 25 (11.4)       | 9.08              | 30 (13.1)          | 10.52             |
| SAEs                                    | 94 (42.7)       | 47.07             | 72 (31.4)          | 30.45             |
| Acute renal failure (SMQ)               | 13 (5.9)        | 4.89              | 7 (3.1)            | 2.45              |
| AEs leading to LLA                      | 0               |                   | 0                  |                   |
| Urinary tract infection (BIcMQ)         | 12 (5.5)        | 4.49              | 4 (1.7)            | 1.41              |
| Genital infection (BIcMQ)               | 2 (0.9)         | 0.73              | 2 (0.9)            | 0.71              |
| Volume depletion (narrow BIcMQ)         | 18 (8.2)        | 6.89              | 18 (7.9)           | 6.55              |
| Hypotension (BIcMQ)                     | 16 (7.3)        | 6.10              | 18 (7.9)           | 6.55              |

<div style=\"page-break-after: always\"></div>

| Category of AEs                         | Placebo       |               | Empa 10 mg    | Rate/100 pt-yrs   |
|-----------------------------------------|---------------|---------------|---------------|-------------------|
| Confirmed hypoglycaemic events 1        | N (%) 4 (1.8) | Rate/100 1.47 | N (%) 3 (1.3) | 1.05              |
| Bone fracture (BIcMQ)                   | 6 (2.7)       | 2.22          | 4 (1.7)       | 1.40              |
| eGFR 60 to <90 mL/min/1.73 m 2          | 738 (100.0)   | 738 (100.0)   | 740 (100.0)   | 740 (100.0)       |
| Any AE                                  | 560 (75.9)    | 152.79        | 548 (74.1)    | 141.23            |
| Leading to discont. of study medication | 108 (14.6)    | 12.07         | 111 (15.0)    | 12.37             |
| SAEs                                    | 343 (46.5)    | 52.87         | 278 (37.6)    | 38.92             |
| Acute renal failure (SMQ)               | 62 (8.4)      | 7.25          | 54 (7.3)      | 6.27              |
| AEs leading to LLA                      | 3 (0.4)       | 0.30          | 5 (0.7)       | 0.49              |
| Urinary tract infection (BIcMQ)         | 22 (3.0)      | 2.49          | 36 (4.9)      | 4.09              |
| Genital infection (BIcMQ)               | 6 (0.8)       | 0.67          | 14 (1.9)      | 1.57              |
| Volume depletion (narrow BIcMQ)         | 63 (8.5)      | 7.39          | 69 (9.3)      | 8.12              |
| Hypotension (BIcMQ)                     | 55 (7.5)      | 6.39          | 63 (8.5)      | 7.39              |
| Confirmed hypoglycaemic events 1        | 12 (1.6)      | 1.35          | 8 (1.1)       | 0.89              |
| Bone fracture (BIcMQ)                   | 9 (1.2)       | 1.01          | 13 (1.8)      | 1.46              |
| eGFR 45 to <60 mL/min/1.73 m 2          | 467 (100.0)   | 467 (100.0)   | 433 (100.0)   | 433 (100.0)       |
| Any AE                                  | 361 (77.3)    | 150.85        | 344 (79.4)    | 163.61            |
| Leading to discont. of study medication | 83 (17.8)     | 14.44         | 75 (17.3)     | 14.37             |
| SAEs                                    | 225 (48.2)    | 52.69         | 188 (43.4)    | 47.00             |
| Acute renal failure (SMQ)               | 49 (10.5)     | 8.93          | 39 (9.0)      | 7.82              |
| AEs leading to LLA                      | 4 (0.9)       | 0.61          | 3 (0.7)       | 0.50              |
| Urinary tract infection (BIcMQ)         | 15 (3.2)      | 2.64          | 23 (5.3)      | 4.54              |
| Genital infection (BIcMQ)               | 3 (0.6)       | 0.52          | 6 (1.4)       | 1.15              |
| Volume depletion (narrow BIcMQ)         | 46 (9.9)      | 8.56          | 55 (12.7)     | 11.30             |
| Hypotension (BIcMQ)                     | 40 (8.6)      | 7.35          | 50 (11.5)     | 10.16             |
| Confirmed hypoglycaemic events 1        | 2 (0.4)       | 0.35          | 7 (1.6)       | 1.34              |
| Bone fracture (BIcMQ)                   | 12 (2.6)      | 2.10          | 16 (3.7)      | 3.10              |
| eGFR 30 to <45 mL/min/1.73 m 2          | 348 (100.0)   | 348 (100.0)   | 345 (100.0)   | 345 (100.0)       |
| Any AE                                  | 307 (88.2)    | 237.46        | 265 (76.8)    | 153.16            |
| Leading to discont. of study medication | 85 (24.4)     | 20.83         | 73 (21.2)     | 17.59             |
| SAEs                                    | 183 (52.6)    | 63.21         | 159 (46.1)    | 50.87             |
| Acute renal failure (SMQ)               | 52 (14.9)     | 13.85         | 50 (14.5)     | 13.07             |
| AEs leading to LLA                      | 3 (0.9)       | 0.62          | 4 (1.2)       | 0.85              |
| Urinary tract infection (BIcMQ)         | 30 (8.6)      | 7.50          | 16 (4.6)      | 3.96              |
| Genital infection (BIcMQ)               | 1 (0.3)       | 0.24          | 8 (2.3)       | 1.96              |
| Volume depletion (narrow BIcMQ)         | 42 (12.1)     | 11.34         | 36 (10.4)     | 9.20              |
| Hypotension (BIcMQ)                     | 39 (11.2)     | 10.48         | 33 (9.6)      | 8.38              |
| Confirmed hypoglycaemic events 1        | 7 (2.0)       | 1.71          | 4 (1.2)       | 0.97              |
| Bone fracture (BIcMQ)                   | 12 (3.4)      | 2.95          | 9 (2.6)       | 2.18              |
| eGFR <30 mL/min/1.73 m 2                | 89 (100.0)    | 89 (100.0)    | 115 (100.0)   | 115 (100.0)       |
| Any AE                                  | 78 (87.6)     | 306.77        | 108 (93.9)    | 268.49            |
| Leading to discont. of study medication | 26 (29.2)     | 29.61         | 33 (28.7)     | 24.34             |
| SAEs                                    | 50 (56.2)     | 84.31         | 75 (65.2)     | 78.45             |
| Acute renal failure (SMQ)               | 16 (18.0)     | 19.13         | 25 (21.7)     | 20.03             |
| AEs leading to LLA                      | 0             | 0             | 1 (0.9)       | 0.63              |
| Urinary tract infection (BIcMQ)         | 4 (4.5)       | 4.55          | 12 (10.4)     | 9.32              |
| Genital infection (BIcMQ)               | 0             |               | 1 (0.9)       | 0.73              |
| Volume depletion (narrow BIcMQ)         | 15 (16.9)     | 19.46         | 19 (16.5)     | 15.33             |
| Hypotension (BIcMQ)                     | 13 (14.6)     | 16.57         | 12 (10.4)     | 9.47              |

<div style=\"page-break-after: always\"></div>

| Category of AEs                  | Placebo   | Empa 10 mg      |         | Rate/100 pt-yrs   |
|----------------------------------|-----------|-----------------|---------|-------------------|
|                                  | N (%)     | Rate/100 pt-yrs | N (%)   |                   |
| Confirmed hypoglycaemic events 1 | 3 (3.4)   | 3.50            | 5 (4.3) | 3.69              |
| Bone fracture (BIcMQ)            | 3 (3.4)   | 3.45            | 3 (2.6) | 2.20              |

Hypoglycaemic AEs with a plasma glucose value of ≤70 mg/dL or where assistance was required

## Use in pregnancy and lactation

The use of empagliflozin in pregnancy and lactation was not specifically studied in the heart failure trials. See the currently approved product information for empagliflozin for the information.

## Safety related to drug-drug interactions and other interactions

Drug interactions were not specifically studied in the heart failure trials. See the currently approved product information for empagliflozin for the information.

## Discontinuation due to adverse events

In 1245.121, the overall frequency of patients reported with AEs leading to discontinuation of study medication was similar between groups. The most commonly reported (&gt;0.2% at PT level) of these events in either group are summarised in Table 49. On the PT level, the most frequently reported AEs leading to discontinuation were cardiac failure and death.

In 1245.121, the overall frequency of patients reported with AEs leading to discontinuation of study medication was similar between groups. The most commonly reported (&gt;0.2% at PT level) of these events in either group are summarised in (Table 478). On the PT level, the most frequently reported AEs leading to discontinuation were cardiac failure and death.

Table 49 Patients with AEs leading to discontinuation of study medication in 1245.121 (frequency &gt;0.2% in either treatment group at the PT level), exposure adjusted - TS

| MedDRA SOC MedDRA PT                                 | Placebo N (%)   | Rate/ 100 pt-yrs   | Empa 10 mg N (%)   | Rate/ 100 pt-yrs   |
|------------------------------------------------------|-----------------|--------------------|--------------------|--------------------|
| Number of patients                                   | 1863 (100.0)    | 1863 (100.0)       | 1863 (100.0)       | 1863 (100.0)       |
| Total with AEs leading to discontinuation            | 328 (17.6)      | 14.63              | 322 (17.3)         | 14.27              |
| Cardiac disorders                                    | 128 (6.9)       | 5.69               | 126 (6.8)          | 5.56               |
| Cardiac failure                                      | 68 (3.7)        | 3.02               | 65 (3.5)           | 2.87               |
| Acute myocardial infarction                          | 6 (0.3)         | 0.27               | 11 (0.6)           | 0.48               |
| Cardiac arrest                                       | 7 (0.4)         | 0.31               | 9 (0.5)            | 0.40               |
| Cardiac failure acute                                | 8 (0.4)         | 0.35               | 6 (0.3)            | 0.26               |
| Myocardial infarction                                | 8 (0.4)         | 0.35               | 8 (0.4)            | 0.35               |
| Cardiac failure congestive                           | 7 (0.4)         | 0.31               | 4 (0.2)            | 0.18               |
| General disorders and administration site conditions | 53 (2.8)        | 2.35               | 42 (2.3)           | 1.85               |
| Death                                                | 26 (1.4)        | 1.15               | 16 (0.9)           | 0.70               |
| Sudden cardiac death                                 | 10 (0.5)        | 0.44               | 8 (0.4)            | 0.35               |
| Cardiac death                                        | 7 (0.4)         | 0.31               | 4 (0.2)            | 0.18               |
| Sudden death                                         | 5 (0.3)         | 0.22               | 5 (0.3)            | 0.22               |
| Infections and infestations                          | 20 (1.1)        | 0.89               | 28 (1.5)           | 1.23               |
| Urinary tract infection                              | 5 (0.3)         | 0.22               | 7 (0.4)            | 0.31               |
| Pneumonia                                            | 6 (0.3)         | 0.27               | 4 (0.2)            | 0.18               |
| Septic shock                                         | 3 (0.2)         | 0.13               | 6 (0.3)            | 0.26               |
| Renal and urinary disorders                          | 24 (1.3)        | 1.07               | 22 (1.2)           | 0.97               |

<div style=\"page-break-after: always\"></div>

| Renal impairment         | 3 (0.2)   |   0.13 | 9 (0.5)   |   0.40 |
|--------------------------|-----------|--------|-----------|--------|
| Acute kidney injury      | 8 (0.4)   |   0.35 | 2 (0.1)   |   0.09 |
| Renal failure            | 5 (0.3)   |   0.22 | 4 (0.2)   |   0.18 |
| Nervous system disorders | 23 (1.2)  |   1.02 | 18 (1.0)  |   0.79 |
| Ischaemic stroke         | 8 (0.4)   |   0.35 | 3 (0.2)   |   0.13 |
| Cerebrovascular accident | 5 (0.3)   |   0.22 | 5 (0.3)   |   0.22 |
| Vascular disorders       | 10 (0.5)  |   0.44 | 15 (0.8)  |   0.66 |
| Hypotension              | 4 (0.2)   |   0.18 | 8 (0.4)   |   0.35 |

In SAF-HF2, the frequency of patients reported with AEs leading to discontinuation was similar between treatment groups (18 patients, 5.8% for empagliflozin vs 18 patients, 5.7% for placebo). At PT level, AEs leading to discontinuation were reported for no more than 1 patient per group, except for cardiac failure (1 patient, 0.3% vs 2 patients, 0.6%) and asthma (0 patient vs 2 patients, 0.6%).

## Post marketing experience

As empagliflozin has not been approved for use in patients with HF and without T2DM, there has been no post-marketing experience in these patients.

## 3.4.1. Discussion on clinical safety

In 1245.121 trial (EMPEROR reduced), the proportion of patient with mild AEs was higher in the empagliflozin group (placebo 393 patients, 21.1% vs empagliflozin 445 patients, 23.9%). However, the proportion of subject with moderate and/or severe AEs was larger in the placebo group (moderate: 568 patients, 30.5% vs 516 patients, 27.7%, severe: 502 patients, 26.9% vs 459 patients, 24.6%). The latter was probably driven by a smaller proportion of the empagliflozin group reporting SAEs that required or prolonged hospitalisation compared with the placebo group. Regarding the most frequently reported AEs, this was in general numerically balanced between both groups.

Evaluating the severe AEs, Table 32 describes the number of patients with AEs by worst intensity and the most frequent severe AEs, showing that infections and infestation were numerically more in the empagliflozin group (80 patients, 4.3%) compared with placebo (66 patients, 3.5%).

Investigator-defined urinary tract infection (including urosepsis and acute pyelonephritis) were reported for 92 patients, 4.9%, in the empagliflozin group and 83 patients, 4.5%, in the placebo group. Although reported urosepsis did not numerically differ between groups (empagliflozin 5 patients, 0.3% vs placebo 4 patients, 0.2%), there was a difference in reported sepsis with source from urinary tract infection (UTI), especially in female subjects (empagliflozin 5 patients, 1.1%, all female vs placebo 1 patient, 0.1%, male).

In 1245.121, the results of the AESIs and specific AEs were in general consistent with the known safety profile of empagliflozin in patients with T2DM. As expected, genital infections were more often reported in the empagliflozin group (31 patients, 1.7% vs. placebo 12 patients, 0.6%). Although the reported complicated genital infections were numerically equally distributed between the treatment groups, the genital infection did lead more often to discontinuation of treatment in the empagliflozin group. This is a known AE and is described in the SmPC Section 4.8. Although genital infections were reported in both male and female subjects and in patients with and without diabetes, the effect of treatment seems more pronounced in male subjects and in subjects with diabetes based on the current results of the trial. This was included in the SmPC Section 4.8.

The AE hypotension is also more often reported during empagliflozin treatment (130 patients, 7.0% vs. placebo 119 patients, 6.4%). This is described in the SmPC section 4.4. and 4.8, but the effect of empagliflozin on hypotension and volume depletion is seemingly more present in patients with T2DM compared to non-diabetic subjects. This could be expected as the effect of glucosuria is more present in

<div style=\"page-break-after: always\"></div>

this patients' group. However, as the presented data does not change the risk for subject with T2DM compared to the described warnings in the SmPC and is not increased for subjects without T2DM, it is acceptable to maintain this information and the related warning in the SmPC on an overall group level for both subjects with and without T2DM.

The MAH provided additional data for the event of volume depletion, hypotension and symptomatic hypotension divided for age and the presence of T2DM. As expected, volume depletion during empagliflozin treatment was more frequent in patients with age ≥ 75 y ears. In elderly patients with T2DM the increase of hypotension and volume depletion was even more pronounced during empagliflozin vs. placebo. This is addressed in the SmPC Section 4.4 and Section 4.8.

The frequencies for volume depletion and hypotension leading to discontinuation (empagliflozin 14 patients, 0.8% vs placebo 6 patients, 0.3%) or reported as SAEs (empagliflozin 43 patients, 2.3% vs placebo 33 patients, 1.8%) were numerically higher in the empagliflozin group compared with the placebo group. This seems clinically relevant.

Volume depletion could also contribute to constipation. Based on relative dehydration, constipation is at least plausible as an ADR. The increased number of constipations with empagliflozin treatment in the EMPEROR-Reduced trial was consisted between subgroups. The difference was also statistically different with a relative risk of 2,11 (CI 1,34; 3,32), the SmPC was updated to include constipation as a common adverse reaction in section 4.8 of the SmPC.

Acute renal failure (empagliflozin 175 patients, 9.4% vs. placebo 192 patients, 10.3%), acute kidney injury (35 patients, 1.9% vs. 55 patients, 3.0%) and renal failure (44 patients, 2.4% vs. 48 patients, 2.6%) were less reported during empagliflozin treatment compared with placebo. However, renal impairment is more often reported during empagliflozin treatment (105 patients, 5.6% vs. placebo 93 patients, 5.0%).

No relevant increase in the frequency of keto-acidosis for the empagliflozin group, but more patients in the empagli flozin group (174 patients, 11.0%) than the placebo group (113 patients, 7.1%) had bicarbonate values that shifted from normal at baseline to below normal at last value on treatment. The frequency of patients with PCSA of low bicarbonate values (&lt;18 mmol/L) was greater in the empagliflozin group (273 patients, 16.1%) than the placebo group (197 patients, 11.6%). This seemingly does not lead to an increased risk for metabolic acidosis. The risk of metabolic acidosis is mainly present when other risk factors are also present, as described in the SmPC Section 4.4. It is therefore considered reasonable to assume that the higher percentage of patients with a decrease in bicarbonate levels is only clinically relevant in patients with other risk factors.

Fall is more often reported during empagliflozin treatment (43 patients, 2.3% vs placebo 27 patients, 1.4%), but further review did not identify any predominant pathophysiological cause for falls (e.g. volume depletion, hypotension, or hypoglycaemia). The MAH suggests that the imbalance in reported falls between the groups is due to external causes and to a higher number of accidental falls. The MAH concludes that considering the late divergence in falls between treatment groups (after about 8 months), the lack of a plausible pathophysiological cause related to empagliflozin's mode of action (e.g. via hypotension, volume depletion, hypoglycaemia) the numerical imbalance of fall observed was likely a chance variation. However, although less pronounced, also in the EMPA-REG OUTCOME trial a slight increase in reported falls was present during empagliflozin and especially in the 25 mg group. Although not confirmed, it is considered plausible that falls are related to the haemodynamic changes related to empagliflozin use. There is indeed no pathophysiological explanation for the increased number of accidental falls during empagliflozin evident yet. However, the higher number of falls with empagliflozin vs. placebo treatment is consistent between all different subgroups and appears more pronounced for female subjects. Although no additional risk factors have been identified, the number of falls is consistently more in the empagliflozin group vs. placebo. Also based on the relative risk of 1,59 (ci: 0,99;

<div style=\"page-break-after: always\"></div>

2,57). However, there was no imbalance of falls defined by the investigators as 'drug related'. In fact, no such cases were reported in the empagliflozin group (0%) but one case in the placebo group (0.1%). Based on this, the risk does not have to be included in the SmPC, section 4.8. However, as the explanation for the increased number of falls during empagliflozin remains uncertain, this risk should remain in the RMP.

Regarding SAEs reported in the SOC cardiac disorders, ventricular tachycardias were more often reported during empagliflozin (55 patients, 3.0%) compared with placebo (37 patients, 2.0%). This difference between treatment groups was not observed for other ventricular tachyarrhythmias. Moreover, it was not observed consistently between different trials with empagliflozin. In the previous large outcome trial in patients with T2DM and established CV disease EMPA-REG OUTCOME, ventricular tachycardia was reported for fewer patients in the two empagliflozin groups than in the placebo group. It could, however, be suggested that the current finding is related to the presence of HFrEF combined with empagliflozin treatment and may therefore not occur as often in patients without HFrEF. But when analysing only the subjects with HFrEF and T2DM in the EMPA-REG trial, the events of ventricular tachycardia were not more during empagliflozin vs. placebo (placebo 7/244 (2.9%), empagliflozin 10mg 0/240 (0%), empagliflozin 25mg 7/222 (3.2%)).

Reported acute myocardial infarction was numerically imbalanced between the groups (empagliflozin 24 patients, 1.3%, placebo 18 patients, 1.0%). However, the MAH also provided the numbers of myocardial infarction adjudicated by an independent CEC, with empagliflozin 10 mg: 19 patients, 1.0%; placebo: 20 patients, 1.1%. This is comparable between groups and although there is a small discrepancy between the reviews of the number myocardial infarction, it appears balanced between the groups.

Nervous system disorders were more often reported during empagliflozin treatment (94 patients, 5.0%) compared with placebo (74 patients, 4.0%). This difference between the groups did not consist of differences in reported ischaemic strokes. Additional data with the most frequent SAEs under the SOC nervous system disorders shows a small imbalance and that this is mainly due to the larger number of cerebrovascular attacks, presyncope and syncope. The latter may be due to the known side-effect of empagliflozin of volume depletion, described in the SmPC section 4.4. Based on the number of strokes adjudicated by the CEC, the numbers between the group appear comparable.

'Bone fracture' is included as an important potential risk in the EU RMP. No imbalance regarding these events were noted for patients with T2DM treated with empagliflozin vs placebo (2.2% vs 2.8%). However, in the non-T2DM group an imbalance were noted, 1.7% (n=16) of in the placebo group compared to 2.7% (n=25) reported any event of bone fracture. This appears contradictive, as patients with T2DM are considered to have a larger risk than the non-diabetic population to develop bone fractures. Most of the studies investigating the effect of empagliflozin are performed in T2DM patients and the body composition sub-study of 1245.28 did not indicate an increased de-mineralisation in bone mineral density with empagliflozin treatment compared with glimepiride in T2DM patients. There is no evident pathophysiological explanation why in patients without T2DM the effect of empagliflozin on bone mineral density and bone fracture would be of a larger risk than in T2DM patients. The difference between patients with and without T2DM on bone fractures with empagliflozin is therefore not considered an issue, but the risk for bone fracture should remain included as an important potential risk in the EU RMP.

## 3.4.2. Conclusions on clinical safety

The safety profile of empagliflozin in HF is similar to the established safety profile in the T2DM indication.

<div style=\"page-break-after: always\"></div>

## 3.4.3. PSUR cycle

Based on safety data of the new indication in HFrEF, the CHMP is of the opinion that the already existing entry in the EURD list for empagliflozin needs to be amended as follows: the PSUR cycle for the medicinal product should follow a one yearly cycle. The next data lock point will be 17/04/2022.

<div style=\"page-break-after: always\"></div>

## 4. Risk management plan

The MAH submitted an updated RMP version 15.2 with this application. The main proposed RMP changes were the following:

## *Part I. Product overview

This part is proposed to be updated in order to include information on the proposed indication of heart failure.

## *Part II. Safety specification .

The following modules have been updated:

## MODULE SI Epidemiology of the indications and target populations

The  MAH  has  added  all  data  of  epidemiology  concerning  the  new  proposed  indication  heart  failure. Moreover, some sections on type 2 diabetes mellitus indication (prevalence and main treatment options) have also been updated with the most recent data.

## MODULE SIII clinical trial exposure

The  MAH  has  updated  this  section  including  data  from  clinical  trials  in  patients  with  HFrEF  (trials 1245.121 and 1245.168).

Three safety analysis sets were described as used for clinical trial exposure calculation:

SIII.Table 1

Overview of safety analysis sets

| SAF          | Description                                                                                                      | Trials included                                                                                                                                                                                                          |
|--------------|------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| SAF-HF5      | Randomised, placebo-controlled clinical trials in patients with HFrEF                                            | 1245.121, 1245.168                                                                                                                                                                                                       |
| SAF-43 1     | Randomised, double-blind, placebo- controlled trials in patients with T2DM                                       | 1245.4, 1245.9, 1245.10, 1245.15, 1245.19, 1245.20, 1245.23 (Met only and Met+SU), 1245.25, 1245.29, 1245.33, 1245.35, 1245.36, 1245.38, 1245.48, 1245.49, 1245.107, 1275.9, 1275.19,                                    |
| SAF- POOL2 1 | Randomised, placebo-controlled clinical trials across indications HFrEF and T2DM (comprising SAF-HF5 and SAF-43) | 1245.4, 1245.9, 1245.10, 1245.15, 1245.19, 1245.20, 1245.23 (Met only, Met+SU), 1245.25, 1245.29, 1245.33, 1245.35, 1245.36, 1245.38, 1245.48, 1245.49, 1245.107, 1245.121, 1245.167, 1245.168, 1275.9, 1275.19, 1276.10 |

1  The data of extension trial 1245.31 are contained in the core trials 1245.19, 1245.20, and 1245.23.Data source: data on file, SAF-43 Table 31.3.1.1, and SAF-HF5(HFrEF), Tables 1.1 and 1.2

## MODULE SIV Populations not studied in clinical trials

The  MAH  has  updated  this  module  describing  exclusion  criteria  in  pivotal  clinical  trials  within  the development programme for all indications, for indication T2DM and for indication HFrEF.

## MODULE SV Post-authorisation experience

This  module  has  been  updated  with  the  most  recent  data  on  post-authorisation  exposure  up  to  April

<div style=\"page-break-after: always\"></div>

2020.

## MODULE SVII Identified and potential risks

No new safety concerns have been identified by the MAH following new data from clinical trials in patients with HFrEF (trials 1245.121 and 1245.168).

The MAH has updated the characterisation of the identified and potential risks, with risk analyses from HFrEF trials (1245.121 and 1245.168). Moreover, characterisation of all risk has also been updated taking into account the new safety analysis set (SAF 43) for T2DM indication.

## *Part VI Summary of the risk management plan

This part has been updated to include information on the proposed indication of heart failure and updated data regarding important risks.

## 4.1. Overall conclusion on the RMP

No new safety concern has been identified regarding the new indication of heart failure.

No new additional pharmacovigilance activities have been proposed, which is endorsed.

No new additional risk minimisation measures have been added either, which is considered acceptable.

The changes to the RMP are acceptable.

The RMP version 15.2 (date of final sign off: 09 April 2021) is acceptable.

<div style=\"page-break-after: always\"></div>

## 5. Changes to the Product Information

As a result of this variation, section(s) 4.1, 4.2, 4.4, 4.8, 4.9 and 5.1 of the SmPC are being updated to reflect the newly proposed indication and the submitted trial results. The Package Leaflet (PL) is updated accordingly.

Please refer to Attachment 1 which includes all agreed changes to the Product Information.

<div style=\"page-break-after: always\"></div>

## 6. Benefit-Risk Balance

## 6.1. Therapeutic Context

Heart failure (HF) has emerged as a global epidemic over the last decades and an estimated prevalence of &gt;37.7 million individuals globally. The rise in cardiovascular risk factors, improved survival from ischaemic heart disease, as well as age distribution will contribute to a sustained increase in the prevalence of HF in developed high-income countries. Despite considerable therapeutic advances in the therapy of HF patients, the normal progression of the disease is still associated with increasingly worsening symptoms, an increasing frequency of re-hospitalisations, and ultimately a high rate of mortality.

## 6.1.1. Disease or condition

Chronic heart failure (HF) is a progressive syndrome characterized by the inability of the heart to provide adequate circulation to meet the metabolic demand of different tissues or do it at the expense of elevated left ventricular filling pressure. HF occurs due to failure of the heart to pump adequately (systolic dysfunction) and/or impaired relaxation (diastolic dysfunction). Two types of HF have been defined mainly based on the Left ventricular ejection fraction (LVEF) and also other structural changes in heart muscle: heart failure with reduced ejection fraction (HFrEF) &lt;40% and heart failure with preserved ejection fraction (HFpEF) ≥ 50%. Patients with HF can clinically be classified according to the severity of their symptoms, and the most commonly used classification system is the New York Heart Association (NYHA) Functional Classification. The clinical course for HFrEF patients is often marked by acute episodes of clinical decompensation with increased symptoms such as dyspnea, fatigue, and oedema and in more severe cases cardiac asthma. The time in between these acute episodes can consist of periods with stability, but the normal progression of the disease is still associated with increasingly worsening symptoms, an increasing frequency of rehospitalizations, and ultimately a high rate of mortality. Approximately 50% of patients who develop HF die within 5 years after diagnosis. Annually, more than 1 million patients are hospitalized with a primary diagnosis of HF. HF is the most common cause of hospitalization among individuals above 65 years of age in the western countries.

## 6.1.2. Available therapies and unmet medical need

Standard medications for patients with HFrEF and medium-to-severe chronic HF (NYHA classes II to IV) are well established and based on large randomized, controlled trials, with the results incorporated into guidelines issued by the ACCF/AHA and the European Society of Cardiology (ESC). The standard medications include an angiotensin-converting enzyme (ACE) inhibitor or/and an angiotensin receptor blocker (ARB), beta-blocker, angiotensin-receptor-neprilysin-inhibitor (ARNIs) and a diuretic in patients with evidence of fluid retention. An aldosterone receptor antagonist may be given, especially those who have experienced an acute myocardial infarction or have a history of diabetes mellitus. Despite considerable advances in the therapy of HF patients, even in patients on optimized therapy the normal progression of the disease is, as described above, still associated with increasingly worsening symptoms, an increasing frequency of rehospitalizations and a high rate of mortality.

Studies investigating the effect sodium-glucose cotransporter-2 (SGLT 2) inhibitors observed beneficial effects on HF-related complications in patients with or without diabetes. Empagliflozin is an orally administered SGLT-2 inhibitor and is approved for the treatment of type 2 diabetes mellitus (T2DM) worldwide. The results of trial 1245.25 (EMPA-REG OUTCOME) in patients with T2DM and established CV disease showed that empagliflozin reduced the risk of hospitalisation for heart failure (HHF) and the composite endpoint of HHF or CV death.

<div style=\"page-break-after: always\"></div>

## 6.1.3. Main clinical studies

Empagliflozin is an orally administered, potent and selective inhibitor of the human sodium-glucose cotransporter-2 (SGLT 2) developed by Boehringer Ingelheim (BI). By inhibition of SGLT 2 in the kidneys empagliflozin reduces the reabsorption of glucose by the kidneys leading to increased urinary glucose excretion and, in consequence, to a lowering of blood glucose. Empagliflozin is approved for the treatment of type 2 diabetes mellitus (T2DM) worldwide as an adjunct therapy to diet and exercise to improve glycaemic control in adults with type 2 diabetes. The results of the EMPA-REG OUTCOME trial (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients) significantly improved the primary composite cardiovascular outcome (MACE-3) and significantly reduced cardiovascular death, hospitalization for heart failure (HHF) as well as death from any cause as compared to standard of care. These beneficial cardiovascular effects were found to be largely independent of the glucose-lowering effect of empagliflozin. Based on the results of trial 1245.25 (EMPA-REG OUTCOME) in patients with T2DM and established CV disease, BI initiated a phase III program for empagliflozin 10 mg once daily in chronic heart failure regardless of diabetes status.

In the current application, the main clinical study was the pivotal trial EMPEROR-reduced, in patients with HFrEF, trial 1245.121. The supportive EMPERIAL trials were also included. The aim of the EMPERIALreduced/preserved trials is to evaluate the effect of empagliflozin 10 mg versus placebo on exercise ability using the 6-minute walking test (6MWT) in patients with HFrEF or HFpEF. The EMPERIAL-reduced and -preserved trial (1245.168 and 1245.167) included 312 and 315 subjects respectively and had a duration of 12 weeks.

## EMPEROR reduced - trial 1245.121

The EMPEROR trial is a phase III international, multicentre, double-blind, parallel-group, randomised, placebo-controlled, event-driven trial investigating the long-term effect of empagliflozin in reducing the risk of hospitalisation for HF and of cardiovascular death in patients with heart failure. The key eligibility criteria for the EMPEROR reduced trial were a population of T2DM and non-T2DM, aged &gt; 18 years, chronic HF (NYHA class II-IV) with reduced EF (LVEF ≤ 40%) and elevated NT-proBNP for patients with/without atrial fibrillation or atrial flutter (AF), eGFR (CKD-EPI)cr ≥ 20 mL/min/1.73 m2 and stable therapy for HF consistent with local and international cardiology guidelines. The design of the study included a screening period of 4-28 days, a randomized, double-blind treatment period (event-driven study duration), in which eligible patients started with 10 mg empagliflozin or matching placebo. The median follow-up was 16 months of treatment. At the end of treatment, each subject was followed for 30 days after the last treatment dose. The aim of the EMPEROR-reduced trial is to investigate the safety and efficacy of empagliflozin versus placebo on top of guideline-directed medical therapy in patients with HFrEF. The primary endpoint was the time to the first event of adjudicated CV death or adjudicated HHF. The two key secondary endpoints (confirmatory) were the occurrence of adjudicated HHF (first and recurrent) and eGFR (CKD-EPI)cr slope of change from baseline. The EMPEROR-reduced trial (1245.121) included 3730 subjects. Subjects who fulfil all eligibility criteria were randomized double -blind in a 1:1 manner.

Based on the results of the pivotal trial 1245.121, BI sought a new indication for empagliflozin to reduce the risk of cardiovascular death and hospitalisation for heart failure and to slow kidney function decline in adult patients with heart failure (NYHA class II-IV) with reduced ejection fraction.

## 6.2. Favourable effects

The primary endpoint of CV death or HHF occurred in a lower proportion of patients in the empagliflozin group (361 of 1863 patients, 19.4%) than in the placebo group (462 of 1867 patients, 24.7%), and the risk of CV death or HHF was significantly reduced with empagliflozin treatment compared with placebo (HR empagliflozin vs. placebo 0.75; 95% CI 0.65 to 0.86, p&lt;0.0001). The treatment effect of empagliflozin became apparent shortly after randomisation and was maintained throughout the trial. In

<div style=\"page-break-after: always\"></div>

general, the results were consistent across the pre-defined subgroups by demographics, baseline characteristics (including T2DM status), and baseline HF medications.

A lower proportion of patients in the empagliflozin group (246 patients, 13.2%) than in the placebo group (342 patients, 18.3%) had an adjudicated HHF event, and the total number of HHF events (first and recurrent) was also lower in the empagliflozin group (388 patients) than in the placebo group (553 patients). Treatment with empagliflozin reduced the risk of recurrent HHF compared with placebo (HR 0.70, 95.04% CI 0.58 to 0.85, p = 0.0003).

Death from any cause occurred in 249 patients (13.4%) in the empagliflozin group and 266 patients (14.2%) in the placebo group (HR 0.92, 95% CI 0.77 to 1.10), but did not reach statistical significance. The majority of the deaths were due to CV causes. However, adjudicated CV death did not differ between the treatment groups and occurred in 187 patients (10.0%) in the empagliflozin group and 202 patients (10.8%) in the placebo group (HR 0.92, 95% CI 0.75 to 1.12, nominal p = 0.4133).

First all-cause hospitalisation was reduced with empagliflozin treatment (688 patients, 36.9% vs placebo 796 patients, 42.6%; HR 0.85, 95% CI 0.75 to 0.95). This finding seems mainly driven by hospitalisation for investigator defined CV cause (empagliflozin 452 patients, 24.3% vs placebo 570 patients, 30.5%; HR 0.75, 95% CI 0.67 to 0.85).

## 6.3. Uncertainties and limitations about favourable effects

Treatment with empagliflozin resulted in a decreased occurrence of the composite primary endpoint of CV death or HHF occurred in patients with or without T2DM. This effect seems mainly driven by a decrease in HHF outcomes. When evaluated separately, a lower proportion of patients in the empagliflozin group than in the placebo group had an adjudicated HHF event. However, this treatment effect was not observed on CV death. The time to adjudicated CV death was a secondary endpoint and occurred in 187 patients (10.0%) in the empagliflozin group and 202 patients (10.8%) in the placebo group (HR 0.92, 95% CI 0.75 to 1.12).

The change of eGFR slope from baseline was a key secondary endpoint as analysed under hierarchical testing to support the indication and showed a slower decline in eGFR in the empagliflozin group, with an estimated difference in slope of 1.733 mL/min/1.73 m2 per year vs placebo (99.9% CI 0.669, 2.796; p&lt;0.0001). However, robustness and clinical interpretation of this finding may be questioned due to several reasons, already reflected in the 2016 scientific advice provided to the MAH.

First of all, a recent large meta-analysis based on efforts from a renal consortium (Inker et al, JASN, 2019; Levey et al, JASN, 2019) suggest at least a minimal mean follow-up of 2 years, and preferably, 3 years follow-up (current analysis only provides a substantially lower mean follow-up) to reliably assess GFR-slope as a potential surrogate for clinical renal outcome.

Also, any potentially surrogacy is further questioned as this meta-analysis provides little support for using GFR slope in HF patients, due to substantial underrepresentation. Further, clinical interpretation is complicated as no minimal threshold has been justified and defined a-priori. Although, some support on clinical relevance based on limited data has been presented on an exploratory endpoint of the composite of GFR&gt;40%, ESRD, and renal death, which was mainly driven by the GFR&gt;40% reduction component (30/1863 in the empagliflozin group and 58/1867 in the placebo group, HR 0.50, 95% CI 0.32 - 0.77) and a beneficial effect as explored on the albuminuria biomarker.

Moreover, the analysis has been performed based on the so called ''chronic slope'' (not from baseline but analysed after the initial GFR dip). Analysis of the ''chronic slope''' can be subject to particular concerns including a non-randomized analysis, potentially inflation of type 1 error with a potential overestimation of the effect in advantage of the intervention, and thus possibly increasing drawing false conclusions. However, results of the preferred (more conservative) overall slope as analysed from baseline confirmed that empagliflozin did affect the slope.

<div style=\"page-break-after: always\"></div>

The KCCQ was used to measure patient-reported outcomes. KCCQ consists of several domains and summary scores. Treatment with empagliflozin improved the KCCQ clinical summary score from baseline to Week 52 compared with placebo (mean change from baseline 1.75, 95% CI 0.51 to 2.99). The MAH justifies the choice for the KCCQ clinical summary score as most relevant to the patient. However, in this trial, each patient was asked to identify the domain that was the most difficult to cope with from the patients' perspective at baseline and the most common domain the patients identified was total symptom (i.e. symptom frequency and burden; 32% of patients) and physical limitation (21% of patients). This patients' preferred KCCQ outcome did not differ between treatment groups. But the 'patient preferred outcome' has limitations, as this was only asked once at baseline and no time-dependency was assessed, in contrast to the standard KCCQ. The validated scores of the KCCQ are therefore considered more reliable to evaluate the patient related outcomes. Change in HF symptoms was measured as improvements in NYHA class with empagliflozin treatment in an exploratory endpoint.

More patients in the empagliflozin group (360 patients, 26.8%) than in the placebo group (303 patients, 22.8%) improved in NYHA class from baseline to Week 52, and fewer patients in the empagliflozin group (48 patients, 3.6%) than in the placebo group (75 patients, 5.6%) worsened. However, the EMPERIAL trials were specifically designed to evaluate the effect of empagliflozin on exercise ability using the 6minute walking test (6MWT) in patients with HFrEF or HFpEF, but in both trials, the primary endpoint (change from baseline to Week 12 in the 6MWT distance) did not show a statistically significant difference between empagliflozin and placebo.

## 6.4. Unfavourable effects

Treatment with empagliflozin 10 mg in patients with HFrEF revealed no new safety findings compared with the known safety profile of empagliflozin in patients with T2DM. The safety profile for patients with HFrEF and without T2DM was in general similar to those with T2DM.

In 1245.121 trial (EMPEROR reduced), the proportion of patient with mild AEs was higher in the empagliflozin group (placebo 393 patients, 21.1% vs empagliflozin 445 patients, 23.9%). However, the proportion of subject with moderate and/or severe AEs was larger in the placebo group (moderate: 568 patients, 30.5% vs 516 patients, 27.7%, severe: 502 patients, 26.9% vs 459 patients, 24.6%).

Evaluating the severe AEs, infections, and infestation were numerically more in the empagliflozin group (80 patients, 4.3%) compared with placebo (66 patients, 3.5%). Although 'urosepsis' did not numerically differ between groups (empagliflozin 5 patients, 0.3% vs placebo 4 patients, 0.2%), there was a difference in 'sepsis with source from urinary tract infection (UTI)', especially in female subjects (empagliflozin 5 patients, (1.1%, all female) vs placebo 1 patient, (0.1%, male).

Genital infections were also more often reported in the empagliflozin group (31 patients, 1.7% vs. placebo 12 patients, 0.6%). Although the reported complicated genital infections were numerically equally distributed between the treatment groups, genital infection did lead more often to discontinuation of treatment in the empagliflozin group. This is a known AE and is described in the SmPC Section 4.8.

The AE hypotension is also more often reported during empagliflozin treatment (130 patients, 7.0% vs. placebo 119 patients, 6.4%). This is described in the SmPC section 4.4. and 4.8. The effect of empagliflozin on hypotension and volume depletion is seemingly more present in patients with T2DM compared to non-diabetic subjects.

Renal impairment was more often reported during empagliflozin treatment (105 patients, 5.6% vs. placebo 93 patients, 5.0%), but importantly acute renal failure (empagliflozin 175 patients, 9.4% vs. placebo 192 patients, 10.3%), acute kidney injury (35 patients, 1.9% vs. 55 patients, 3.0%) and renal failure (44 patients, 2.4% vs. 48 patients, 2.6%) were less reported during empagliflozin treatment compared with placebo.

<div style=\"page-break-after: always\"></div>

Fall was more often reported during empagliflozin treatment (43 patients, 2.3% vs placebo 27 patients, 1.4%).

Also, constipation was reported for more patients in the empagliflozin group (57 patients, 3.1%) than in the placebo group (27 patients, 1.4%), which was observed across all subgroups.

From SAEs reported in the SOC cardiac disorders, ventricular tachycardia was more often reported during empagliflozin (55 patients, 3.0%) compared with placebo (37 patients, 2.0%). Acute myocardial infarction was numerically imbalanced between the groups (empagliflozin 24 patients, 1.3%, placebo 18 patients, 1.0%).

SAEs in the SOC nervous system disorders were more often reported during empagliflozin treatment (94 patients, 5.0%) compared with placebo (74 patients, 4.0%). This difference between the groups did not consist of differences in reported ischaemic strokes but was mainly due to the larger number of cerebrovascular attacks and presyncope/syncope. The latter may be due to the known side-effect of empagliflozin of volume depletion, described in the SmPC section 4.4.

## 6.5. Uncertainties and limitations about unfavourable effects

Genital infections occurred as expected more in the empagliflozin group (31 patients, 1.7% vs. placebo 12 patients, 0.6%). Although genital infections were reported in both male and female subjects and in patients with and without diabetes, the effect of treatment seems more pronounced in male subjects and in subjects with diabetes; this was included in the SmPC Section 4.8.

The AE hypotension was more often reported during empagliflozin treatment. The MAH considered the increases not clinically relevant, as the frequencies of investigator-defined symptomatic hypotension events, which would represent clinically relevant hypotension events, were balanced in the empagliflozin (106 patients, 5.7%) and placebo groups (103 patients, 5.5%). However, the frequencies for volume depletion and hypotension leading to discontinuation (empagliflozin 14 patients, 0.8% vs placebo 6 patients, 0.3%) or reported as SAEs (empagliflozin 43 patients, 2.3% vs placebo 33 patients, 1.8%) were numerically higher in the empagliflozin group compared with the placebo group. This seems, therefore, clinically relevant.

Moreover, the effect of empagliflozin on hypotension and volume depletion is seemingly more present in patients with T2DM compared to non-diabetic subjects. This could be expected, as the effect of glucosuria is more present in this patients' group. In the current SmPC, it is already described that patients aged 75 years or older are more at risk to develop volume depletion with empagliflozin and additional analysis of the EMPEROR-Reduced showed that the risk is even more pronounced for elderly patients with HFrEF and with T2DM.

More patients in the empagliflozin group (174 patients, 11.0%) than the placebo group (113 patients, 7.1%) had bicarbonate values that shifted from normal at baseline to below normal at last value on treatment. The frequency of patients with a clinically significant abnormality of low bicarbonate values (&lt;18 mmol/L) was greater in the empagliflozin group (273 patients, 16.1%) than the placebo group (197 patients, 11.6%). Importantly, no increase in the frequency of keto-acidosis was reported for the empagliflozin group (11 patients, 0.6% vs placebo 18 patients, 1.0%).

In the EMPEROR reduced trial, the acute myocardial infarction was numerically imbalanced between the groups (empagliflozin 24 patients, 1.3%, placebo 18 patients, 1.0%). This is small difference which has not been reported before. However, the MAH provided the numbers of myocardial infarction adjudicated by an independent CEC, with empagliflozin 10 mg: 19 patients, 1.0%; placebo: 20 patients, 1.1%. This is comparable between groups and although there is a small discrepancy between the reviews of the number myocardial infarction, it appears balanced between the groups.

<div style=\"page-break-after: always\"></div>

In addition, ventricular tachycardia were more often reported during empagliflozin (55 patients, 3.0%) compared with placebo (37 patients, 2.0%). In the previous large outcome trial in patients with T2DM and established CV disease EMPA-REG OUTCOME, ventricular tachycardia was reported for fewer patients in the two empagliflozin groups than in the placebo group. It could, however, be suggested that the current finding is related to the presence of HFrEF combined with empagliflozin treatment and may therefore not occur as often in patients without HFrEF. Evaluating only the subjects with HFrEF and T2DM in the EMPA-REG trial, the events of ventricular tachycardia were not more during empagliflozin vs. placebo (placebo 7/244 (2.9%), empagliflozin 10mg 0/240 (0%), empagliflozin 25mg 7/222 (3.2%)).

Fall is more often reported during empagliflozin treatment (43 patients, 2.3% vs placebo 27 patients, 1.4%). Review of the cases did not identify any predominant pathophysiological cause for falls (e.g. volume depletion, hypotension, or hypoglycaemia). The MAH attributes this finding to chance, also considering the late divergence in falls between treatment groups (after about 8 months), the presumed lack of a plausible pathophysiological cause related to empagliflozin's mode of action (e.g. via hypotension, volume depletion, hypoglycaemia), and the lack of consistency between the clinical trial results. However, although less pronounced, in EMPA-REG OUTCOME an increase in reported falls was present during empagliflozin and especially in the 25 mg group. Post-marketing data for empagliflozin were examined, and no specific cause other than falls as a consequence of presyncope was identified. Although this could not be confirmed, it is considered plausible that falls are related to the haemodynamic changes related to empagliflozin use.

No imbalance regarding 'Bone fracture' were noted for patients with T2DM treated with empagliflozin vs placebo (2.2% vs 2.8%). However, in the non-T2DM group an imbalance were noted, 1.7% (n=16) of in the placebo group compared to 2.7% (n=25) reported any event of bone fracture. Most of the studies investigating the effect of empagliflozin are performed in T2DM patients and the body composition substudy of 1245.28 did not indicate an increased de-mineralisation in bone mineral density with empagliflozin treatment compared with glimepiride in T2DM patients. There is no evident pathophysiological explanation why in patients without T2DM the effect of empagliflozin on bone mineral density and bone fracture would be a larger risk than in T2DM patients. The difference between patients with and without T2DM on bone fractures with empagliflozin is therefore not considered an issue, but the risk for bone fracture should remain included as an important potential risk in the EU RMP.

## 6.6. Effects Table

Table 50 Effects Table for empagliflozin in heart failure

| Effect                  | Short description          | Unit                 | Empagliflozin (10mg)   | Control (placebo)    | Uncertainties / Strength of evidence                                       |
|-------------------------|----------------------------|----------------------|------------------------|----------------------|----------------------------------------------------------------------------|
| Favourable Effects      | Favourable Effects         | Favourable Effects   | Favourable Effects     | Favourable Effects   | Favourable Effects                                                         |
| CV death or HHF         | Composite primary endpoint | N (%)                | 361/1863 (19.4)        | 462/1867 (24.7)      | SoE : HR 0.75; 95% CI0.65 to 0.86 p<0.0001 Unc: seems mainly driven by HHF |
| First and recurrent HHF | adjudicated HHF event      | N (%)                | 246 (13.2)             | 342 (18.3)           | SoE: 0.70; 0.58 to 0.85,p= 0.0003                                          |
| Mortality               | all-cause mortality        | N (%)                | 249 (13.4)             | 266 (14.2)           | Unc:, 0.92; 0.77 to 1.10, p = 0.3536                                       |
| CV death                | adjudicated CV death       | N (%)                | 187 (10.0)             | 202 (10.8)           | Unc: .92; 0.75 to 1.12, p = 0.4133                                         |
| Unfavourable Effects    | Unfavourable Effects       | Unfavourable Effects | Unfavourable Effects   | Unfavourable Effects | Unfavourable Effects                                                       |
| SAEs                    | On treatment period        | N (%)                | 772 (41.4)             | 896 (48.1)           | Mainly driven by cardiac events                                            |
| Volume depletion        | (including hypotension)    | N (%)                | 197 (10.6)             | 184 (9.9)            |                                                                            |
| Genital infections      |                            | N (%)                | 31 (1.7)               | 12 (0.6)             | Seemingly effect of treatment more outspoken for men and T2DM              |
| Ventricular tachycardia |                            | N (%)                | 56 (3.0)               | 37 (2.0)             | No differences between groups for other ventricular tachyarrhythmia        |

<div style=\"page-break-after: always\"></div>

| Effect   | Short description   | Unit   | Empagliflozin (10mg)   | Control (placebo)   | Uncertainties / Strength of evidence                                                                            |
|----------|---------------------|--------|------------------------|---------------------|-----------------------------------------------------------------------------------------------------------------|
| Fall     |                     | N (%)  | 43 (2.3)               | 27 (1.4)            | No predominant pathophysiological cause found for falls (e.g. volume depletion, hypotension, or hypoglycaemia). |

All effects based on EMPEROR (Trial 1245.121)

Abbreviations : AE, adverse events; CI, confidence interval; CV, cardio vascular; GFR, glomerular filtration rate; HR, hazard ratio; N, number; OR, odds ratio; SAE, serious adverse events

## Notes :

1  Chronic dialysis was defined as dialysis with a frequency of twice per week or more for at least 90 days

2  Sustained was determined by two or more consecutive post-baseline central laboratory measurements separated by at least 30 days (the first to last of the consecutive eGFR values)

3  Reduction in eGFR (CKD-EPI)cr was defined as reduction in eGFR from baseline of ≥40%, eGFR &lt;15 mL/min/1.73 m 2 for patients with baseline eGFR ≥30 mL/min/1.73 m 2 , or eGFR &lt;10 mL/min/1.73 m 2  for patients with baseline eGFR &lt;30 mL/min/1.73 m 2

## 6.7. Benefit-risk assessment and discussion

## 6.7.1. Importance of favourable and unfavourable effects

HF is a progressive syndrome with a high, global prevalence. Treatment-induced decrease in HF-related complications such as HHF and CV death are therefore important. The finding in the EMPEROR-reduced trial of decreased occurrence of HHF or CV death with empagliflozin treatment (HR 0.75; 95% CI 0.65 to 0.86) is an important benefit. During the trial period, the number of patients who would need to be treated with empagliflozin to prevent one primary event (NNT) was 19 (95% CI, 13 to 37). Although this effect seems mainly due to the decrease in HHF and to a lesser extent to the decrease in CV death, it is still regarded as clinically relevant, especially as the normal progression of HF is still associated with a high frequency of rehospitalizations and HF is the most common cause of hospitalization among individuals above 65 years of age in the western countries.

The finding of a slower eGFR slope decline with empagliflozin treatment (estimated difference in slope of 1.733 mL/min/1.73 m2 per year vs placebo (99.9% CI 0.669, 2.796; p&lt;0.0001)), is not regarded as convincing as the findings described above. Although this endpoint was a key secondary endpoint, from a clinical perspective, the approach is questionable. The slope analysis modelling is regarded as better suited to providing some descriptive information on renal outcomes, than providing definitive statistical and clinical evidence of an effect as it is used now. This data was supported by a beneficial effect on the exploratory renal composite endpoint of (i.e. chronic dialysis, renal transplant, or sustained reduction in eGFR), HR 0.50, 95% CI 0.32 - 0.77). This analysis was also driven by change in eGFR and therefore partly represents the same information. Even if this may be regarded as promising results, this finding is not importantly contributing to the benefit-risk ratio for the indication of HFrEF.

The potential beneficial effects of empagliflozin on HF-related symptoms are not established in a statistically robust way and are, therefore less important. In the EMPEROR-reduced trial, the KCCQ 'clinical summary score' was used to measure the patent reported outcomes, and this was an exploratory secondary endpoint. A higher proportion of patients in the empagliflozin group than in the placebo group showed a clinically meaningful improvement in this score, but this was not confirmed by the KCCQ score of 'patients preferred outcome'.

The supportive EMPERIAL trials had the 6MWT distance at 12 weeks as the primary endpoint but did not find a treatment benefit. Taken together, the potential beneficial effects on HF-related symptoms are, therefore, not importantly contributing to the benefits of treatment with empagliflozin.

<div style=\"page-break-after: always\"></div>

Treatment with empagliflozin in patients with HFrEF generally revealed no new major safety findings compared with the known safety profile of empagliflozin used in patients with T2DM. The numbers of reported AEs were equally distributed between the treatment groups, and the SAEs were numerically lower in the empagliflozin group. As expected, genital infections, hypotension and volume depletion were more reported during empagliflozin treatment, but these are known side-effects included in the SmPC. They have previously not affected the benefit-risk balance to a negative ratio for the indication for the treatment of T2DM.

Two new AEs were identified in the EMPEROR-reduced trial: fall (empagliflozin 43 patients, 2.3% vs placebo 27 patients, 1.4%) and constipation (empagliflozin 57 patients, 3.1% vs placebo 27 patients, 1.4%).

## 6.7.2. Balance of benefits and risks

The MAH agreed to amend the initially applied indication i.e. to include the target condition and target population, but no clinical trial endpoints.

The final agreed indication is: ' Jardiance is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction'.

The finding of reduced occurrence of HHF or CV death is an important benefit. It is, however, important to point out that this finding seems mainly due to the effect on HHF, as no relevant reduction in CV death was observed. With the current indication, the beneficial effect on HFF or CV death results in a positive benefit-risk ratio, especially as no new major safety issues have been observed.

The findings on change eGFR slope and renal outcomes are supportive and promising and are addressed in section 5.1 of the SmPC.

## 6.8. Conclusions

The overall B/R of Jardiance in the treatment of heart failure is positive.

## MAH request for additional market protection

The MAH requested consideration of its application in accordance with Article 14(11) of Regulation (EC) 726/2004 - one year of market protection for a new indication. However, as part of their Reponses to the CHMP request for supplementary information, the MAH informed the CHMP/ EMA that they do not intend to pursue the claim for the additional year of market protection in the context of the present procedure.